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RESUMEN 
Los feocromocitomas (PCC) son tumores neuroendocrinos, desarrollados a partir del tejido cromafín de la 
médula adrenal, que suelen causar hipertensión arterial por sobre-secreción de catecolaminas. Los 
paragangliomas (PGL) son PCCs, en su mayoría secretores y con un gran riesgo de malignizar, que se 
desarrollan a partir de paraganglios localizados fundamentalmente en la región intra-abdominal o 
torácica. Algunos PGLs pueden desarrollarse en la región de la cabeza y el cuello, y en esa localización 
suelen comportarse como masas benignas no secretoras. Los PCCs presentan una incidencia anual en 
población española de 2 casos por millón de habitantes y son por tanto una enfermedad rara. Tanto la 
secuenciación masiva del genoma completo, como la limitada a las regiones codificantes (secuenciación 
exómica, SE), se han convertido a lo largo de los últimos años en herramientas de gran utilidad para el 
descubrimiento de genes de susceptibilidad responsables de enfermedades mendelianas. De este modo, 
el objetivo principal de esta tesis doctoral fue la identificación de nuevos genes de susceptibilidad 
implicados en el desarrollo de PCC/PGL mediante el uso de la SE aplicada a 3 proyectos independientes. 
En el primer proyecto, se llevó a cabo la SE de tres pacientes no relacionados, con antecedentes 
familiares de la enfermedad y sin mutaciones en ninguno de los genes conocidos. Los pacientes fueron 
seleccionados como candidatos para el estudio debido a que sus correspondientes tumores presentaban 
perfiles de expresión muy homogéneos. El filtrado y posterior análisis de los datos de secuenciación 
permitió identificar mutaciones germinales patogénicas en el gen MAX  en los tres pacientes. Además, la 
pérdida de heterocigosidad del alelo silvestre, la ausencia de proteína MAX en los tumores y el 
descubrimiento de otras 5 mutaciones en pacientes aquejados de la enfermedad  permitió demostrar que 
MAX constituía un nuevo gen supresor de tumores asociado con el desarrollo de PCC hereditario. En un 
segundo trabajo, el estudio de una serie compuesta por más de 1500 pacientes no relacionados permitió 
establecer tanto la prevalencia de las mutaciones en MAX en pacientes con PCC/PGL (1,12%), como el 
fenotipo asociado a dichas mutaciones. Por último, con el objeto de determinar la patogenicidad de las 
variantes con significado desconocido halladas en el gen MAX, se llevó a cabo un estudio funcional de las 
mismas en células de  PCC de rata (PC12) y se implementó una herramienta de predicción in silico basada 
en el consenso de 5 predictores. En el segundo proyecto, los candidatos a estudio mediante SE (3 tríos 
paciente/madre/padre) fueron seleccionados en base a la presencia de una característica fenotípica poco 
frecuente en pacientes con PCC/PGL: policitemia idiopática. Durante el análisis de los datos, se publicó el 
descubrimiento de mutaciones somáticas post-zigóticas en el gen EPAS1 en pacientes con PCC/PGL 
múltiple y policitemia idiopática. El análisis de EPAS1 en los correspondientes tumores de los pacientes 
seleccionados para la SE, reveló la presencia de mutaciones somáticas en mosaico en el gen EPAS1 en 
todos ellos. Además, el estudio de una serie adicional de tumores identificó mutaciones somáticas en 
tumores de pacientes sin policitemia. Finalmente, se identificó la ganancia de la región 2p como exclusiva 
de tumores con mutación en EPAS1. En el tercer proyecto, se llevó a cabo una selección de pacientes 
basada en la presencia de tumores múltiples (más de 5) como indicador de  la existencia de una 
enfermedad hereditaria. Durante el filtrado de las variantes encontradas en uno de los pacientes 
seleccionados, se identificó una mutación en el gen MDH2, implicado en el ciclo de Krebs. La ausencia de 
RNAm, proteína y actividad enzimática malato deshidrogenasa, así como el diagnóstico de la enfermedad 
en un pariente portador de la variante permitió concluir que el gen MDH2 es un nuevo gen supresor 
tumoral responsable de susceptibilidad a desarrollar PCC/PGL. La identificación de este segundo gen de 
susceptibilidad a desarrollar PCC/PGL  demuestra la eficacia de la SE en la identificación de nuevos genes 
responsables de enfermedades mendelianas. 
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ABSTRACT 
Pheochromocytomas (PCCs) are neuroendocrine tumors arising from the medulla of the adrenal gland 
that usually cause hypertension due to oversecretion of cathecolamines. On the other hand, 
paragangliomas (PGLs) are normally secretor tumors with high risk of malignancy that arise from the 
paraganglia of the intra-abdominal or thoracic regions. Some PGLs arise in the head and neck region, 
usually as benign, non-secretor tumors. PCC/PGL is a rare disease, with an incidence in the Spanish 
population of approximately 2 cases per million habitants. High-throughput techniques such as whole-
genome sequencing (WGS) and whole-exome sequencing (WES) are nowadays widely applied to discover 
susceptibility genes involved in mendelian diseases. Thus, the main objective of this thesis was to identify 
new genes related to the susceptibility to develop PCC/PGL by applying WES in three independent 
projects. In the first project, we applied WES to three unrelated patients with a family history of disease 
testing negative for mutations in the major PCC/PGL susceptibility genes. The three patients were 
selected because they shared a common homogeneous transcriptional profile, suggesting a common 
underlying genetic alteration. The variant filtering process and the posterior analysis of the WES data 
allowed us to identify pathogenic germline mutations in the MAX (MYC associated factor X) gene in all 
three patients. Moreover, loss of heterozygosity of the wild type allele, loss of the protein in the tumors 
and the identification of MAX mutations in additional patients with the disease, together indicated that 
MAX constitutes a novel tumor suppressor gene. In a posterior international collaborative study, we 
recruited more than 1500 unrelated patients and established the prevalence of MAX mutations to be 
1.12%; we also characterized the associated phenotype. Finally, we developed a functional model to 
determine the pathogenicity of variants of unknown significant (VUS) found in MAX. This model was 
implemented based on a consensus in silico prediction obtained from five algorithms available online. In 
the second project, the selection of three trios (patient/mother/father) was based on the presence of a 
very infrequent phenotypic characteristic in patients suffering for PCC/PGL: idiopathic polycythemia. 
While the analysis of the WES data was underway, a study was published reporting the presence of 
somatic post-zygotic mutations in the gene EPAS1 (HIF2A) in patients presenting multiple PCC/PGL and 
idiopathic polycythemia. Our posterior screening for EPAS1 mutations in the tumors from the index 
patients revealed the presence of somatic mutations in all of them. In addition, the analysis of an 
additional series of tumors identified somatic mutations in tumors from patients without polycythemia. 
Finally, we indentified a gain of the chromosomic region 2p exclusive to tumors harboring EPAS1 
mutations. In the last WES Project, we selected patients based on the presence of multiple (more than 
five) tumors as phenotypic marker of hereditary disease. We identified a splice-site mutation affecting 
the MDH2 gene involved in the Krebs cycle. The observed absence of the messenger RNA, protein and 
malate dehydrogenase enzymatic activity, as well as the positive diagnosis for the disease of a family 
member, led us to conclude that MDH2 is a novel tumor suppressor gene implicated in susceptibility to 
develop PCC/PGL. The identification of this second susceptibility gene implicated in PCC/PGL 
development demonstrates the efficacy of WES in discovering susceptibility genes involved in Mendelian 
diseases.  
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1. GENERAL ASPECTS OF THE DISEASE  
 Pheochromocytomas (PCCs) are rare neuroendocrine tumors that arise from the chromaffin cells 
of the adrenal medulla, and usually cause secondary hypertension via over secretion of catecholamines. 
On the other hand, paragangliomas (PGLs) are secreting or non-secreting tumors that develop from 
paraganglia of the sympathetic or parasympathetic chains, respectively. PCCs and PGLs share their origin 
in the neural-crest, and though they are usually benign, between 10 and 15% develop distant metastases 
in embryologically different tissues such as bone, liver, lungs or lymph nodes. 
 
1.1 HISTORY 
 
 The adrenal glands were first described in 1563 by Eustachius in the study Opscula anatomica1, in 
which he established their division into cortex and medulla. It was not until 1855 that Addison described 
the pivotal role of the adrenal glands in releasing hormones (e.g. catecholamines) in response to stress in 
patients with tuberculosis1. Almost thirty years later, in 1884, the first diagnosis of what was later to 
become known as PCC was reported in a 18 year-old woman from a small village near Lahr in Germany2. 
The patient was admitted to hospital because of palpitations, anxiety, vomiting, headache, and muscle 
weakness. Ten days later, she died and the autopsy revealed two adrenal tumors that were initially 
diagnosed as sarcoma and adrenal angiosarcoma. Interestingly, one century later this case was reviewed 
by Neumann et al.3 who concluded that the patient, diagnosed at an early age and presenting with 
bilateral adrenal tumors (PCCs), was really the first reported case of multiple endocrine neoplasia (MEN) 
type 2. The descriptive term PCC was formulated in 1912 by the pathologist Ludwig Pick because of its 
colourful reaction in fixatives containing chromic acid salts, something lately corroborated by Manasse4. 
The term PGL had been adopted previously, in 1908, by Alezais and Peyron to describe extra-adrenal 
chromaffin tumors arising from paraganglia. 
 
1.2 EPIDEMIOLOGY 
 Together, PCCs and PGLs have an overall annual incidence of 2 per million in the Spanish 
population and 3-8 per million in the United States5, and although their prevalence is unknown it has 
been estimated to lie between 1/6500 and 1/2500 in the United States6. However, these figures are 
probably under-estimates, taking into consideration the high frequency of incidental diagnoses from 
autopsies7,8. Of note, PCC is the most common endocrine tumor diagnosed in children, despite the fact 
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that the mean age at diagnosis is approximately 43 years9. Thus, between 10 and 20% of patients affected 
with the disease are diagnosed during childhood, which is usually associated with a genetic germline 
alteration10-12. No difference is seen between males and females in the incidence of pheochromocytoma. 
 
1.3 CLINICAL PRESENTATION 
 
 Patients suffering from PCC/PGL can present with a variety of nonspecific symptoms that may 
suggest other diseases. Given the frequent finding of incidental masses in autopsies, the identification of 
signs and symptoms of PCC/PGL has become one of the most challenging aspects in the clinical 
management of the disease7,8.  
 The most frequent symptoms of catecholamine-secreting PCCs/PGLs are sustained or paroxysmal 
hypertension, headaches, sweating and palpitations. Less frequent are pallor, anxiety or panic attacks, 
fever, nausea and vomiting6,13. Patients with non-secreting PGLs in the intra-abdominal region suffer from 
hydroureteronephrosis or renal hypertension due directly to the tumor mass. In patients with non-
secreting head and neck PGLs, unilateral hearing loss, pulsate tinnitus, hoarseness, cough, headache, 
difficulty swallowing, tongue mobility problems or feeling of pharyngeal fullness can be found, depending 
on the size and location of the tumor6,13. 
 As mentioned above, one of the main differences between PCCs and PGLs is the anatomical 
location of the tumor, which is also related to the underlying germline alteration. Whereas 70% of tumors 
appear in the adrenal medulla, around 30% present as highly vascular masses within sympathetic and, 
more rarely, parasympathetic paraganglia distributed along the paravertebral and paraaortic axis. The 
main anatomical locations of PGLs are (Figure 1): 
a) Abdominal and retroperitoneal sympathetic paraganglia (81%), mainly located in the 
Zuckerkandl organ, the bladder, the renal hilum, the urethra or the prostate gland14.  
b) Thoracic (11%) and cranial sympathetic (3%) paraganglia, mainly located at the median region of 
the thorax or the base of the heart. 
c) Head and neck parasympathetic paraganglia (5%), mostly occurring at the carotid bifurcation, 
the jugular bulb or the tympanic plexus on the promontory and the vagal nerve. 
 
Both, PCCs and PGLs can present as single, bilateral or multiple tumors distributed across any of 
the aforementioned anatomical locations. Moreover, their clinical presentation is often associated with 
the presence of germinal alterations affecting specific susceptibility genes15. 
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1.4 DIAGNOSIS 
 The vast majority of patients suffering from PCC/PGL presents with the symptoms mentioned 
previously. However, a small percentage presents with less specific symptoms which makes diagnosis 
much more complicated. Regardless of the symptoms, the main procedures used to detect the presence 
of these tumors are biochemical tests and imaging. 
 1.4.1 Biochemical testing 
 Catecholamines are hormones mainly synthesized by the adrenal medulla, the sympathetic 
nerves and the central nervous system (CNS), although other non-neuronal cells located in the digestive 
tract and the kidneys are also able to produce them in smaller amounts16. The diagnosis of PCC and 
sympathetic PGL is based on biochemical evidence of the hypersecretion of catecholamines6 since these 
tumors produce, store, synthesize and metabolize high levels of these hormones. The most abundant 
catecholamines in the human body are epinephrine (adrenaline), norepinephrine (noradrenaline) and 
dopamine. In addition, PCC/PGL chromaffin cells have specific catecol-O-methyltransferase (COMT) 
activity that metabolizes catecholamines (epinephrine, norepinephrine and dopamine) into 
metanephrines (metanephrine, normetanephrine and methoxytyramine)17. 
Figure 1. Overview of the main locations for PCC and PGL of the parasympathetic and sympathethic 
nerve system. A) Anatomic distribution of PCC and PGL in the thoraco-abdominal region. B) Distribution 
of the paragangliomas of the head and neck. Ilustration A was published in The Netter Collection of 
Medical Illustrations - Endocrine System. Image B was created by Frank Gaillard and the original 
background image by Gray's Anatomy 1918.  
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 The production of catecholamines in tumors is highly fluctuating13 and may lead to false-negative 
results, making the diagnosis of PCC/PGL based on measurement of catecholamine levels in plasma or 
urine unreliable and outdated. In contrast, the release of metanephrines (epinephrine and 
norepinephrine) by the tumor is very stable in time and is consistently elevated in patients with 
biochemically active PCC/PGL6, unless the tumor mass is very small18. There is little consensus on the 
utility of urine or plasma to perform the measurement of metanephrines. While the determination of 
metanephrines in plasma has greater specificity and sensitivity (98% and 100%, respectively) than that in 
urine (both 96%), it requires that the patient meet the following conditions in order to minimize the 
number of false positives: free of stress, 8-12 hours fasting, supine position and extraction after 20-30 
minutes following insertion of the venous cannula (reviewed in19). In general, when a level more than 
four-times greater than the upper limit of the normal range is observed, the chance of finding PCC/PGL is 
high and further analysis to determine the tumor location is indicated. When a smaller increase is 
observed or when the result is unclear, checks should be carried out for technical errors, inadequate 
sample extraction and other clinical conditions that could elevate catecholamines. Results can be 
confirmed in plasma if originally determined in urine, or vice versa. Finally, in rare cases PCCs/PGLs can 
secrete dopamine only, and the diagnosis of these tumors can be overlooked by the metanephrine 
measurement tests. Recent studies have demonstrated that methoxytyramine, a metabolite of 
dopamine, can be used to detect these particular secreting PCCs/PGLs20.  
 1.4.2 Imaging-based determination of tumor location 
 Studies to determine tumor location should only be carried out following a positive biochemical 
diagnosis, except for non-secreting parasympathetic PGLs (mainly located in the head and neck region). 
Computed tomography (CT) or magnetic resonance imaging (MRI) are the imaging techniques most 
widely used to detect PCC/PGL; they have sensitivity and specificity of 90-100% and 70-80%, 
respectively21. CT scans can visualize adrenal tumors larger than 1cm and extra-adrenal tumors larger 
than 2cm9. MRI is more expensive but has three key advantages: 1) intravenous contrast is not required; 
2) it is better than CT at detecting extra-adrenal tumors; 3) it does not emit ionizing radiation22. Thus, MRI 
is preferred in patients with extra-adrenal tumors, CT-contrast allergies, in pregnant or pediatric patients 
and in patients in whom radiation exposure should be limited13. 
 Functional tests may be carried out to determine PCC/PGL location when other methods fail or 
require confirmation, or in order to identify metastatic disease overlooked by the anatomic techniques 
explained above. In these tests, detection of the tumors is based on their in vivo metabolic activity. 123I- or 
131I-metaiodobenzylguanidine (MIBG) scintigraphy is usually the functional test of choice since the 
molecular structure of MIBG resembles norepinephrine and it may enter tumor cells via the same 
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transporters. 131I-MIGB is most widely used because of its high sensitivity, better detection rate, higher 
possible doses, and shorter required intervals between injection and image acquisition23. MIBG has some 
limitations in detecting metastases, extra-adrenal tumors or tumors harboring SDHB mutations24. More 
recently, positron emission tomography (PET) has come to be considered a better functional test because 
of its high sensitivity, shorter image acquisition times and higher image resolution23,25. This technique 
uses radiotracers such as 18F-fluorodeoxyglucose (FDG), which are taken up by the glucose transporter25. 
Other radiotracers used include 18F-fluorodopamine (FDA) and 18F-fluorodopa (FDOPA), the latter of 
which is highly specific for head and neck PGL26. Techniques involving radiotracers FDOPA and FDG are 
especially effective in detecting metastasis in patients carrying mutations in SDHB6,9,22,27,28. Additional 
imaging techniques include OctreoScan® and 68-Ga-DOTA peptides23,29,30. 
 
1.5 TREATMENT 
 Surgery is currently the only option to treat PCC/PGL with the possibility of curing the disease. 
Biochemically active tumors, once localized, should be treated immediately with antihypertensive 
medications (α- and β-blockers) to control symptoms and reduce the risk of hypertensive crises. 
Treatment is preferentially initiated with α-blockers, and after this β- blockers should be introduced if 
tachyarrhythmia appears31,32; these may not eliminate the possibility of hypertensive crisis during 
surgery, but reduce the severity should one occur33. Laparoscopic intervention has lower associated 
morbidity and mortality than open procedures, and thus is preferred, when possible, both for PCC and 
sympathetic PGL33, and also for large, multiple, bilateral or recurrent tumors. If metastases are suspected, 
open resection is recommended in order to remove as much malignant tissue as possible34. Bilateral 
adrenalectomy is an option for cases of hereditary PCC, but bilateral partial adrenalectomy can be a 
better option because it preserves partial function of the organ6. The choice of surgery or chemotherapy 
treatment for patients with head and neck PGLs depends on the accessibility of the tumor, the size, and 
possible secondary effects of its location and vascularisation. If surgery cannot be performed, is critical to 
closely follow-up the patient in order to avoid damage (local vessel and nerve compression) triggered by 
the tumor. 
The therapeutic options for malignant cases are limited and rarely curative. For unresectable 
tumors detected by 123I-MIBG scintigraphy, radiotherapy with 131I is recommended. When the tumor is 
negative for 123I-MIBG scintigraphy or is fast-growing, chemotherapy (cyclophosphamide, vincristine or 
dacarbazine) alone, or in combination with radiotherapy, may be a feasible option35. Our increasing 
knowledge of the molecular biology of these tumors is helping to extend the therapeutic options 
applicable to unresectable tumors. There are currently two types:  
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a) Pro-apoptotic agents: somatostatin analogues, histone deacetylase (HDAC) inhibitors, 
eicosapentaenoic acid, triptolide/capsaicin, gamitrinib and camptothecin36-41. 
b) Anti-proliferative agents: everolimus (a mammalian target of rapamycin [mTOR] pathway 1 
inhibitor), AEZS-131 (ERK inhibitor), AZD-8055 (mTOR1 and mTOR2 inhibitor), sunitinib42,43 and 
other tyrosine kinase inhibitors44, LB1 (inhibitor of serine/threonine protein phosphatase 2A) 
combined with temozolomide and inhibitors of carboxypeptidase E35. 
 There are several treatment options to alleviate pain or symptoms due to local compression, 
including radiotherapy (especially for bone metastases) and local treatments such as cryo- and 
radiofrequency ablation, radionucleotides and or/embolization6,28 
 
1.6 GENETICS 
 Many years ago, PCC was dubbed the “10 percent tumor” since it was thought that 10% of 
tumors were bilateral, 10% ocurred in childhood, 10% were extra-adrenal, 10% were hereditary and 10% 
were malignant14. However, studies published since 2000 have shown that some of these percentages are 
quite different to 10%. Thus, nowadays we know that more than 30% of patients develop extra-adrenal 
tumors45,46, that malignancy depends on the location of the primary tumor and/or the gene mutated (e.g. 
more than 30% of tumors harboring mutations in the SDHB gene are malignant)47, and that 
approximately 40% of cases carry a germline mutation in one the known susceptibility genes15, which 
means that PCC/PGL has the highest heritability of all human tumors. This figure is even higher for 
pediatric disease since up to 80% of children with PCC harbor mutations, regardless of their family 
history10,26. 
 Despite being rare tumor entities, PCC and PGL are the common phenotypes across the major 
hereditary endocrine cancer syndromes: neurofibromatosis type 1 (NF1), MEN types 1, 2A and 2B, and 
von Hippel-Lindau (VHL) syndrome. Moreover, PCC and PGL susceptibility can be inherited, with or 
without the presence of other tumors that form part of these paraganglionic syndromes (PGL1-5). They 
can be also found associated with gastrointestinal tumors (GIST) in Carney-Stratakis syndrome (OMIM: 
#606864) or with GIST and pulmonary chondromas in the Carney Tryad (OMIM: #604287). Finally, PCC 
and PGL susceptibility can be inherited alone via germline mutations in transmembrane protein 127 
(TMEM127)48,, MYC associated factor X (MAX)49, the fumarate hydratase (FH)50 gene, or the malate 
dehydrogenase (MDH) 2 gene (in press). Overall, 16 different susceptibility genes15,51 (in press) have been 
shown to be mutated in the germline of patients with PCC/PGL. In addition, around 25-30% of PCCs/PGLs 
are caused by somatic mutations affecting the same susceptibility genes involved in hereditary cases. 
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 Ten yeas ago, Eisenhofer et al. (2004)52 performed the first transcriptional profiling study of PCC. 
In this study, the authors compared tumors harboring mutations in VHL (norepinephrine secreting 
tumors) versus tumors carrying mutations in the RET proto-oncogene (epinephrine secreting tumors) with 
the aim of identifying differences in gene expression patterns. Thus, they observed for the first time an 
enrichment of the hypoxia-driven angiogenic pathways in VHL-mutated tumors. A second transcriptional 
profiling study performed by Dahia et al. (2005)53 described a functional link between tumors with VHL 
mutations and those with disruption of the genes encoding succinate dehydrogenase (SDH) subunits B 
(SDHB) and D (SDHD). Moreover, they proposed that PCCs and PGLs can be segregated into two clusters 
based on their genetic background: Cluster 1, enriched with tumors carrying alterations in genes related 
to the hypoxic response (VHL and the SDH genes), and Cluster 2, containing tumors that activate kinase 
signaling (via mutations in RET and NF1). Subsequently, studies performed by Favier et al54 and our 
group55 replicated the two characteristic transcriptional clusters, and demonstrated that tumors 
belonging to Cluster 1 can be further distinguished into two sub-clusters (VHL- and SDH gene-related) 
based on the activation of distinct pseudo-hypoxic pathways. Studies since then have demonstrated the 
utility of “omics”-based classification tools in the discovery of hidden alterations in PCC/PGL patients 
without mutations in the known susceptibility genes49,50. 
The known susceptibility genes (Figure 2) can be described in the context of this transcriptional 
classification of PCCs/PGLs into two clusters:  
a) Cluster 1: the hypoxia-driven angiogenesis cluster enriched with tumors carrying alterations in 
genes implicated in the hypoxic response, including VHL, the SDH genes (SDHA, SDHB, SDHC, 
SDHD and SDHAF2), FH, MDH2, and hypoxia-inducible factor (HIF)-2α (also known as endothelial 
PAS domain protein 1, EPAS1). 
b) Cluster 2: the RAS/mTOR cluster composed of tumors harboring mutations in genes involved in 
the activation of kinase signaling, such as RET, NF1, MAX, TMEM127 and the Harvey rat sarcoma 
viral oncogene (HRAS).  
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Cluster 1 genes: VHL, the SDH genes, EPAS1, FH and MDH2 
 Under normal conditions, the hypoxic response is activated to adapt the organism to a lack of 
oxygen56. However, this pathway can be activated regardless of oxygen levels as a consequence of 
mutations in one of several genes; this process is called pseudo-hypoxia57. 
 
- VHL 
 The VHL protein is the substrate recognition component of a very important E3 ubiquitin ligase 
complex that plays a central role in the ubiquitination and posterior degradation of the transcription 
factors HIF-1, HIF-2 and HIF-3α by the proteosome, preventing the subsequent activation of genes 
implicated in the hypoxic response58. The inactivation of VHL triggers the stabilization of the HIF family of 
transcription factors (pseudo-hypoxia) and the consequent expression of HIF-target genes involved in 
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Figure 2. Schematic representation of the canonical pathways for PCC/PGL susceptibility genes (filled in 
red). 
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transformation, angiogenesis and glucose uptake. It also triggers an increase in expression of growth 
factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGFB), 
transforming growth factor (TGF) and erythropoietin (EPO)59. 
VHL (OMIM: #193300) is an autosomal dominant syndrome with a prevalence of 1 in 36,000, and 
variable clinical manifestation. The syndrome is caused by germline mutations affecting the tumor 
suppressor gene VHL60. Besides the development of PCC, and more rarely PGL, VHL patients are at high 
risk of developing hemangioblastoma (HB) of the retina and CNS, clear cell renal cell carcinoma (ccRCC), 
renal and pancreatic cysts, neuroendocrine pancreatic tumors, endolympathic sac tumors, pancreatic 
serous cystadenomas and papillary cystadenomas of the epididymis in men and of the broad ligament in 
women61. 
 VHL families are categorised into two main types based on the risk of developing PCC62: 
VHL type 1: the most common form of the disease. Patients can present with all the conditions described 
above, have a low risk of PCC, and can be classified in two subtypes depending on ccRCC risk: 
i. Subtype 1A: high risk of ccRCC. 
ii. Subtype 2B: low risk of ccRCC. 
 
VHL type 2: patients have high risk of PCC and HB and can be classified in three subtypes depending on 
ccRCC risk: 
i. Subtype 2A: low risk of ccRCC. 
ii. Subtype 2B: high risk of ccRCC. 
iii. Subtype 2C: PCC is the unique sign in the disease. 
 
Approximately 20% of patients with VHL develop PCC. VHL has a high mutation rate (20-21%)19, 
and so mutation testing of this gene is specifically recommended for detecting de novo cases amongst 
apparently sporadic and non-syndromic patients. In fact, somatic mutations affecting VHL are frequent in 
sporadic PCCs, being the second most prevalent somatic alteration found in PCC/PGL after NF1 
mutations15. Other clinical and molecular characteristics associated with VHL-mutated PCCs/PGLs, as well 
as with mutations affecting the susceptibily genes, are described in Table 1. 
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Gene 
Secretory 
phenotyp
e 
Mean age at 
diagnosis 
(years) 
Inheritance (proportion of 
mutation carriers) 
Predominant 
tumor location 
Number of 
tumors 
Frequenc
y of 
somatic 
mutations 
Risk of 
Malignanc
y  
Hereditary syndrome: PCC-associated pathologies 
VHL NA 30 Autosomal dominant (9%) Adrenal>>TA, H&N Bilateral Frequent Low VHL: ccRCC and CNS hemangioblastomas 
EPAS1 NA 33 Somatic mosaicism TA>Adrenal Multiple Frequent Unknown Hereditary polycythemia: somatostatinoma polycythemia 
SDHA Unknown 40 Autosomal dominant (<1%) Adrenal, TA Single Unknown Unknown 
PGL5: Leigh syndrome (homozygous mutations), ccRCC, GIST, 
PA 
SDHB NA/DA 30 Autosomal dominant (8%) TA>H&N>Adrenal Single and multiple Very rare High PGL4: ccRCC, GIST, PA, neuroblastoma 
SDHC 
NS or 
NA/DA 
40-50 Autosomal dominant (1%) H&N>>TA, Adrenal Multiple Very rare Low PGL3:  ccRCC, GIST, PA 
SDHD 
NS or 
NA/DA 
35 
Autosomal dominant with 
maternal imprinting (5%) 
H&N>>TA, Adrenal Multiple Very rare Low PGL1:  ccRCC, GIST, PA 
SDHAF2 NS 30-40 
Autosomal dominant with 
maternal imprinting (<1%) 
H&N Multiple Unknown Low PGL2: none 
FH NA 46 Autosomal dominant (0.8%) TA>Adrenal>>H&N Multiple Unknown High HLRCC syndrome: none 
MDH2 Unknown Unknown Autosomal dominant (Unknown) TA Multiple Unknown Unknown Hereditary PCC/PGL 
RET A 30-40 Autosomal dominant (5%) Adrenal Bilateral Frequent Low 
MEN2: MTC, PHPT, marfanoid habitus and mucosal 
ganglioneuroma 
NF1 A 42 Autosomal dominant (3%) Adrenal>>TA Single Frequent Moderate 
NF1: neurofibromas, cafe au lait spots, axillary freckling, optic 
gliomas, pigmented harmatomas of the iris 
TMEM127 NA/A 43 Autosomal dominant (<2%) Adrenal Bilateral Unknown Low Hereditary PCC/PGL 
MAX NA/A 32 
Autosomal dominant with 
paternal transmission (1,6%) 
Adrenal Bilateral Frequent Moderate Hereditary PCC/PGL 
HRAS NA/A 59 - Adrenal>>TA Single Frequent Low Costello syndrome: none 
KIF1B Unknown Unknown Autosomal dominant (unknown) Adrenal Bilateral Unknown Unknown Hereditary cancer: neural and non-neural tumors 
EGLN1/2 Unknown Unknown Autosomal dominant (unknown) TA>>Adrenal Multiple Unknown Unknown Hereditary polycythemia:  polycythemia 
MEN1 Unknown Unknown Autosomal dominant (unknown) Adrenal Single Unknown Unknown 
MEN1: PHPT, PA, neuroendocrine gastroenteropancreatic 
tumors 
IDH1 Unknown Unknown - H&N Single Very rare Unknown - 
Table 1. Summary of phenotypic and genetic features associated with the described PCC/PGL predisposing genes 
NA: noradrenergic; DA: dopaminergic;  NS: non-secretory; A: adrenergic; H&N: head and neck; TA: thoracic-abdominal; >: more frequent than; >>: much more frequent than; PCC: 
pheochromocytoma; ccRCC: clear cell renal cell carcinoma; CNS: central nervous system; PGL1-5: paraganglionic syndromes 1-5; GIST: gastrointestinal tumor; PA: pituitary 
adenoma; HLRCC: hereditary leiomyomatosis and renal cell cancer; MEN2: multiple endocrine neoplasia type 2; MTC: medullary thyroid cancer; PHPT: primary 
hyperparathyroidism; NF1: neurofibromatosis type 1; MEN1: multiple endocrine neoplasia type 1. The colour of the rows, purple, green and white, represents Cluster 1, Cluster 2 
and other genes respectively.  
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- EPAS1 
As mentioned previously, the HIF family of transcription factors (HIF-1α, HIF-2α [EPAS1] and HIF-
3α) plays a key role in the regulation of hypoxia response to counteract the lack of oxygen in normal 
homeostasis. HIF-1α has been suggested to preferentially drive genes implicated in apoptosis and 
glycolisis, while HIF-2α is involved in cell proliferation and angiogenesis56,57. Recently, a new and direct 
link between HIF proteins and PCC/PGL development has been found63; post-zygotic somatic mutations in 
EPAS1 were found in two unrelated patients with multiple PGLs, somatostatinomas and polycythemia. 
The mutations were found in the residues located close to the prolyl hydroxylation site of the protein 
(proline 531) which was shown to disrupt the recognition of EPAS1 by the PHD (EGLN) family members, 
its hydroxylation and the consequent degradation by VHL64,65. Thus, mutations affecting the EPAS1 gene 
stabilize the protein, causing the aforementioned pseudohypoxia, indicating that EPAS1 behaves as an 
oncogene. A germline alteration affecting EPAS1 has been recently found in a patient with multiple PGLs 
and polycythemia. Although it has been demonstrated that the variant stabilizes the protein, its location 
outside the prolyl hydroxylation sites and the absence of segregation with the disease in the family of the 
variant carrier makes this result somewhat controversial66. 
 A detailed description of our findings on the involvement of EPAS1 in the pathogenesis of 
PCC/PGL67 will be provided and discussed throughout this thesis. 
 
- The SDH genes 
 The SDH enzyme is a heteroligomer located in the mitochondrial inner membrane and is 
composed of four subunits: SDHA, SDHB, SDHC and SDHD. Two additional enzymes, SDHAF1 and SDHAF2,  
are implicated in the flavinization of the SDHA component, thus making possible the assembly of the 
complex68. SDH, also called complex II, is a part of the mitochondrial respiratory chain, which reduces 
ubiquinone during ATP synthesis. In addition, SDH catalyzes a pivotal step in the Krebs Cycle, converting 
succinate into fumarate by means of an oxidative dehydrogenation process68. In 2000 mutations in the 
SDHD gene were linked for the first time with the development of PGL69. Since then, all the genes 
encoding the subunits of the complex, as well as the gene encoding the related enzyme SDHAF2, have 
been implicated in the development of PCC and/or PGL within the five paraganglionic syndromes: PGL1 
(OMIM: #168000), PGL2 (OMIM: #601650), PGL3 (OMIM: #605373), PGL4 (OMIM: #115310) and PGL5 
(OMIM: #614165) (Table 1)69-73. 
 As mentioned previously, based on gene expression profiling, tumors harboring mutations in the 
SDH genes cluster together with tumors presenting with activation of the pseudohypoxic pathway (i.e 
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VHL-mutated tumors)52,55. The regulation of the HIF family of transcription factors depends on the activity 
of a family of prolyl hydroxylases (PDHs 1-3)74,75, which hydroxylates HIF, promoting its degradation by 
the VHL protein76. Succinate accumulation due to SDH impairment triggers the inhibition of the PDHs in 
the cytosol because of the competitive inhibition that this oncometabolite exerts due to its similarity to 
α-ketoglutarate (αKG), the normal substrate of the PHD family members. This inhibition leads to HIF 
stabilization and the subsequent expression of its hypoxic-response target genes53,55,77,78. 
 
 Recently, genome-wide hypermethylation associated with SDH impairment has been 
demonstrated in SDH gene-mutated tumors50. This hypermethylation, and the resulting CpG island 
methylator phenotype (CIMP), are due to the accumulation of succinate which leads to the inhibition of 
two types of αKG-dependent dioxygenases: the histone demethylases of the Jumonji (JMJ) demethylase 
family and the TET family of 5-methycytosine (5-mC) hydroxylases. This hypermethylation has been 
demonstrated in vitro, in vivo and in a subset of PCCs/PGLs affected by mutations in the SDH genes50,79. In 
addition, a similar CIMP has been observed for one tumor carrying a mutation affecting FH50, as well as in 
glioblastomas and other CNS tumors carrying mutations in the isocitrate dehydrogenase (IDH) genes 1 
and 280 . 
 
- FH 
 FH is the Krebs cycle enzyme involved in the reversible hydration/dehydration of fumarate to 
malate. It is known that germline mutations in FH predispose to leiomyomas and ccRCC in an autosomal-
dominant hereditary syndrome named hereditary leiomyomatosis and renal cell cancer (HLRCC)81. Loss-
of-function mutations of FH lead to the accumulation of fumarate in the tumors which, like succinate, 
promotes the inhibition of the αKG-dependent dioxygenases79.  Very recently, Letouze et al.50 
identified a germline mutation in FH by whole-exome sequencing applied to blood and tumor DNA 
obtained from a 63 year-old female presenting with one PCC. The patient was selected to be sequenced 
because the tumor showed a methylome- and transcriptome-based profile very similar to that found in 
tumors carrying mutations in the SDH genes. The subsequent screening of almost 600 patients with 
PCC/PGL but no mutations in the major susceptibility genes revealed that five carried pathogenic 
germline FH mutations, providing further evidence of the involvement of this gene in the development of 
PCC/PGL82. 
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- MDH2 
 The MDH2 gene encodes mitochondrial malate dehydrogenase 2, a key Krebs cycle enzyme 
implicated in the reversible conversion of malate to oxaloacetate with the concurrent reduction of NAD 
to NADH. The discovery of MDH2 as a new tumor susceptibility gene involved in PCC/PGL development 
(in press) will be described throughout this thesis. 
Cluster 2 genes: RET, NF1, TMEM127, MAX and HRAS  
 Tumors belonging to this cluster carry mutations affecting genes involved in apparently different 
processes, however disruption of the PIK3CA-AKT1-mTOR axis appears to be a common characteristic, by 
RET-mediated cell transformation82, inactivation of the tumor suppressor NF183, oncogenic activation of 
HRAS84, loss of the mTOR negative regulator TMEM12748, or by deregulation of the proto-oncogene MYC 
caused by MAX mutations49. 
 
- RET 
The RET gene encodes a tyrosine-kinase receptor mainly expressed in cells derived from the neural 
crest (C cells, parafollicular thyroid cells, adrenal medulla cells and others) and in urogenital system 
precursor cells85. Ligand-induced activation of RET (via glial cell line-derived neurotrophic factor, GDNF) 
involves dimerization and autophosphorylation of the receptor86, and the subsequent stimulation of 
multiple signal transduction pathways, including the MAPK/ERK and the PIK3CA-AKT1 pathways87. 
Germline gain-of-function mutations in RET cause MEN2, an autosomal dominant hereditary syndrome 
characterized by the presence of medullary thyroid cancer (MTC), PCC and/or primary 
hyperparathyroidism (PHPT)88. MEN2 can be classified into 3 sub-types: 
MEN2A (OMIM: #171400): the most common form of the disease (90%), characterized by a 95% 
risk of developing MTC, a 50% risk of PCC, and a 15%-30% risk of developing 
hyperparathyroidism. 
 
MEN2B (OMIM: #162300): representing approximately 5% of all cases. Patients typically present 
with MTC, PCC, marphanoid body habitus and multiple neuromas in mucosal tissue. 
 
FMTC (OMIM: #155240): characterized by MTC only.  
Mutations in the intracytoplasmic region of the receptor lead to constitutive activation of the 
protein without dimerization, triggering the activation of the aforementioned downstream pathways 
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involved in cellular proliferation and apoptosis89. RET mutations have variable clinical expression and 
penetrance that depends on their transformative capacity, giving rise to a genotype-phenotype 
relationship which is used to classify the aggressiveness of the disease90. In MEN2A patients the specific 
altered codon influences the level of mutant RET expression at the cell surface, contributing to signal 
variability91. On the other hand, MEN2B patients harbor alterations in codons localized in the catalytic site 
of the kinase, leading to loss of substrate specificity and more aggressive disease92. 
 Approximately 50% of patients harboring RET pathogenic mutations develop PCC and, as occurs 
with VHL, de novo mutations are relatively common. In addition, somatic RET mutations are detected in 
approximately 5% of sporadic PCC/PGL77. 
 
- NF1 
 NF1 (neurofibromin) is a GTPase-activating protein that negatively regulates the RAS family of 
oncogenes, suppressing cell proliferation93. Germline mutations affecting the NF1 gene cause NF1 
(OMIM: #162200), an autosomal dominant disorder characterized by the presence of neurofibromas, cafe 
au lait spots, axillary freckling, optic gliomas, pigmented hamartomas of the iris, carcinoid tumors, 
parathyroid tumors, PCC, peripheral nerves tumors, long-term myeloid leukemia and other 
conditions27,93. Genetic testing of NF1 is challenging because the gene is very large, and diagnosis is 
usually based on clinical criteria (i.e. cafe au lait spots or neurofibromas). Of note, NF1 has one of the 
highest rates of spontaneous mutation of any known gene94, and therefore the percentage of patients 
harboring de novo mutations is very high (between 30-50%). An estimated 0.1-5.7% of NF1 patients 
develop PCC. 
 In 2012, two independent studies found that mutations in NF1, and a concomitant chromosomal 
loss of the wild-type allele, are the most frequent somatic alterations found in sporadic PCCs (Table 
1)95,96. 
 
- TMEM127 
The TMEM127 gene encodes a transmembrane protein, associated with the endomembrane and 
the vacuolar network, that negatively regulates the mTOR pathway. In 2010, Qin et al. used linkage 
analysis, gene expression profiling and mapping of chromosomal gains and losses to identify the first 
germline mutations in TMEM127 in patients with PCC48. Alterations of the TMEM127 protein lead to the 
activation of phosphorylation of mTOR targets (for example, 4EBP1 and S6K), triggering cell growth and 
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proliferation48. A subsequent study of a large series of patients revealed a modest role of the gene in 
hereditary susceptibility to PCC (Table 1)97. 
 
-  MAX 
 MAX is a ubiquitously expressed basic helix-loop-helix leucine zipper (bHLHZip) protein that plays 
a central role in the regulation of the transforming protein MYC. MYC, via heterodimerization with MAX, 
activates the transcription at thousands of target promoters binding hexameric DNA consensus 
sequences “CANNTG” (E-boxes), and promoting the expression of genes involved in cell proliferation, dif-
ferentiation and apoptosis98. In addition, MAX antagonizes MYC-dependent cell transformation through 
its interaction with several negative regulators (MNT, MXD proteins, and MGA)99, competing for the same 
E-boxes100. The discovery of MAX mutations in PCCs49, the genetic characterization of MAX VUS, and the 
genetic screening for mutations in a large and well-characterized series of PCC/PGL patients will be 
extensively discussed throughout this thesis. 
 
- HRAS 
The members of the RAS family of oncoproteins (e.g. HRAS, NRAS, and KRAS) are small GTP-binding 
proteins that affect multiple downstream pathways related to cell growth and homeostasis. They were 
first linked to cancer in 198284, and nowadays it is known that together they represent around 30% of the 
total oncogenic activating mutations distributed across many different cancers84,101. Mutations in KRAS 
appear in 21.6% of human cancers, NRAS is mutated in 8.0% of tumors and HRAS mutations are found in 
3.3% of cancers (www.sanger.ac.uk/genetics/CGP/cosmic/)102. A mutation affecting HRAS was first 
described in one PCC by Yoshimoto et al.103. Crona et al.104 recently applied whole-exome sequencing to 
58 PCCs and found that four harbored somatic mutations in the gene. The subsequent study of a large 
series of tumors determined that 10% of sporadic PCCs have mutations in HRAS, and ruled out the 
involvement of NRAS and KRAS in the disease105. The presence of mutations in one of the isoforms of RAS 
is not a new issue in the development of endocrine tumors since they are present in around 10-20% of 
follicular cell-derived thyroid cancers and in 18% of RET-negative sporadic MTCs106-108. Although the gene 
expression profile of HRAS-mutated tumors has not been studied to date, the pivotal role of RAS genes in 
the PIK3CA-AKT1-mTOR pathway suggests that they would group within the so-called transcriptional 
Cluster 2. Unpublished data from our laboratory have confirmed that this is indeed the case.  
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OTHER GENES 
 Besides the major susceptibility genes described above, there are other genes anecdotally 
implicated in the disease. One of these is kinesin family member 1B (KIF1B), a gene involved in apoptosis, 
that has been found mutated in one sporadic PCC, and in the germline of one apparently sporadic patient 
and a single family affected by PCC and neuroblastoma109-111. Of note, it has been suggested that this 
gene could have a more relevant role in PCC development than expected, but the large size of its coding 
sequence makes screening for additional deleterious mutations a difficult task (commented at the 2014 
International Symposium on Pheochromocytoma and Paraganglioma, Kyoto, Japan). Moreover, EGLN1 
(PHD2) and EGLN2 (PHD1) have been found mutated in one and two patients, respectively, suffering from 
multiple PGLs and congenital polycythemia51,112. While it is known that, apart from tumors in the 
parathyroid glands, pancreatic islet cells and anterior pituitary gland, MEN1 patients can develop 
PCC113,114, little is known about which patients are at highest risk. Finally IDH1, another Krebs cycle-
related gene, was found to be somatically mutated in one sporadic tumor amongst 365 PCCs/PGLs115. It is 
known that the two PCCs carrying KIF1B mutations group within the transcriptional PIK3CA-AKT1-mTOR 
Cluster 2110 and, considering their respective alterations, we suppose that tumors carrying IDH1 or 
EGLN1/2 mutations would be grouped with tumors belonging to the pseudohypoxic Cluster 1. 
 
2. NEXT GENERATION SEQUENCING 
 
One of the central goals of human genetics is to identify genetic variants responsible for complex 
(common, multigenic) and for Mendelian (rare, monogenic) diseases. Geneticists have attempted over 
the last 30 years to identify cancer predisposition genes, rare mutations in which confer high or moderate 
risks of cancer. Thus, at least one new cancer predisposition gene has been identified each year since 
1990, the majority of them responsible for Mendelian diseases116. Genome-wide linkage analyses have 
been successfully performed to identify high-penetrance alterations in families in which multiple cases of 
a particular disease have occurred. These mutations are typically rare in the population. Genome-wide 
association studies (GWAS) are another methodology used to identify cancer predisposition genes. 
Genetic variants identified by GWAS typically are common in the population and have low effect sizes 
associated with cancer risk. In addition, many other genes have been identified through various 
candidate-based strategies: candidate genes that have been chosen because they act in pathways similar 
to those of known cancer genes or genes found to be somatically mutated in other cancers. However, for 
rare Mendelian disorders, several factors including rarity of the disease, locus heterogeneity and low 
penetrance, make linkage and GWAS suboptimal for the discovery of susceptibility genes117. 
 Introduction 
 
41 
 
 In the early 2000’s the first draft of the human genome was published, and this finding was the 
turning point for human genetics and the starting point for human genomics, something that completely 
changed the approaches adopted for the identification of cancer predisposition genes. The Human 
Genome Project (HGP) was an international scientific research project with the goals of determining the 
sequence of chemical base pairs that make up human DNA, and of identifying and mapping all of the 
genes in the human genome. The HGP, funded by the US government, started in 1990 and required 3.4 
billion USD, 13 years, and collaboration of hundreds of international laboratories. In 2003, the human 
genome assembly representing 99% of the euchromatic sequence was almost finalized118,119. The human 
reference genome generated was a haploid consensus mosaic sequence derived from multiple 
individuals, which includes variations such as single nucleotide polymorphisms (SNPs), segmental 
duplications, deletions (INDELs) and low-copy repeats. Nowadays, this information is freely available in 
the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/), created with the collaboration of the 
National Human Genome Research Institute and The National Center for Biotechnology Information 
(NCBI). This database contains information of more than 10 million well-characterized common variants 
in different world populations. 
 In the last 10 years through the availability of the HGP data we have witnessed a revolution in the 
development of massively parallel next-generation sequencing (NGS). The technical development of 
whole-genome sequencing (WGS) began with a series of experiments which demonstrated the utility of 
NGS in the generation of complete diploid sequences of human genomes. These included the sequencing 
of James D. Watson’s120 (first human genome sequenced by NGS) and J. Craig Venter’s121 genomes. Later, 
the genomes of people from different ethnical origins were also sequenced122-127. The first application of 
WGS to discover cancer-initiating mutations was published in 2008 by Ley et al., and was based in 
sequencing the genome of a cytogenetically normal acute myeloid leukemia128.  
 Rapid advances in the NGS field enabled the development of what is currently one of the most 
frequently used human genetics technologies worldwide: whole-exome sequencing (WES). The term 
exome refers to the protein-coding regions of the genome (i.e. the ~180,000 exons of the ~19,000 human 
genes), and represents a very small portion of the genome, around 1%. WES is possible by means of a first 
capture step followed by massive parallel sequencing129, that makes this technique cheaper, reducing the 
cost by a third to a tenth compared to WGS, and more easily managed from a bioinformatic point of view. 
Ng et al. published the first WES in 2009 after sequencing eight HapMap individuals as well as four 
additional exomes of previously genetically diagnosed Freeman-Sheldon syndrome patients (OMIM 
#193700) in order to demonstrate the sensitivity and specificity of the technique in the identification of 
rare and common variants130. Subsequent use of WES has demonstrated the utility of the technique to 
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discover the genetic causes of Mendelian genetic traits131-134. Despite biases introduced during the exome 
capture and amplification steps, the fact that most alleles underlying Mendelian disorders disrupt 
protein-coding sequences135 has meant that WES and targeted-WES (using commercial or home-made 
gene panels) have become standard tools for analyzing cancer-prone families showing monogenic modes 
of disease inheritance.  
 Two crucial considerations before starting a NGS project are the adequate selection of patients 
and the choice of the inheritance model to be considered. To select patients for study, and in order to 
avoid genetic heterogeneity, finding specific molecular or clinical markers may be essential to find a 
common causal gene. Moreover, the inheritance model assumed can determine not only the sampling 
but also the filtering process. On average, exome sequencing performed in one individual identifies 
~20,000 variants. More than 95% of these variations are polymorphisms present in the general 
population. In the case of very rare Mendelian diseases, such as hereditary PCC/PGL, filtering the list of 
candidate variants by ruling out those alterations found in in-house exomes or described in data bases 
such as dbSNP, 1000 genomes (http://www.1000genomes.org/) or ESP data server 
(http://evs.gs.washington.edu/EVS/) makes the identification of the causal gene more likely132. Further to 
these and other quality-based filtering steps, several approaches can be adopted in order to maximise the 
chances of finding the causal variant of a rare monogenic disorder by NGS136: 
 
a) Sequence multiple unrelated affected individuals and consider only those variants affecting the 
same gene in all or a subset of the sequenced patients. The more affected individuals sequenced, 
the greater the power to identify the causal mutation. This requires a reliable method to select 
the patients for inclusion in NGS studies, such as a common molecular or clinical marker or the 
presence of very specific clinical features. 
b) Sequence multiple affected and unaffected individuals from the same pedigree, in order to 
identify the altered gene (or genes) segregating with the disease. 
c) Sequence one or more trios (an affected individual and each of their biological parents) sharing 
similar clinical characteristics. This approach is suitable if the hypothetical inheritance model is a 
recessive or a de novo mutation is the cause. 
d) Analyze and compare matched tumor and normal genomes/exomes of the same patient, in the 
case of cancer-prone syndromes. The main advantage of this approach is to identify and assess 
germline and somatic alterations at the same time (for example, a germline mutation in a given 
gene and somatic loss of the corresponding wild-type allele). 
 
 Introduction 
 
43 
 
When the final list of candidate variants is obtained, stratification based on the effect of the change 
(e.g. truncating or missense variants) is usually applied. For instance, variants leading to a premature stop 
codon (truncating mutations caused by nonsense, splice site or frameshift variants) are usually 
considered the best candidates for study since the effect of the variant on encoded protein is more 
obvious. In the case of missense variants causing the substitution of one amino acid for another, the 
predicted functional impact obtained from in silico prediction programs such as SIFT (http://sift.jcvi.org/) 
or PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) can be considered. In addition, the presence of 
the candidate variant in databases of proven disease-causing alterations (e.g. The Catalogue of Somatic 
Mutations in Cancer, COSMIC; http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/, in the case of 
cancer) and the biological meaning of a given alteration in the context of the disease of interest are 
usually taken into account in the assessment of potentially causal variants.
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NGS, and more specifically WES, has become a very useful tool in the discovery of new 
susceptibility genes involved in genetic diseases showing a Mendelian pattern of inheritance. Thus, the 
main objective of this thesis was: 
 
1) To identify using WES new susceptibility genes involved in PCC/PGL development in patients with 
clinical characteristics of heritability and without mutations in the main susceptibility genes. Once 
a new PCC/PGL susceptibility gene (s) was identified we aimed: 
 
a) To develop adequate cellular models in order to demonstrate the impact of mutations in the 
gene; 
 
b) To assess the prevalence of mutations in new gene in a large series of PCC/PGL patients, and 
establish the associated clinical presentation. 
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ARTICLE 1: Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. 
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Bobisse, Giuseppe Pica, Paola Loli, Rafael Hernández-Lavado, José A Díaz, Mercedes Gómez-Morales, 
Anna González-Neira, Giovanna Roncador, Cristina Rodríguez-Antona, Javier Benítez, Massimo Mannelli, 
Giuseppe Opocher, Mercedes Robledo, Alberto Cascón. 
Published in Nature Genetics 2011 Jun 19;43(7):663-7 
 
ABSTRACT 
 Around 40% of PCC cases are due to germline mutations affecting  one of the major susceptibility 
genes described so far, however there are some cases (<10%) that present with clinical characteristics of 
heritability but aren’t found to carry mutations in the known genes. In this study, we took advantage of 
an expression profiling analysis performed in a large series of PCCs/PGLs to select for NGS three 
independent hereditary cases without germline mutations in the known susceptibility genes. The patients 
were selected because their tumors showed a very homogeneous transcriptional profile, suggesting a 
possible genetic alteration affecting the same gene in the three cases. 
 For the exome analysis, a bioinformatic pipeline was developed that enabled the identification of 
germline mutations affecting the same gene in the three individuals. We also sequenced and used as 
quality and filtering controls seven Hap Map individuals. We focused on heterozygous SNSs and indels, 
discarding variants present in the Hap Map controls or reported in the dbSNP130, 132 or 1000 Genomes 
Project databases, as well as variants in intergenic or intronic regions, and synonymous amino acid 
changes. Only variants affecting the same gene in the three samples were considered. 
 A variant affecting the MYC associated factor X (MAX) gene was validated by Sanger Sequencing 
and segregated with the disease. The absence of MAX protein in all tumors carrying mutations, and loss 
of heterozygosity (LOH) caused by paternal uniparental disomy (UPD), provided evidence of the 
involvement of MAX alterations in the disease, playing a role as tumor suppressor gene. 
 Further analysis of 59 cases with PCC/PGL selected because they had clinical features of 
heritability such as familial history of the disease, early age at onset (less than 30 years) and/or 
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multiplicity, identified five additional MAX mutations (two truncating and three missense). The clinical 
characteristics of MAX mutation-carriers suggested preferential paternal transmission of MAX mutations 
and initially an association with malignant outcome. Further evidence of the involvement of the MYC-
MAX-MXD1 network in the development and progression of neural crest cell tumors is provided by the 
lack of functional MAX in rat PCC (PC12) cells and by the amplification of MYCN observed in 
neuroblastoma, a tumor closely related to PCC. 
 
Personal contribution: I participated in the analysis of the raw NGS data and in the subsequent filtering 
process. Further, I participated in the identification of the LOH and the paternal origin of the UPD 
demonstrated by SNP-array and methylation-specific PCR, the western blot analyses, and the screening 
for MAX mutations in the additional selected series of patients. I also participated in the drafting of the 
paper. 
 
Nature GeNetics  VOLUME 43 | NUMBER 7 | JULY 2011 663
l e t t e r s
Hereditary pheochromocytoma (PCC) is often caused by 
germline mutations in one of nine susceptibility genes 
described to date1–4, but there are familial cases without 
mutations in these known genes. We sequenced the exomes 
of three unrelated individuals with hereditary PCC (cases) 
and identified mutations in MAX, the MYC associated factor 
X gene. Absence of MAX protein in the tumors and loss of 
heterozygosity caused by uniparental disomy supported the 
involvement of MAX alterations in the disease. A follow-up 
study of a selected series of 59 cases with PCC identified  
five additional MAX mutations and suggested an association 
with malignant outcome and preferential paternal transmission 
of MAX mutations. The involvement of the MYC-MAX-MXD1  
network in the development and progression of neural crest 
cell tumors is further supported by the lack of functional MAX 
in rat PCC (PC12) cells5 and by the amplification of MYCN 
in neuroblastoma6 and suggests that loss of MAX function is 
correlated with metastatic potential.
PCC is a rare neural crest cell tumor mainly localized within the 
adrenal medulla that usually causes secondary hypertension by 
oversecretion of catecholamines and which rarely metastasizes. 
Around 30–40% of individuals with PCC are familial cases7,8 who 
show dominant autosomal inheritance caused by germline mutations 
affecting one of nine susceptibility genes: RET, VHL, SDHA, SDHB, 
SDHC, SDHD, SDHAF2, NF1 or TMEM127. However, there are some 
hereditary cases (<10%)7,8 not explained by mutations in these genes. 
Recent gene expression analyses have identified a common transcrip-
tional profile for tumors carrying germline mutations altering the 
same gene9,10. Moreover, we showed that a subset of tumors from 
familial cases with PCC without germline alterations in the suscep-
tibility genes identified to date showed a homogeneous expression 
profile (GEO accession number GSE19422)11, suggesting that muta-
tions in the same as yet unidentified gene could be responsible for 
these cases.
Here we used next-generation sequencing to analyze the exomes 
of three independent familial cases with PCC without any known 
predisposing germline alteration and whose tumors had a common 
transcriptional profile11. We also included seven HapMap individuals 
(three males and four females) as quality and filtering controls. As it is 
very unlikely that homozygous variants can act as founder mutations, 
we focused on studying single nucleotide substitutions (SNSs) and 
small insertions and deletions (indels) in heterozygosity. We selected 
the heterozygous SNSs and consecutively filtered them by discard-
ing (i) variants present in the sequenced HapMap controls or in the 
dbSNP130 database and (ii) variants in intergenic or intronic regions 
(Table 1 and Supplementary Table 1). Next, we selected only those 
variants within coding regions not predicted to produce synonymous 
amino acid changes, affecting the same gene in all three samples and 
presenting sufficient depth and quality. After that, we checked can-
didate variants against the last version of dbSNP (dbSNP132) and 
the 1000 Genomes Project data (see URLs). This resulted in only five 
SNSs, corresponding to two genes (MAX and ADCY6), that passed 
the filtering process. We performed filtering for indels in a similar 
manner, but no variant passed the filtering criteria.
After validation by Sanger sequencing, we discarded ADCY6 as a 
PCC susceptibility gene because one of the variants (p.Arg1065Gln; 
Supplementary Table 1) did not segregate with the disease in the 
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affected relatives of the family. On the other hand, we observed segre-
gation of MAX c.1A>G (p.Met1Val) and c.223C>T (p.Arg75X) variants 
with disease in the two families for which DNA from affected relatives 
was available (Supplementary Fig. 1). We did not detect these vari-
ants in more than 750 population-matched control chromosomes. The 
three mutations found in MAX (Supplementary Fig. 2a) were pre-
dicted to alter the initiation ATG codon (c.1A>G), introduce a prema-
ture stop signal (c.223C>T) and cause exon 4 skipping (c.295+1G>A) 
(Supplementary Fig. 2b). Immunohistochemical analysis of the three 
PCCs carrying MAX mutations showed a lack of full-length MAX 
 protein (Fig. 1). Next, we analyzed the tumor DNA and found loss of the 
wild-type MAX allele in all three cases, indicating loss of heterozygos-
ity (LOH) (Fig. 2a). By array CGH analysis, we had previously ruled 
out the presence of chromosomal losses affecting the MAX locus in 
the same tumors (I.C.-M., F.S., G.O., A.C. & M.R., data not shown). 
Thus, to decipher the mechanism responsible for the LOH, we carried 
out a genome-wide SNP array analysis for one of the tumors and found 
copy-neutral homozygosity caused by uniparental disomy (UPD) affect-
ing almost the entire chromosome 14q (Fig. 2b). Multiplex PCR micro-
satellite analysis confirmed that the LOH found in the remaining MAX 
PCCs was also caused by UPD (Fig. 2c). The paternal origin of the UPD 
was clear for one of the hereditary cases because of his familial anteced-
ents (Supplementary Fig. 1a). To investigate the origin of the UPD in the 
other two cases, we studied the methylation status of MEG3 (the mater-
nally expressed gene 3), an imprinted gene within the disomy region. 
We detected only the silenced paternal allele in the tumors of these indi-
viduals (Supplementary Fig. 3), showing that loss of the maternal allele 
accounted for the LOH in the three cases. Taken together, these data sug-
gest that MAX germline mutations are associated with PCC susceptibility 
and that MAX behaves as a classic tumor suppressor gene.
MAX is the most conserved dimerization component of the 
MYC-MAX-MXD1 network of basic helix-loop-helix leucine zipper 
(bHLHZip) transcription factors that regulate cell proliferation, dif-
ferentiation and apoptosis12. In this network, MAX plays an essential 
role, as it is the common interaction partner for both MYC and MXD1 
proteins. Whereas heterodimerization of the MYC family of proteins 
with MAX mediates their function as transcription factors, hetero-
dimers of MAX with MXD1 family members (MXD1, MXI1, MXD3 
and MXD4), MNT and MGA antagonize MYC-dependent cell trans-
formation by transcriptional repression of the same E-box target DNA 
sequences13. The conservation of the MAX sequence is particularly 
high in the bHLHZip domain, which is involved in protein-protein 
interactions and DNA binding. In addition, it has been reported that 
phosphorylation of N- or C-terminal consensus signals for casein 
kinase II modulates MAX DNA binding properties14,15. With respect 
to PCC, it is well known that PC12 cells, derived from rat adrenal 
PCC, express a mutant form of MAX lacking the carboxyl terminus 
of the protein that is incapable of repressing transcription from E-box 
sequences5,16. Reintroduction of MAX in these cells results in tran-
scriptional repression and reduction in growth rate. These findings 
suggest that MAX disruption leads to increased cell proliferation and 
that MYC functions as a transcriptional regulator despite the lack of 
normally functioning MAX protein in PCC cells. In addition, the 
NRAS-PIK3CA-AKT1-mTOR axis is essential for the development 
of PCCs related to oncogenic c-RET–mediated cell transformation17, 
inactivation of the tumor suppressor NF1 (ref. 18) and mutation of 
the mTOR regulator TMEM127 (ref. 19). Because crosstalk between 
the NRAS-PIK3CA-AKT1-mTOR and MYC-MAX-MXD1 pathways 
has been reported20,21, it is not surprising that alterations in the cen-
tral regulating protein of the MYC network could also lead to PCC 
development. In agreement with this, it has been reported that MYC 
inhibits NRAS-mediated neuronal differentiation of PC12 cells by 
blocking c-Jun upregulation22. In addition, amplification and over-
expression of MYCN is a genetic hallmark in neuroblastoma6, another 
neural crest cell tumor mainly originating in the adrenal gland. Thus, 
MAX mutations in PCCs could avoid transcriptional repression by 
MAX of E-box target DNA sequences, leading to oncogenic MYCN 
deregulation as in neuroblastoma.
We decided to extend our screening for MAX mutations to a 
selected series of 59 cases with PCC without germline alterations in 
table 1 single nucleotide substitution filtering steps
Sample  
number
Total number 
of SNSs
Heterozygous  
SNSs
SNSs after  
HapMap control  
filtering
SNSs after  
dbSNP130  
filtering
SNSs after removing 
intronic and  
intergenic variants
SNSs affecting the 
same gene in the 
three samples
SNSs in coding 
regions  
(not in UTR)
SNSs after  
removing  
synonymous, 
deep<7, and 
Phred_qual<20
SNSs after 
removing entries 
in additional 
databasesa
924 95,100 28,292 9,088 2,911 763 41b 17 9 5
3037 92,855 26,859 7,884 3,066 789
3121 89,784 26,232 8,292 3,676 743
Average 92,580 27,128 8,421 3,218 765 41 17 9 5
Percent  
of SNSs  
remainingc
100 29.30 9.10 3.48 0.83 0.04 0.02 0.01 0.005
a1000 Genomes and dbSNP132. bA complete list of these variants is shown in supplementary table 1. cPercentage of single nucleotide substitutions (SNSs) after each filtering step.
Figure 1 Detection of MAX by immunohistochemistry with a MAX  
C-terminus–specific antibody. (a) Negative staining of tumor cells in a 
MAX-mutation–positive PCC compared to positive stromal cells (indicated 
with arrows). (b) Positive staining of a RET-mutated PCC. (c) Normal 
adrenal tissue showing MAX-positive staining.
a
100 µm
c
100 µm
100 µm
b
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the known susceptibility genes and who were 
highly suspected of having hereditary tumors 
because of the presence of bilateral adrenal PCC, age of onset below 
30 years and/or familial antecedents of the disease (Supplementary 
Table 2). We detected two additional truncating MAX mutations affect-
ing exon 3 (c.97C>T) and 4 (c.185_186delA) and three missense vari-
ants (c.67G>A, c.281T>C and c.425C>T) located in exons 3, 4 and 5, 
respectively (Table 2). Immunohistochemical analysis confirmed 
the lack of full-length MAX in the tumors with truncating variants. 
The c.67G>A and the c.425C>T variants affect two highly conserved 
amino acids (aspartic acid and serine) within two different casein 
kinase II recognition sites (Fig. 3), which suggests that these muta-
tions alter MAX function by modifying its DNA binding abilities. The 
c.281T>C mutation changed one of the conserved leucines located in 
the leucine zipper motif of the protein, which is necessary for MAX 
protein-protein interactions and oligomerization23,24. However, fur-
ther functional studies are needed to provide direct evidence of the 
pathogenic character of these three MAX missense variants. We found 
none of the five new variants in controls, and we confirmed chromo-
some 14q LOH caused by either chromosomal loss or UPD in three 
more tumors (Table 2), which is consistent with a pathogenic role of 
these MAX germline variants. The paternal transmission of the muta-
tion was known in the two hereditary cases and was confirmed by 
MEG3 methylation analysis in another case for which tumor material 
was available. Acquired segmental UPD is being increasingly recog-
nized as one of the mechanisms of LOH, and it therefore constitutes 
the somatic second hit of Knudson’s hypothesis for tumor suppres-
sor genes in a wide variety of neoplasms25–27. Moreover, paternal 
and maternal chromosome 14 UPD are known to contribute to the 
development of several malformation syndromes28, and interestingly, 
bilateral PCC was recently found in an individual with mosaicism 
for genome-wide paternal UPD29. Taking all these findings into 
account, it seems that MAX is mainly inactivated by this mechanism 
in the tumors. In addition, the paternal origin of the mutated allele 
detected in six families suggests a preferentially paternal transmis-
sion of the disease (P = 0.031). Regarding this, we confirmed both 
the absence of methylation in various CpG islands of the MAX pro-
moter in normal lymphocytes and the biallelic expression of MAX 
mutations in the mRNA of four cases (I.C.-M., A.C. & M.R., data not 
shown), which ruled out that the expression of this gene is affected 
a
C-MAX
D14S588 D14S1051 D14S1044
C-14q
C-1q
b
c
c.1A>G
T AGG AAG TG AGC G TA TA T G T GAAG GA
c.223C>T
CA GCA A G A TGA GC A
c.295+1G>A
1.00
B
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R
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51
C-
14
q
p13 p12 p11.2 q11.2 q12 q21.1 q24.3q31.1 q31.3 q32.2
Figure 2 Loss of heterozygosity (LOH) analysis 
of three tumors with MAX mutations. (a) Tumor 
DNA sequence chromatograms of the three 
MAX mutations showing, in each case, loss 
of the wild-type allele. (b) SNP array analysis 
of chromosome 14 performed with tumor 
DNA from the individual carrying the c.1A>G 
mutation shows uniparental disomy (UPD). The 
lower panel shows the genomic plots of the 
log R ratio (log2 Rcase/Rreference) indicating the 
presence of two alleles, and the upper panel 
shows the allele frequency parameters along 
chromosome 14, indicating LOH. Chromosomal 
locations of MAX, MEG3, C-14q control and 
microsatellites are indicated. (c) Multiplex PCR  
microsatellite analysis performed in blood 
(red) and tumor (blue) DNA from the individual 
carrying the c.223C>T mutation shows biallelic  
chromosome 14 amplification and LOH of the  
three informative microsatellites caused by UPD.  
C-14q, control amplicon from chromosome  
14q; C-1q, control amplicon from chromosome 
1q; C-MAX, control amplicon from the MAX locus.
table 2 Clinical features of individuals with MAX mutations
Family ID Sex
Age at  
onset
Familial  
antecedents Tumor Malignant
cDNA  
mutationa
Protein  
alterationa Tumor 2nd hit pMEG3
a 3121 M 29 Yesb bPCC No c.223C>T p.Arg75X UPD Yes
a 3119 M 35 – bPCC No c.223C>T p.Arg75X n.a. n.a.
a 1090 F 34 – bPCC No c.223C>T p.Arg75X n.a. n.a.
a 3122 F 28 – bPCC No c.223C>T p.Arg75X n.a. n.a.
b 3037 M 32 Yesc bPCC Yes c.295+1G>A p.? UPD Yes
c 924d F 46 Yesc bPCC Yes c.1A>G p.Met1? UPD Yes
c 922 M 29 – PCC No c.1A>G p.Met1? n.a. n.a.
d 190 M 17, 20 No bPCC No c.97C>T p.Arg33X 14q loss Yes
e 1016 F 47 Yesb bPCC No c.185_186delA p.Gln62AsnfsX23 14q loss Yes
f 368 F 26 No PCC Yes c.67G>A p.Asp23Asn n.a. n.a.
g 1075 F 22 No PCC No c.425C>T p.Ser142Leu n.a. n.a.
h F31S F 41 Yesb PCC No c.281T>C p.Leu94Pro UPD Yes
The three cases whose exomes were sequenced are shown in bold.
aAll cDNA and protein nomenclature is based on reference sequence ENST00000358664. bPaternal familial antecedents. cUnknown. dDeceased. bPCC, bilateral adrenal pheochromocytoma. 
UPD, uniparental disomy; n.a., not available; pMEG3, exclusive paternal MEG3 allele detection; cDNA, complementary DNA.
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by imprinting. This model of inheritance, if 
confirmed, would constitute the third example 
of sex-linked transmission in hereditary PCC, 
in addition to inheritance of mutated SDHAF2 
and SDHD (refs. 2,30). The absence of PCC in two children who 
inherited the mutation from their mother and in two obligate carriers 
of a different family further supports this theory (Supplementary 
Fig. 1a,c). The absence of familial antecedents in three of the eight 
MAX-mutation–positive cases with germline mutations is not unusual 
and could be caused by the suggested preferential paternal transmis-
sion. In fact, a substantial proportion of cases with PCC with apparently 
sporadic tumors harbor a germline mutation in one of the susceptibil-
ity genes described so far8. The appearance of bilateral adrenal PCC 
in eight of the twelve cases studied (Table 2) is in agreement with the 
association between bilaterality and the presence of germline altera-
tions in cases with PCC8 and underscores the importance of selecting 
cases with multiple tumors in screening for PCC susceptibility genes. In 
addition, malignant adrenal PCC is a rare condition, with the exception 
of cases carrying SDHB germline mutations. Notably, three out of eight 
probands showed metastases at diagnosis and another had familial 
antecedents of PCC-related malignancy, suggesting the association of 
MAX mutations with PCC aggressiveness.
Next-generation sequencing is steadily attracting interest as one of 
the most important tools for discovering genes responsible for geneti-
cally heterogeneous diseases. Moreover, exome sequencing represents 
the best option in this type of agnostic causal variant identification 
study over other strategies such as whole-genome sequencing. In the 
present study, next-generation sequencing allowed us to identify MAX 
as a new PCC tumor suppressor gene. The discovery of MAX germline 
mutations in individuals with hereditary adrenal tumors supports a 
key role for the MYC-MAX-MXD1 network in the development and 
progression of neural crest tumors. Moreover, the malignant behavior 
of MAX-related PCCs, similar to neuroblastomas with MYCN ampli-
fication, supports the idea that MAX loss of function is correlated to 
metastatic potential. The analysis of a larger series of cases will pro-
vide further information about the prevalence of MAX mutations in 
PCC and will clarify the phenotype associated with MAX mutations, 
which is of fundamental importance for both genetic counseling and 
genetic testing algorithms.
URLs. 1000 Genomes Project, http://www.1000genomes.org/; 
Novoalign, http://www.novocraft.com; R, http://www.r-project.org.
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Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. A full listing of the sequencing results have been 
deposited in the ArrayExpress database under accession number 
E-MTAB-591.
Note: Supplementary information is available on the Nature Genetics website.
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Cases and controls. Cases were clinically diagnosed with functioning or non-
functioning adrenal PCC in Spanish and Italian public hospitals. All cases 
tested negative for mutations in the seven major PCC susceptibility genes: 
VHL, RET, SDHB, SDHC, SDHD, SDHAF2 and TMEM127. Genomic DNA was 
extracted from blood following a standard method31. Tumor DNA from frozen 
and paraffin-embedded tissues was obtained using the DNeasy kit (QIAGEN) 
following the manufacturer’s instructions. Informed consent was obtained 
from all subjects. DNA samples from at least 375 unrelated, unaffected indi-
viduals were analyzed as controls. HapMap DNA samples used as quality 
and filtering controls for next-generation sequencing were extracted from 
the cell lines of seven individuals of European-American ancestry (NA11881, 
NA12144, NA12750, NA12761, NA12763, NA12813 and NA12892) originally 
sourced from Coriell Cell Repositories.
Exome enrichment and next-generation sequencing. DNA samples from 
cases and controls were enriched for exomic regions according to Agilent’s 
SureSelect Human All Exon Kit protocol (Agilent Technologies). Resulting 
DNA libraries were sequenced using 78-bp paired-end technology on an 
Illumina Genome Analyzer II following the manufacturer’s protocol. Two 
sequencing lanes per sample were used in order to obtain sufficient sequenc-
ing depth for the final variant analysis. Real-time image analysis and base 
calling was performed using Illumina’s Real Time Analysis software version 
1.6 using standard parameters.
Next-generation sequencing data analysis. Unaligned data from each of the 
four sequence files generated per individual (two files per sequencing lane, 
one for each of the pair ends) were merged into two files, one containing 
the information for the first sequencing pair for both lanes and the other 
containing the corresponding information for the other pair. Both files were 
then filtered coordinately to remove low-quality reads (containing six or more 
undefined bases), homopolymers and dinucleotide repetitions using an in-
house–developed Perl script (Quality-Control-1). Filtered files were aligned 
against the whole human genome (hg18 assembly) using Novoalign version 
2.06.09 (see URLs). Standard alignment settings were used, except for the 
gap extension penalty (set to five) and the option of reporting up to three 
alignment locations for those reads matching more than one region on the 
genome. Aligned SAM files were sorted by chromosome and coordinate and 
then analyzed with the Perl script Read_selection in order to select on-target 
reads with sufficient quality for subsequent analysis. SAMtools version 0.1.8 
(ref. 32) was used to remove PCR duplicates (rmdup option) and for variant 
calling (pileup option). SNS and indel data was extracted from pileup files 
using a Perl script (Pileup4annotation), which also calculated two scores: deep 
score and quality score (Supplementary Table 1). These scores represent a 
ratio between the read depth (deep) or the Phred-scaled quality score for the 
variant allele (Xv) and the reference allele (Xr):
Deepscore(or quality score) Xv
 Xr
= 

 × 100
Variant selection. SNS and indel data were analyzed separately. Using a series 
of newly developed Perl scripts, they were first confronted against two sets 
of variants (SNSs and indels, respectively) obtained from the seven HapMap 
controls using specific thresholds (see above) (Table 1). This comparison was 
performed with Perl scripts (Comp_against_controls-SNSs, Comp_against_
controls-INDELs). Next, both variant types were filtered against the informa-
tion in dbSNP130 and annotated using the Ensembl database in Annovar33. 
Variants in intergenic or intronic regions were subsequently discarded, and 
high-quality variants (deep > 7 and Phred quality > 20) affecting the same 
gene in all three samples and not producing synonymous amino acid changes 
in the resulting protein were selected.
MAX Sanger sequencing. Primers spanning the five exons of the major MAX 
transcript (ENST00000358664) were used to amplify germline DNA from the 
selected cases with PCC. The purified products were subsequently sequenced 
using the automatic sequencer ABI 3730xl (Applied Biosystems). Primer 
sequences and PCR conditions are available upon request.
RT-PCR. Total RNA was isolated from frozen tumor tissue carrying the muta-
tion c.295+1G>A using the TRI Reagent kit (MRC) following the manufactur-
er’s instructions. First-strand complementary DNA was synthesized from 2 µg 
of total RNA by oligo(dT)14 primer reverse transcription with Superscript II 
Reverse Transcriptase (Invitrogen) following the manufacturer’s instructions. 
PCR was then performed to generate a fragment spanning exons 1–5 of MAX 
transcript 2 (ENST00000358664) using the primers shown in Supplementary 
Table 3. The PCR products were analyzed by electrophoresis on a 2% agarose 
gel. Complementary DNA from peripheral blood lymphocytes of a healthy 
volunteer was used as control.
Loss of heterozygosity (LOH) and uniparental disomy (UPD) analyses. 
LOH analysis of the MAX locus was performed on seven tumors for which 
blood and tumor DNA were available. We first performed direct sequencing 
of tumor DNA using the same PCR conditions as we applied for germline 
DNA. To investigate the origin of the LOH found in the tumors, we performed 
high-density SNP-array analysis in one of the tumors. A genome-wide scan of 
616,795 markers was conducted on 250 ng of tumor DNA using the Illumina 
Human610-Quad BeadChip according to the manufacturer’s specifications. 
Image data was analyzed using the Chromosome Viewer tool contained in 
GenomeStudio 2010.2 (Illumina). The metric used was the log R ratio, which 
is the log ratio of the observed normalized R value for a SNP divided by the 
expected normalized R value34. In addition, an allele frequency analysis was 
applied for all SNPs. UPD or chromosomal loss was assessed in the other 
MAX-mutation–positive tumors by microsatellite analysis. Three polymorphic 
markers spanning chromosome 14 from the MAX locus to the telomere were 
selected (Supplementary Table 3) and analyzed by multiplex amplification. 
We first designed and labeled (5′ 6-FAM) a pair of primers for each marker. 
We used labeled control fragments from MAX and from chromosomes 1q and 
14q as internal controls. We amplified genomic and tumor DNA separately by 
means of a multiplex PCR kit (QIAGEN, GmbH), as previously described35. 
Purified PCR amplification products were used for fragment analysis on an 
ABI PRISM 310 capillary sequencer (Applied Biosystems) and analyzed using 
Peak Scanner Software v1.0 (Applied Biosystems). Normalization was per-
formed by overlapping each germline DNA sample with the corresponding 
tumor sample, determining the peak surface of all fragments and calculating 
the normal peak fractions. A second multiplex PCR that included control 
peaks from three different regions (chromosomes 5, 12 and 15), as well as 
one MAX amplicon and two 14q fragments, was performed to determine the 
loss of chromosome 14q. Finally, we genotyped various subtelomeric SNPs 
(Supplementary Table 3) both in blood and tumor DNA to assess the exten-
sion of the LOH.
Methylation of MEG3. To show the paternal origin of the mutated allele, we 
analyzed the methylation status of the MEG3 promoter in six cases for which 
tissue was available by conventional methylation-specific PCR using previ-
ously described primers and conditions36. Bisulphite treatment of tumor DNA 
was performed using the EZ DNA methylation kit (Zymo Research) accord-
ing to the manufacturer’s instructions. DNA from normal lymphocytes and 
from a RET-mutation–positive PCC were used as controls. PCR products were 
visualized by ethidium bromide staining after 2.5% agarose gel electrophoresis. 
A 160-bp PCR product represented the methylated state, and a 120-bp PCR 
product corresponded to the unmethylated maternal allele of MEG3. Statistical 
evidence for paternally transmission was assessed by a two-tailed binomial test 
using R version 2.9.0 (see URLs).
MAX protein analyses. Prior to showing the absence of full-length MAX 
in tumors carrying MAX truncating mutations, we evaluated the specificity 
of the sc-197 antibody (Santa Cruz Biotechnology) by protein blot in HeLa, 
Jurkat and PC12 cells (Supplementary Fig. 4). This is a commercial polyclo-
nal antibody raised against the C terminus of the human MAX protein that 
specifically recognizes translated MAX transcripts 1 (ENST00000358402) and 
2 (ENST00000358664). Proteins were separated by 4–12% SDS-PAGE and 
transferred to a polyvinylidene fluoride membrane as previously described37. 
The membrane was blocked and then incubated with a 1:200 dilution of the 
antibody following the manufacturer’s instructions. Equal protein loading 
was assessed using a 1:12,000 dilution of β actin antibody (A5441, Sigma). 
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Immunohistochemical staining was performed using 3 µm formalin-fixed 
 paraffin-embedded tumor sections from the five PCCs carrying truncat-
ing MAX mutations. Two normal adrenal sections and ten tumors carrying 
mutations in other PCC susceptibility genes (RET, NF1, SDHB, SDHD and 
TMEM127) were used as controls. After drying the sections in a 60 °C oven 
overnight, they were placed in a Bond MAX Automated Immunohistochemistry 
Vision Biosystem (Leica Microsystems GmbH) according to the following pro-
tocol: first, tissues were deparaffinized and pretreated with Epitope Retrieval 
Solution 2 (EDTA-buffer pH 8.8) at 98 °C for 20 min. After several washing 
steps, peroxidase blocking was carried out for 10 min using the Bond Polymer 
Refine Detection Kit DC9800 (Leica Microsystems GmbH). Tissues were again 
washed and then incubated with sc-197 MAX primary antibody (1:1600) for 
30 min. Subsequently, tissues were incubated with polymer for 15 min and 
developed with DAB-Chromogen for 10 min. Only cases showing nuclear 
staining of stromal cells were considered scorable.
31. Sambrook, J., Maniatis, T. & Fritsch, E.F. Molecular Cloning: A Laboratory Manual, 
3 v. (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).
32. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 
25, 2078–2079 (2009).
33. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic 
variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 
(2010).
34. Simon-Sanchez, J. et al. Genome-wide SNP assay reveals structural genomic 
variation, extended homozygosity and cell-line induced alterations in normal 
individuals. Hum. Mol. Genet. 16, 1–14 (2007).
35. Cascón, A. et al. Gross SDHB deletions in patients with paraganglioma detected 
by multiplex PCR: a possible hot spot? Genes Chromosom. Cancer 45, 213–219 
(2006).
36. Astuti, D. et al. Epigenetic alteration at the DLK1–GTL2 imprinted domain in human 
neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms’ tumour. 
Br. J. Cancer 92, 1574–1580 (2005).
37. Landa, I. et al. Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an 
increased risk of thyroid cancer and alters mRNA levels. Endocr. Relat. Cancer 17, 
317–328 (2010).
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Supplementary Figure 1. Pedigrees (a, b, and c) of the three patients (3121, 3037, and 924, respectively) 
used for NGS analysis (marked with an arrow). Studied carriers and non-carriers of the corresponding 
MAX mutation are indicated by the mutated and the wild type (WT) allele, respectively. Complete and 
partial filled symbols represent individuals with bilateral and unilateral PCC, respectively. 
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Supplementary Figure 2. MAX germline mutations identified by exome sequencing. a, DNA sequence 
chromatograms of the three MAX mutations. The left panels show the wild type (WT) alleles, and the 
right panels show the corresponding heterozygous germline mutation (indicated by an arrow); b, RT-PCR 
amplification, encompassing exons 1–5, of MAX wild type (WT) and c.295+1G>A tumor cDNAs. The 
arrows indicate the size of the WT (313bp) and the mutant (189bp) cDNAs. The lower part of the figure 
shows complete exon 4 skipping by direct sequencing of the mutated transcript. M: molecular size 
marker.
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Supplementary Figure 3. MEG3 methylation-specific PCR analysis. The study was performed in the tumor 
with known paternal transmission of the mutated allele (3121-T), and the two tumors with unknown 
origin of the mutated MAX allele (924-T and 3037-T). The methylated (160pb) and the unmethylated 
(120pb) alleles are denoted by arrows. NL: normal lymphocytes; C-T: RET PCC used as control.
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Supplementary Figure 4. Immunoblot experiment performed to assess the specificity of the C-terminus 
specific sc-197 MAX antibody. Band corresponding to MAX protein is absent in extracts from rat PC12 
cells, which express a defective protein lacking the C-terminus. ACTB: beta actin; NL: normal lymphocytes.
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Sample Consequence Ensembl gene Chr. Chromosomal position Reference Variant QUAL SNP_QUAL DEEP DS QS
924 UTR3 ENSG00000006634 7 87375469 T C 127 116 33 94,12 86,37
3037 UTR3 ENSG00000006634 7 87375469 T C 114 114 55 111,54 111,17
3121 UTR3 ENSG00000006634 7 87375469 T C 89 69 51 142,86 145,94
924 nonsynonymous SNV ENSG00000093010: 22 18330164 A G 36 36 25 200 73,86
3037 nonsynonymous SNV ENSG00000093010: 22 18330164 A G 18 18 16 166,67 51,18
3121 UTR3 ENSG00000093010 22 18336270 G C 36 36 27 28,57 25,93
924 nonsynonymous SNV ENSG00000106665: 7 73409685 C A 17 17 18 157,14 82,07
3037 nonsynonymous SNV ENSG00000106665: 7 73412498 C T 3 3 11 22,22 32,64
3121 nonsynonymous SNV ENSG00000106665: 7 73409685 C A 24 24 29 145,45 85,32
924 nonsynonymous SNV ENSG00000125952: 14 64638810 T C 49 49 19 58,33 45,12
3037 splicing ENSG00000125952: 14 64614383 C T 185 144 65 156 131,11
3121 stopgain SNV ENSG00000125952: 14 64614456 G A 97 97 139 76,92 79,72
924 UTR5 ENSG00000128059 4 56996426 A C 7 7 44 90,91 57,3
3037 synonymous SNV ENSG00000128059: 4 56963085 T C 130 130 129 98,46 99,08
3121 synonymous SNV ENSG00000128059: 4 56963085 T C 27 15 178 113,25 114,44
924 downstream ENSG00000163060 2 94906374 G A 34 34 16 33,33 35,03
3037 nonsynonymous SNV ENSG00000163060: 2 94901320 C G 19 19 36 25 20,98
3121 nonsynonymous SNV ENSG00000163060: 2 94901320 C G 53 53 33 37,5 35,96
924 nonsynonymous SNV ENSG00000169876: 7 100466086 A G 23 23 644 96,64 96,85
3037 nonsynonymous SNV ENSG00000169876: 7 100468685 A C 61 61 857 89,33 90,93
3121 nonsynonymous SNV ENSG00000169876: 7 100464350 C T 228 228 1605 77,61 76,6
924 nonsynonymous SNV ENSG00000174233: 12 47463072 C T 61 61 16 128,57 114,22
3037 nonsynonymous SNV ENSG00000174233: 12 47463072 C T 21 21 12 50 51,34
3121 nonsynonymous SNV ENSG00000174233: 12 47450878 C T 191 165 108 118,37 118,45
924 nonsynonymous SNV ENSG00000178209: 8 145064257 G A 88 32 14 333,33 245,61
3037 nonsynonymous SNV ENSG00000178209: 8 145096771 C T 76 73 12 100 82,7
3121 synonymous SNV ENSG00000178209: 8 145074058 G A 68 23 11 120 182,65
924 nonsynonymous SNV ENSG00000178401: 12 48029409 G A 228 191 56 143,48 155,48
3037 nonsynonymous SNV ENSG00000178401: 12 48029409 G A 195 195 76 92,31 109,36
3121 UTR3 ENSG00000178401 12 48031596 G A 67 67 71 62,79 64,09
Supplementary Table 1. List of variants that passed the first six filtering steps
924 nonsynonymous SNV ENSG00000184185: 17 21260453 C A 22 16 97 96,67 77,72
3037 nonsynonymous SNV ENSG00000184185: 17 21260360 C G 9 9 243 77,91 74,92
3121 UTR3 ENSG00000184185 17 21260582 C A 42 18 22 125 145,61
924 nonsynonymous SNV ENSG00000184584: 5 138838109 C G 212 212 68 71,79 79,05
3037 nonsynonymous SNV ENSG00000184584: 5 138838109 C G 183 183 63 65,79 70,77
3121 nonsynonymous SNV ENSG00000184584: 5 138838109 C G 200 200 72 84,62 74,7
924 synonymous SNV ENSG00000187634: 1 856285 C T 100 100 23 53,33 54,63
3037 nonsynonymous SNV ENSG00000187634: 1 868971 A C 9 9 12 125 61,11
3121 nonsynonymous SNV ENSG00000187634: 1 867426 A G 9 9 10 28,57 26,25
924 nonsynonymous SNV ENSG00000198502: 6 32597822 C T 96 65 17 183,33 112,02
3037 UTR5 ENSG00000198502 6 32606012 G C 44 38 14 140 145,51
3121 nonsynonymous SNV ENSG00000198502: 6 32597744 A G 15 15 14 62,5 31,95
924 downstream ENSG00000200434 16 33873213 T C 6 6 14 100 79,66
3037 downstream ENSG00000200434 16 33873128 T C 44 5 85 175 174,31
3121 downstream ENSG00000200434 16 33873188 C T 57 57 12 50 49,34
924 nonsynonymous SNV ENSG00000204525: 6 31432910 A C 51 51 14 55,56 60,28
3037 upstream ENSG00000204525 6 31432975 G A 19 19 7 40 43,37
3121 nonsynonymous SNV ENSG00000204525: 6 31432003 C A 133 68 36 176,92 170,54
924 nonsynonymous SNV ENSG00000206503: 6 30020321 G A 65 65 136 56,98 59,5
3037 UTR5 ENSG00000206503 6 30018244 G T 61 61 9 80 82,78
3121 UTR3 ENSG00000206503 6 30021323 G C 36 11 103 43,48 43,64
QUAL: Phred-scaled consensus quality for the site.
SNP_QUAL: Phred-scaled probability of the consensus being identical to the reference.
DEEP: Number of reads covering a given position. Also known as read depth.
DS: Deep Score
QS: Quality Score
Supplementary Table 2. Clinical features of selected patients screened for 
MAX mutations 
ID Sex Age at onset Tumor Malignant Familal antecedents 
100 M 11 bPCC* No No 
475 M 16 bPCC No No 
249 M 19 bPCC No No 
1694 M 19 bPCC No No 
190 M 22 bPCC No No 
554 F 34 bPCC No No 
60 M 36 bPCC No No 
83 M 37 bPCC No No 
416 F 38 bPCC No No 
974 M 38 bPCC No No 
329 F 40 bPCC Yes No 
3468 F 43 bPCC No No 
183 M 44 bPCC No No 
525 F 46 bPCC No No 
796 F 46 bPCC No No 
1016 F 47 bPCC No Yes 
874 M 48 bPCC No No 
3514 F 56 bPCC No No 
1049 M 59 bPCC No No 
F004 F 62 bPCC No No 
1299 M 74 bPCC No No 
912 M 75 bPCC Yes No 
490 M 80 bPCC No No 
960 M 5 PCC No No 
754 F 9 PCC No No 
115 M 11 PCC No No 
92 F 11 PCC No No 
F084 F 13 PCC No No 
F132 F 13 PCC No No 
3406 M 14 PCC No No 
555 M 15 PCC No No 
F088 F 15 PCC No No 
3558 M 17 PCC No No 
424 F 19 PCC No No 
908 M 21 PCC No No 
1078 F 22 PCC No No 
650 F 22 PCC No No 
1075 F 22 PCC No No 
S190 M 23 PCC No No 
285 F 23 PCC No No 
473 F 23 PCC Yes No 
3245 M 23 PCC No No 
1746 M 24 PCC No No 
1048 M 25 PCC Yes No 
368 F 26 PCC Yes No 
717 F 26 PCC No No 
F011 M 26 PCC No No 
F021 F 26 PCC No No 
258 M 26 PCC Yes No 
671 F 27 PCC No No 
F015K F 27 PCC No No 
246 F 28 PCC No No 
3388 M 28 PCC No No 
565 M 29 PCC No No 
1079 F 29 PCC No No 
1351 M 42 PCC No Yes 
3030 F 48 PCC No Yes 
612 F 50 PCC No Yes 
3510 M 50 PCC No Yes 
 
*bPCC,
 
bilateral adrenal pheochromocytoma 
 
 
Supplementary Table 3. Primers used for amplification of cDNA and polymorphic markers 
 
 
Name Primer sequence 5’-3’ 
 
cDNA 
 
 
 
Microsatellites 
 
 
 
 
 
 
 
SNPs 
 
MAX-F 
MAX-R 
 
 
D14S588-F 
D14S588-R 
D14S1044-F 
D14S1044-R 
D14S1051-F 
D14S1051-R 
 
 
rs17101145-rs13379319-F 
rs17101145-rs13379319-R 
rs3783398-F 
rs3783398-R 
rs56729078-rs60916402-F 
rs56729078-rs60916402-R 
rs3730358-rs2494737-F 
rs3730358-rs2494737-R 
  
AGAGCGACGAAGAGCAACCGA 
TTGGTCTGCAGTTGGGCACT 
 
 
GCCGAAAGAAAGAAAAAAGG 
CGAATGCATACTTGCTGTTG 
AAGTCCTTGCTTTGCAGGTT 
ATTGTTTTCACTGGTTGTTGTTCAT 
TCAATGAGGCCAAAGC 
TGTTGACGGTCCCTTG 
 
 
TATCATCAGGGGCTGACCTC 
CGTTACAGCATGGTTTGGAG 
TTAAAAGACAGGGCCCATTG 
TGCCGAAGAAGTCATCTGTG 
CAGGCTGGTCCTGTCTCCT 
GGGACCATTAGCAGAGAAAGC 
AGTCTGCCTTCCCGTTGAC 
CAGCCAGTGCTTGTTGCTT 
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ABSTRACT 
 In the first NGS-based project we discovered the involvement of the MAX gene in susceptibility to 
develop PCC/PGL. How this gene contributes to tumor development and the associated phenotype 
remains unclear. The second aim of this thesis was to study the prevalence of MAX mutations in PCC/PGL 
patients and the associated phenotypic features of MAX-mutated patients. 
 We first sequenced MAX in 1,694 patients with PCC or PGL, without mutations in other major 
susceptibility genes, from 17 independent referral centers. We also screened for large 
deletions/duplications in 1,535 patients using a multiplex PCR-based method. We screened the tumors 
from an additional 245 patients for somatic mutations.  
 Sixteen pathogenic MAX mutations were identified in 23 index patients. All had adrenal tumors, 
13 were bilateral or multiple PCCs within the same gland and 3 developed additional tumors at thoraco-
abdominal sites. This latter finding extends the implication of MAX to extradrenal tumors. Moreover, it 
was found that 37% of mutation carriers had familial antecedents appearing in the paternal branch of 
their pedigree, with more than one generation of affected members. The age at diagnosis was 
significantly lower for MAX mutation carriers than for non-carrier cases. Besides, only 10.5% of patients 
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developed metastatic disease, so we reconsidered our initial hypothesis about the metastatic potential of 
MAX-related tumors. Five tumors carried mutations in MAX, four of them confirmed as somatic (1.6%) 
pointing the importance of the MAX gene in this disease. Regarding catecholamines secretion, MAX 
tumors were characterized by substantial increases in normetanephrine, associated with normal or minor 
increases in metanephrine.   
 In summary, we determined that germline mutations in MAX are responsible for 1.1% of PCC/PGL 
in patients without evidence of other known mutations and should be considered in the genetic work-up 
of these patients. 
 
Personal contribution: I participated in the conception and design of the study and the acquisition of the 
data. I was actively involved in the screening for the large insertions/deletions using a multiplex PCR-
based method and in the posterior computational analysis. Finally, I contributed to the discussion of the 
results and the drafting of the paper. 
Human Cancer Biology
MAX Mutations Cause Hereditary and Sporadic
Pheochromocytoma and Paraganglioma
Nelly Burnichon1,2,3, Alberto Cascon8,11, Francesca Schiavi12, Nicole PaesMorales14, I~naki Comino-Mendez8,
Nassera Abermil1,2,3, Lucía Inglada-Perez8,11, Aguirre A. de Cubas8, Laurence Amar2,3,4, Marta Barontini16,
Sandra Bernaldo de Quiros17, Jero^me Bertherat2,5, Yves-Jean Bignon18, Marinus J. Blok19, Sara Bobisse12,
Salud Borrego11,20, Maurizio Castellano21, Philippe Chanson6, María-Dolores Chiara17,
Eleonora P.M. Corssmit22, Mara Giacche21, Ronald R. de Krijger24, Tonino Ercolino25, Xavier Girerd7,
Encarna B. Gomez-García19, Alvaro Gomez-Gra~na8, Isabelle Guilhem28, Frederik J. Hes23, Emiliano Hon-
rado29, Esther Korpershoek24, JacquesW.M. Lenders30, Rocío Leton8, Arjen R.Mensenkamp31, AnnaMerlo17,
Luigi Mori21, Arnaud Murat33, Peggy Pierre34, Pierre-Franc¸ois Plouin2,3,4, Tamara Prodanov36,
Miguel Quesada-Charneco37, Nan Qin38, Elena Rapizzi26, Victoria Raymond39, Nicole Reisch40,
Giovanna Roncador9, Macarena Ruiz-Ferrer11,20, Frank Schillo41, Alexander P.A. Stegmann19,
Carlos Suarez17, Elisa Taschin12, Henri J.L.M. Timmers32, Carli M.J. Tops23, Miguel Urioste10,11,
Felix Beuschlein40, Karel Pacak35, Massimo Mannelli26,27, Patricia L. M. Dahia14,15, Giuseppe Opocher13,
Graeme Eisenhofer38, Anne-Paule Gimenez-Roqueplo1,2,3, and Mercedes Robledo8,11
Abstract
Purpose: Pheochromocytomas (PCC) and paragangliomas (PGL) are genetically heterogeneous neural
crest–derived neoplasms. Recently we identified germline mutations in a new tumor suppressor suscep-
tibility gene, MAX (MYC-associated factor X), which predisposes carriers to PCC. How MAX mutations
contribute to PCC/PGL and associated phenotypes remain unclear. This study aimed to examine the
prevalence and associated phenotypic features of germline and somatic MAX mutations in PCC/PGL.
Design: We sequenced MAX in 1,694 patients with PCC or PGL (without mutations in other major
susceptibility genes) from 17 independent referral centers. We screened for large deletions/duplications in
1,535 patients using a multiplex PCR-based method. Somatic mutations were searched for in tumors from
an additional 245 patients. The frequency and type of MAX mutation was assessed overall and by clinical
characteristics.
Results: Sixteen MAX pathogenic mutations were identified in 23 index patients. All had adrenal
tumors, including 13 bilateral or multiple PCCs within the same gland (P < 0.001), 15.8% developed
additional tumors at thoracoabdominal sites, and 37% had familial antecedents. Age at diagnosis was
lower (P ¼ 0.001) in MAX mutation carriers compared with nonmutated cases. Two patients (10.5%)
developed metastatic disease. A mutation affecting MAX was found in five tumors, four of them
confirmed as somatic (1.65%). MAX tumors were characterized by substantial increases in normeta-
nephrine, associated with normal or minor increases in metanephrine.
Conclusions: Germline mutations in MAX are responsible for 1.12% of PCC/PGL in patients without
evidence of other known mutations and should be considered in the genetic work-up of these patients.
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Introduction
Pheochromocytoma (PCC)has been referred to as "the 10
percent" tumor due in part to the belief that 10% are
hereditary and usually associated with 3 well-known cancer
syndromes: vonHippel–Lindau disease,multiple endocrine
neoplasia type 2, and neurofibromatosis type 1 due to
mutations in VHL (1), RET (2), and NF1 (3), respectively.
The 10 percent rule was challenged after identification of
germline mutations in SDHD, SDHB, and SDHC as impor-
tant causes of familial paraganglioma (PGL; refs. 4–6) that
ledNeumannand colleagues to establish that up to a quarter
of affected patients carried a PCC/PGL susceptibility gene
mutation (7). Since then 3 additional susceptibility genes
(SDHAF2, SDHA, and TMEM127) (8–10) have been iden-
tified. Thus, the proportion of hereditary PCC/PGLs may
exceed estimates of 30% to 40% (11, 12), rendering PCC/
PGL one of the most inherited tumor entities in existence.
Findings of other patients with a clinical presentation of
PCC/PGL that includes a positive family history, early age of
presentation, and bilateral adrenal or multiple tumors, but
without known mutations, has suggested the presence of
further susceptibility genes. With this observation in mind,
we recently identified MAX (MYC-associated factor X) as a
new PCC tumor suppressor susceptibility gene in 3 inde-
pendent patients with familial antecedents of the disease
(13). Further analysis of 59 patients, selected because they
hadbilateral PCCand/or anearly ageofdiseasepresentation,
allowed detection of 5 additional cases withMAXmutations
(13). Preliminary genotype–phenotype associations sug-
gested MAX mutations were associated with bilateral PCC
and an apparent paternal transmission of the disease (13).
Although little is known about genetic alterations in spora-
dic tumors, it has been proposed that mutations in PCC/PGL
susceptibility genes are detrimental for neuronal precursor
cells, explaining the apparent rarity of somatic mutations in
thesegenes in apparently sporadic PCC/PGL (14, 15).Guided
by transcriptome classification and LOH profiles of a large
series of 202 PCC/PGL, we nevertheless recently established
that 14% of sporadic tumors harbored somatic mutations
in VHL or RET genes (16). Because deregulation of MYC is
a prominent hallmark in numerous forms of cancer (17),
with activation of MYC genes commonly detected in solid
human tumors (18), it is plausible thatMAX somatic muta-
tions may also occur in sporadic PCC/PGL.
Establishing the above associations and the prevalence of
MAX mutations among patients with PCC/PGL requires
analysis of a larger cohort of patients. In a large interna-
tional collaborative effort, we therefore screened for the
presence of germline mutations affecting MAX in 1,694
patients without mutations in major PCC/PGL susceptibil-
ity genes. Somatic mutations were searched for in tumors
from an additional 245 patients.
Materials and Methods
Patients
The study population consisted of 1,694 apparently
unrelated index cases with PCC or PGL, from whom
blood-leukocyte DNA samples were available and in whom
familial antecedents, presence of metastasis, and number of
primary tumors are shown in Table 1. Clinical variables
collected for this study were the following: gender, number
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of PCC/PGLs, tumor location, age of diagnosis for each
tumor (in patients with multiple tumors), the biochemical
secretion when available, as well as other malignancies
developed by probands. These clinical variables were col-
lected electronically into preformatted forms provided to all
contributors, and statistically analyzed in a single center.
More detailed assessment of clinical data was further
obtained for MAX mutation carriers. Mutations in RET,
VHL, SDHB, SDHC, SDHD, and TMEM127 were excluded,
and there were no clinical features of neurofibromatosis
type 1. Patients were referred from 15 participating centers
of the EuropeanNetwork for the Study of Adrenal Tumours
(ENS@T) consortium[Madrid,Oviedo, andSeville in Spain
(12), Paris, Marseille and Angers in France (19, 20), Leiden,
Rotterdam, Nijmegen, and Maastricht in The Netherlands,
Padua, Florence, and Brescia in Italy (11), Munich and
Dresden in Germany] and 2 centers in the United States
(SanAntonio andBethesda).Diagnosis of PCCand/or PGL,
including tumors of both sympathetic (thoracic or abdom-
inal) and parasympathetic (head and neck) origin, was
established following conventional procedures (including
clinical, biochemical, and imaging tests).
Written informed consent to collect phenotypic and
genotypic data was obtained from all participants in accor-
dance with institution review board–approved protocols
for each center. DNA from 400 unrelated and unaffected
individuals was analyzed as controls.
Tumors
Frozen tumors obtained from a total of 245 apparently
unrelated patients without known mutations in the men-
tioned susceptibility genes were collected through the Spanish
National Tumor BankNetwork inMadrid (Spain; ref. 21), the
ErasmusMCTissueBank inRotterdam(Netherlands),Munich
(Germany), the International Familial Pheochromocytoma
Consortium of San Antonio and Bethesda (22), Nijmegen
Pheochromocytoma Tissue Bank, and the COMETE network
in Paris, France (Table 1; refs. 16, 23). From these 245
samples, 106 belonged to patients included in the germline
screening. The remaining 139 tumors represented indepen-
dent cohort. For samples with identified MAX mutations,
the corresponding mutation was assessed in constitutive
DNAwhenavailable to classify themas germlineor somatic.
Molecular genetic analyses
Complete genetic characterization of MAX included
both point mutation and gross deletion/duplication ana-
lyses, the latter done in 1,535 cases with good DNA
quality. Primers spanning the 5 exons and intron–exon
boundaries of the MAX transcript 2 (ENST00000358664,
NM_002382.3) were used as previously described (13).
To assess for rearrangements, a semiquantitative multi-
plex-PCR method using labeled primers was designed as
previously described for other genes (24). PCR conditions
and primers are available upon request. To assess the
pathogenicity of variants we used Alamut mutation inter-
pretation software (http://www.interactive-biosoftware.
com/software.html).
LOH was estimated by direct sequencing when tumor
DNA was available. Uniparental disomy or chromosomal
loss was assessed by microsatellite analysis as previously
described (13).
Immunohistochemistry
Immunohistochemical staining was done using 3-mm
formalin-fixed paraffin-embedded tumor sections from
Table 1. Clinical features of the entire pheochromocytoma and paraganglioma cohort
Analysis Clinical features n Single PCC Single PGL
H&N/TA
mPGL
H&N/TA/both
PCC&PGL
H&N/TA/both
bPCC/mPCC
Index
cases
Total 1,694a 1,252 315 29 35 63
110/205 1/23/5 1/34/0
With familial antecedentsb (%) 37 (2.18%) 24 (1.91%) 5 (1.58%) 0 2 (5.71%) 6 (9.52%)
Malignantc (%) 129 (7.61%) 79 (6.30%) 27 (8.57%) 2 (6.89%) 15 (42.85%) 6 (9.52%)
Gender (female/male/unknown) 1,003/682/9
Median age ﬁrst tumor (range) 48 (3–88)
Total 245d 216 29
Tumors Gender (female/male) 150/95
Median age (range) 52 (11–83)
Abbreviations: PCC, adrenal pheochromocytoma; PGL, paraganglioma; mPGL, multiple paragangliomas; bPCC, bilateral adrenal
pheochromocytoma; mPCC, multiple pheochromocytomas within the same gland; H&N, Head and Neck; TA, thoracoabdominal;
Both – H&N and TA PGL.
aIndex cases origin (n): France (664), Italy (428), Spain (245), The Netherlands (166), United States (152), Germany (39).
bA hereditary cause of PCC/PGL was considered likely when disease affected at least two family members.
cMalignancy was deﬁned as the presence of metastases in which chromafﬁn cells are normally absent.
dTumor origin (n): France (106), United States (75), The Netherlands (39), Spain (17), Germany (8).
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tumors carrying MAX mutations, as previously described
(13). Normal adrenal sections and tumors carrying muta-
tions in other PCC susceptibility genes were used as con-
trols. Only cases showing nuclear staining of stromal cells
were considered as evaluable.
Biochemical test results and biologic features
Biochemical test results available in patients with MAX
mutations included urinary fractionated metanephrines
in 16 patients measured as part of the routine diagnostic
work-up at participating centers, either by liquid chro-
matography with electrochemical detection (LC-EC) or
tandem mass spectrometry. Concentrations of catechola-
mines (epinephrine, norepinephrine, and dopamine) in
tumor tissue available from 7 patients with MAX muta-
tions were quantified in frozen specimens by LC-EC as
described elsewhere (25). Results were compared with
historical data from 57 patients in one group with muta-
tions of VHL (n¼ 44), SDHB (n¼ 10), and SDHD (n¼ 3)
and 36 patients in the other group with RET (n ¼ 31)
and NF1 (n ¼ 5) mutations, in all of whom tumor
tissue catecholamine results were available (26). Tran-
scriptomic data, involving 2 different microarray plat-
forms (Affymetrix for the French series and Agilent for
Spanish series; refs. 27, 28), were further used to deter-
mine the expression of mRNA for phenylethanolamine
N-methyltransferase (PNMT).
Statistical analysis
Statistical analyses were carried out using SPSS software
package version 17.0 (SPSS, Inc.). The 4 patients carrying
variants of unknown significance (VUS) and a subject in
whom it was not possible to establish the germline status
were not considered for statistical purposes. Thus, only
patients with mutations leading to truncated proteins or
affecting conserved amino acids were included in the final
analysis. Differences between mutation carriers and non-
mutation carriers for gender, adrenal multiple tumors,
familial history, and malignancy were assessed using a c2
test or Fisher exact test, where appropriate. Because age,
biochemical, and gene expression data could not be estab-
lished to be normally distributed, nonparametric analysis
by Mann–Whitney and Kruskal–Wallis tests were used to
assess statistical significance of differences in these variables
among the different groups examined.
Results
Germline and somatic MAX variants
Among the 1,694 patients with PCC and/or PGL and no
evident germline mutations in RET, VHL, SDHB, SDHC,
SDHD, and TMEM127 genes (Table 1), we identified 16
different heterozygous variants affecting 23 subjects that
spanned all 5 exons of the MAX gene (Fig. 1; Table 2). In
addition, we analyzed MAX in 245 tumors (Table 1) and
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Figure 1. Schematic representation ofMAX [transcript ENST00000358664] mutations identiﬁed in this study. The bottom panel shows the conservation of the
amino acids altered by pathogenic missense changes (underlined). Double arrows delimit protein domains between the ﬁrst and the last missense mutation.
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found 4 cases (1.65%) carrying a mutation that was con-
firmed as somatic by the finding of no mutation in the
germline DNA (Table 2). A fifth tumor with a MAX muta-
tion (case 24, Table 2)wasnot considered in further analysis
because it was not possible to establish its germline status.
None of the variants were found in at least 400 controls, or
in public databases (dbSNP132 and1000Genomes Project;
www.1000genomes.org/).
Table 2. Genetic and clinical features of the 28 MAX positive patientsa and tumorsW
ID Gender/
age
Fam PCC PGL Mets Other
diseased
cDNA mutationb/
Protein alterationb
Predicted
Pathogenicityc
LOH IHC
1 M/27 No PCC No No No c.1-?_483þ?del/p.? n.a. Yes Neg
2 F/46 No bPCC 1 TA No No c.2T>A/p.? n.a. YesUPD Neg
3 F/43 No bPCC 4 TA No BrC, RO c.73C>T/p.(Arg25Trp) Y — —
4 M/23 Yes bPCC No No No c.97C>T/p.(Arg33) n.a. — —
5 M/27 Yesp bPCC &
mPCC
No No No c.97C>T/p.(Arg33) n.a. Yes —
6 M/34 Nodn bPCC No No No c.97C>T/p.(Arg33) n.a. Yes Neg
7 F/58 Yes mPCC No No No c.97C>T/p.(Arg33) n.a. Yes Neg
8 F/26 Yesp PCC No No No c.97C>T/p.(Arg33) n.a. Yes Neg
9 M/38 No PCC No No SCCT c.97C>T/p.(Arg33) n.a. — —
10 M/24 Yes bPCC No No CCH c.97C>T/p.(Arg33) n.a. — —
11 F/43 No PCC 1TA No No c.97C>T/p.(Arg33) n.a. Yes —
12 F/18 No bPCC No No No c.171þ1G>A/p.? n.a. Yes —
13 F/55 No bPCC No No No c.178C>T/p.(Arg60Trp) Y — —
14 F/34 No bPCC No No No c.212T>G/p.(Ile71Ser) Y YesUPD Pos
15 M/57 No mPCC No No PA c.220A>G/p.(Met74Val) Y Yes Pos
16 M/18 No bPCC No No 1oHPT c.223C>T/p.(Arg75) n.a. — —
17 F/18 Yes PCC No Yes No c.244C>T/p.(Gln82) n.a. — —
18 F/40 No bPCC 1 TA Yes No c.295þ1G>T/p.? n.a. Yes Neg
19 M/13 Yesp PCC No No No c.305T>C/p.(Leu102Pro) Y — —
20e F/48 No — 1 H&N No No c.-18C>T/p.(¼) N — —
21e M/13 No PCC 1 TA No No c.25G>T/p.(Val9Leu) N No Pos
22e M/22 No PCC No No No c.63G>T/p.(¼) N No —
23e F/80 No PCC No No No c.414G>A/p.(¼) N — —
24Wg F/29 No PCC No No No c.269G>C/p.(Arg90Pro) Y Yes —
25W f M/39 No PCC No No No c.223C>T/p.(Arg75) n.a. Yes Neg
26W f F/57 No PCC No No RC c.103C>T/p.(Arg35Cys) Y Yes Pos
27W f M/24 No PCC No No No c.140_157del/p.(Arg47_Ser52del) n.a. Yes Neg
28W f F/56 No PCC No No No c.25del/p.(Val9Trpfs56) n.a. YesUPD Neg
Abbreviations. Gender: F, female; M, male. Fam: familial antecedents; PCC, adrenal pheochromocytoma; bPCC, bilateral adrenal
pheochromocytoma; mPCC, multiple pheochromocytomas within the same gland; PGL, paraganglioma; H&N, Head and Neck; TA,
thoracoabdominal; Mets, presence of metastases in which chromafﬁn cells are normally absent; Other disease: BrC, breast Cancer;
RO, renal oncocytoma; SCCT, squamous cell carcinoma of the tongue; CCH, C-cell hyperplasia; PA, pituitary adenoma; 1oHPT,
primary hyperparathyroidism; RC, renal carcinoma; n.a., not applicable;—, not available; UPD, uniparental disomy; IHC, immuno-
histochemistry: Pos, positive; Neg, negative.
aOnly data from probands are shown in the table.
bAll cDNA and protein nomenclature is based on reference sequence ENST00000358664. All MAX variants were named following
Human Genome Variation Society and checked using Mutalyzer Name Checker (www.mutalyzer.nl).
cPathogenicity potential of missense variants was examined by Alamut mutation interpretation software (version 2.5), which provides
variant interpretation according to several prediction methods (AlignGVGD, Polyphen, SIFT, ESEﬁnder, GeneSplicer, RESCUE-ESE).
dOther tumors in the proband.
pPaternal familial antecedents.
dnde novo case.
eVUS, not considered for examination of phenotypic associations.
fSomatic mutation.
gThis tumor was not considered in further analysis because it was not possible to establish its germline status.
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Overall, taking into account the germline and the
somatic findings, we identified 18 novel variants affecting
MAX and 2 previously reported mutations, c.97C>T and
c.223C>T (13). Seven mutations disrupted the MAX
protein because they affected the initial methionine
(c.2T>A), created a premature stop codon (c.25del,
c.97C>T, c.223C>T, and c.244C>T) or affected a donor/
acceptor splice site (c.171 þ 1G>A and c.295 þ 1G>T;
Fig. 1). In addition, 2 deletions were identified: the first
caused an in-frame loss of 6 highly conserved amino
acids within the first helix of the protein (c.140_157del),
and the second, detected by multiplex-PCR (Supplemen-
tary Fig. S1), spanned the whole gene (c.1-?_483þ?del).
Immunohistochemical detection of MAX in tumor-
embedded paraffin slides showed complete loss of the
protein in all analyzed tumors that carried truncating
mutations (Supplementary Fig. S2).
Among the 11 nontruncating variants, 7 mutations
(c.73C>T, c.103C>T, c.178C>T, c.212T>G, c.220A>G,
c.269G>C, and c.305T>C) changed conserved or highly
conserved amino acids located within the basic helix-
loop-helix leucine zipper (bHLH-Zip) domain of the MAX
protein (Fig. 1) and were classified as deleterious by the
Alamut software. The remaining 4 nontruncating variants
(c.25G>T, c.63G>T, c.414G>A, and c.-18C>T) were classi-
fied as VUS because these were predicted as benign through
bioinformatic tools; it was also not possible to show their
pathogenicity with further analyses (Table 2). Positive im-
munohistochemistry staining was observed in all nontrun-
cating variants assessed (Supplementary Fig. S2).
LOH of the MAX wild-type allele was found in 16 of
18 tumors analyzed (Table 2). MAX wild-type allele was
present in 2 tumor associated with the variants c.25G >
T/p.(Val9Leu), and c.63G>T/p.(¼), both considered as
VUS.
In summary, we found pathogenic germline MAX var-
iants in the 1.12% of the 1,694 index cases included in this
analysis. All mutations, except one gross deletion, consisted
of a single nucleotide substitution.
Clinical presentation of MAX carriers
Only those 19 patients who harbored a germline var-
iant defined as pathogenic were considered for examina-
tion of phenotypic associations (Table 2). The presence
of familial antecedents of disease was found in 7 of the
19 patients (37%) and appeared in the paternal branch
in the 3 pedigrees with more than one generation
of affected members (Supplementary Fig. S3). These 19
patients developed at least one PCC, with 13 (68.4%)
showing either bilateral PCC or multiple PCCs within the
same gland, a 48-fold higher rate (P < 0.001) than in
MAX-negative cases (4.28%). Age at diagnosis was lower
(P < 0.001) in mutation carriers than in cases without
mutations (median 34, range 13–58 years vs. 48 range
3–88 years). Three of the 19 patients (15.8%) developed
additional tumors at thoracoabdominal sites at a median
age of 48 years (range 44–64 years). Importantly, these
tumors presented as PGLs, distinct from recurrences of
the earlier adrenal tumors. Two patients (10.5%) devel-
oped metastatic disease.
Among 4 sporadic cases with MAX somatic mutations,
the median age at diagnosis was 47.5 years (range 24–
57 years), which was not significantly different from those
with MAX-negative sporadic tumors (median 52, range
11–83 years; Table 1).
Biochemical test results and biologic features
All patients with MAX mutations showed increased
urinary outputs of normetanephrine that did not differ
from patients in the group with VHL and SDHB/D muta-
tions or the other with RET and NF1 mutations (Fig. 2A).
In contrast, urinary outputs of metanephrine were either
normal or moderately increased in patients with MAX
mutations and showed an intermediate distribution,
significantly (P < 0.001) higher than in the VHL/SDH
group, but lower than in the RET/NF1 group (Fig. 2B).
Similarly, tumor tissue concentrations of epinephrine
also showed an intermediate distribution, representing
8.4% of total catecholamine contents in MAX tumors, a
proportion 5.6-fold higher (P < 0.001) than in VHL/SDH
tumors, but a sixth (P ¼ 0.003) that in RET/NF1 tumors
(Fig. 2C). Furthermore, levels of PNMT expression
in MAX tumors were 14-fold higher (P < 0.001) than in
VHL/SDH tumors and a little under a half (P ¼ 0.05) than
in RET/NF1/TMEM127 tumors (Fig. 2D).
Discussion
It is widely accepted thatMYCderegulation is not restrict-
ed to translocations and amplifications at the MYC locus,
which suggests that the impact of its deregulation onhuman
cancer incidence is higher than previously thought (18).We
recently found MAX germline mutations in patients with
PCC (13), suggesting that alterations in thismost important
regulator of theMYC/MAX/MXD1 network promote hered-
itary susceptibility to neoplasias. This study followed up on
these observations, taking advantage of a large international
collaborative network to determine the prevalence and the
genotype–phenotype correlations of MAX mutations in
1,694 PCC/PGL patients previously negative for 6 major
PCC/PGL susceptibility genes. We establish here that MAX
germlinemutations are responsible for the disease in 1.12%
of cases, a similar contribution to that of the recently
reported TMEM127 mutation (29). Furthermore, our find-
ings reveal the presence of MAX somatic mutations in
sporadic tumors, extend the spectrum of MAX-related
tumors to PGLs, ascertain that MAX tumors are not partic-
ularly prone to malignancy, and show that MAX tumors
produce predominantly norepinephrine, but with some
capacity to also produce epinephrine.
Though it has been reported that somatic mutations in
the known PCC susceptibility genes constitute an extremely
rare event, we recently found 14% of sporadic PCC/PGL
carrying somatic mutations in VHL or RET (16). The pres-
ence of somatic MAX mutations in 1.65% of sporadic
tumors described here is in agreement with this latter
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finding and highlights the importance of the MYC/MAX/
MXD1 network in the development of neural crest tumors.
It is well known that somatic amplification and overexpres-
sion of MYCN is a genetic hallmark in neuroblastoma
(30), so ablation of MAX transcriptional repression of
MYC in PCC could lead to the same oncogenic MYC
dysregulation that occurs in neuroblastoma. Nevertheless,
no meaningful trend for a contribution ofMAX mutations
to other neoplasms, including neuroblastoma, was found
in the current series.
The identified variants were distributed along the gene
but were especially frequent in exons 3 and 4, matching
some of the most important residues within the conserved
bHLH-Zip domain of MAX. The majority of mutations lead
to truncated proteins, and the expected LOH affecting the
remaining wild-type allele of the MAX tumor suppressor
gene was further supported by the absence of the protein
by immunohistochemistry.
The most frequently found mutation was the previously
described c.97C > T variant (13) discovered in 8 unrelated
Figure 2. Dot-box plots illustrating
urinary outputs of normetanephrine
(A) and metanephrine (B), tumor
tissue contents of epinephrine (C),
and expression of PNMT mRNA (D)
for patients with MAX mutations
compared with those with VHL and
SDHB/Dmutations or RET,NF1, and
TMEM127 mutations.
B P < 0.001
P = 0.001P < 0.001
Not significant
Not significant
A
Upper limits of 
1,000,000
100,000
10,000
1,000
100
70
50
30
20
7
5
3
2
0.7
0.5
0.3
0.2
0.1
0.07
0.05
0.03
10
1
10
7
5
4
3
2
1
0.7
0.5
0.4
0.3
0.2
0.1
0.07
0.05
0.04
0.03
0.02
700
7,000
70,000
700,000
500,000
300,000
200,000
50,000
30,000
20,000
5,000
3,000
2,000
500
300
200
100,000
10,000
1,000
700
7,000
70,000
50,000
40,000
30,000
20,000
5,000
4,000
3,000
2,000
500
400
300
200
reference intervals
Upper limits of 
reference intervals
C P < 0.001P = 0.05P < 0.001
DP < 0.001
P = 0.003P = 0.001
VHL/SDH RET/NF1 MAXVHL/SDH
Ur
in
e 
no
rm
et
an
ep
hr
in
e 
ou
tp
ut
 (n
mo
l/d
)
Tu
m
or
 e
pi
ne
ph
rin
e 
co
nt
en
t (
%)
PN
M
T 
m
R
N
A
 e
xp
re
ss
io
n 
(n
or
ma
liz
ed
)
Ur
in
e 
m
et
an
ep
hr
in
e 
ou
tp
ut
 (n
mo
l/d
)
RET/NF1 MAX
VHL/SDH RET/NF1 MAX VHL/SDH RET/NF1
TMEM127
MAX
MAX Causes Pheochromocytoma and Paraganglioma
www.aacrjournals.org Clin Cancer Res; 18(10) May 15, 2012 OF7
 American Association for Cancer Research Copyright © 2012 
 on May 4, 2012clincancerres.aacrjournals.orgDownloaded from 
Published OnlineFirst on March 27, 2012; DOI:10.1158/1078-0432.CCR-12-0160
patients from 5 nations (Italy, Spain, United States, France,
and The Netherlands). This recurrent mutation affects a
CpG dinucleotide located contiguous to Glu32, the crucial
residue for DNA binding, and represents the first hotspot
mutation affectingMAX. In agreement with this, one of the
c.97C > T mutation carriers was a de novo case, further
suggesting the high mutability of this dinucleotide. The 6
missense variants that altered conservedMAX residues were
predicted as deleterious by the Alamut software (Table 2)
andhavebeen reported as critical for dimerization andDNA
binding of HLH proteins or for interactions within the
protein structure (31, 32). Mutations affecting highly
conserved amino acids within the bHLH-Zip domain of
MAX, involved in protein–protein interactions and DNA
binding, can be expected to destroy the ability of MAX to
antagonize MYC-dependent cell transformation leading
to tumor development.
The absence of familial antecedents in more than 65% of
individuals, as well as the paternal transmission identified
in 3 pedigrees, further supports previous suggestions of a
paternal mode of transmission (13). This mode of inher-
itance, with its consequence of generation skipping, com-
plicates identification of candidate mutation carriers. In
general, the phenotypic characteristics of MAX mutant
patients overlap with clinical features observed for other
PCC/PGL-related hereditary disorders. For example, the
presence of a significant proportion of bilateral/multiple
PCC cases among MAX germline mutation carriers, repre-
senting 21% (13 of 63) of patients included in this cohort
(Table 1), is in agreement with the high percentage (35%–
60%) of bilateral tumors found in patients with mutations
in VHL, RET, or TMEM127 (7, 29, 33, 34). The age at
diagnosis of PCCs inMAXmutation carriers (34 years) was
clearly lower than in negative cases (48 years), also lower
than the reported on average in patients with TMEM127,
RET, and NF1 mutations (38–42 years), but higher to that
for VHL and SDH mutation carriers (27–32 years; refs. 19,
20, 29, 33–35).
Extraadrenal thoracoabdominal PGL are relatively com-
mon compared with adrenal tumors in patients with SDHB
and SDHDmutations, less common in TMEM127 and VHL
mutation carriers, and rarely associated with RET and NF1
germline mutations (12, 33, 36). Interestingly, in all MAX
patients with PGL, the extraadrenal tumor was diagnosed
after the adrenal tumor. This contrasts with VHL patients
with head andneck PGLs, 50%ofwhomshowedno adrenal
tumors (34). In this study, only 2 patients developedmetas-
tasis, suggesting that unlike SDHBmutations, mutations of
MAX are not associated with a high risk of malignancy.
The catecholamine-related information available from
patients withMAXmutations indicated a biochemical phe-
notype intermediate between the established phenotypes of
epinephrine producing tumors due to NF1 and RET muta-
tions and the predominantly norepinephrine producing
tumors due to VHL or SDHB/Dmutations (26). This inter-
mediate diagnostic phenotype,manifested by at least 3-fold
larger tumor-associated increases in urinary outputs of
normetanephrine than of metanephrine, was explained by
a significant but limited capacity to produce epinephrine.
This latter finding is supported by the intermediate tissue
concentrations of epinephrine and expression of mRNA for
PNMT, the enzyme responsible for conversion of norepi-
nephrine to epinephrine. The intermediate biochemical
phenotype associated with MAX mutations, together with
lack of MAX immunohistochemical staining of tumor tis-
sue,may prove useful for guiding testing of theMAX gene in
patients with PCC/PGLs.
In summary, this study involving an unprecedented
international effort to genotype and phenotype a substan-
tial number of patients with PCC/PGLs reveals the impor-
tance of theMYC/MAX/MXD1 network in the development
of bothhereditary and sporadic forms of these tumors.MAX
is the tenth PCC/PGL susceptibility gene described to date,
which now should be considered in the genetic work-up of
affected patients.
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Supplementary material: 
Supplementary figure S1. Gross MAX deletion analysis 
 
Peak Scanner analysis of amplified PCR fragments using MAX multiplex assay (including all exons) of a 
control sample (blue) overlapped with the proband’s sample (red). Fragments MP-C1, MP-C2, MP-C3, 
and MP-C4 were used as internal controls of the assay. 50% of amplification (indicating the presence of 
only one allele) is denoted by a horizontal dotted line. 
 
Supplementary figure S2. Immunohistochemical assesment. 
 
Detection of MAX by immunohistochemistry with a MAX C-terminus–specific antibody. (a) Negative 
staining of tumor cells in a PCC of a patient carrying a MAX truncating mutation, compared to positive 
stromal cells (indicated with arrows). (b) Positive staining of PCC tumor cells in a case with a MAX 
missense mutation. (c) Positive staining of a RET-mutated PCC.  
 
 
Supplementary figure S3. Pedigree of 3 families with affected relatives in more than one generation. 
 
Probands are denoted by arrows. Unilateral PCC are represented by black semi-circles or semi-squares 
and bilateral PCC are represented by black squares.  #denotes an obligate carrier, affected with a 
lymphoma, and lung cancer, represented by a black upper left segment.  
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ABSTRACT 
 Besides clearly pathogenic mutations, the two previous studies included in this thesis, identified 
an appreciable number of variants of unknown significance (VUS) affecting MAX. In order to establish the 
potential role of MAX VUS in the disease and help in the clinical management of carriers of these variants, 
we constructed a PC12-based functional model. In addition, we proposed a consensus computational 
prediction method based on five “state of the art” algorithms, combined with relevant clinical data. For 
all but two of the twelve VUS considered, the functional assay and the consensus computational 
prediction gave consistent results; seven variants were classified as pathogenic and three as non-
pathogenic. The introduction of wild-type MAX cDNA into PC12 cells significantly decreased MYC’s ability 
to bind to canonical E-boxes, while pathogenic MAX proteins were not able to fully repress MYC activity. 
This latter result further suggested that, at least in PCC/PGL, MAX exerted a predominant role as a 
negative regulator of the MYC/MAX/MXD1. Further clinical and molecular evaluation of variant carriers 
corroborated the results obtained with our functional assessment. 
 In summary, in the absence of clear heritability, a combination of clinical and molecular data, with 
consensus computational prediction and a reliable functional model, are able to correctly classify VUS in 
MAX. 
 
Personal contribution: I participated in the conception and design of the study as well as in the 
acquisition of the data. I carried out the cloning and site-directed mutagenesis assays, the luciferase 
experiments, the consensus in silico prediction and other experiments. Finally, I contributed to the 
discussion of the results and the drafting of the paper. 
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ABSTRACT 
The presence of germline mutations affecting the MAX gene has recently been identified as one of the 
now eleven major genetic predisposition factors for the development of hereditary pheochromocytoma 
and/or paraganglioma. Little is known regarding how missense variants of unknown significance (VUS) in 
MAX affect its pivotal role in the regulation of the MYC/MAX/MXD axis. In the present study, we propose 
a consensus computational prediction based on five “state of the art” algorithms. We also describe a 
PC12-based functional assay to assess the effects that twelve MAX VUS may have on MYC’s E-box 
transcriptional activation. For all but two of these twelve VUS, the functional assay and the consensus 
computational prediction gave consistent results; we classified seven variants as pathogenic and three as 
non-pathogenic. The introduction of wild-type MAX cDNA into PC12 cells significantly decreased MYC’s 
ability to bind to canonical E-boxes, while pathogenic MAX proteins were not able to fully repress MYC 
activity. Further clinical and molecular evaluation of variant carriers corroborated the results obtained 
with our functional assessment. In the absence of clear heritability, clinical information and molecular 
data, consensus computational predictions and functional models are able to correctly classify VUS 
affecting MAX. 
 
KEY WORDS: Pheochromocytoma; paraganglioma; PC12 cells; variants of unknown significance; MAX. 
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INTRODUCTION 
 Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors; PCC are 
localized in the adrenal medulla and PGL in the intra-abdominal, thoracic or head and neck paraganglia. 
Around 30–40% of individuals with PCC/PGL are familial cases [1-4] due to germline mutations affecting 
one of five succinate dehydrogenase genes (SDHA, SDHB, SDHC, SDHD and SDHAF2), the RET oncogene, 
or the tumor suppressor genes (TSG) VHL, NF1, FH, TMEM127 and KIF1B beta [5-17]. Recently, we 
identified MYC-associated protein X (MAX) as new PCC susceptibility gene by sequencing the exomes of 
three patients with shared clinical features of hereditary disease [18]. The subsequent analysis of an 
independent series of patients with PCC/PGL showed that around one percent of cases negative for 
mutations in the other known susceptibility genes carried a germline mutation affecting MAX [19]. This 
result confirmed that MAX is a new TSG associated with the development of hereditary PCC/PGL and 
highlighted the importance of including MAX in the algorithms used in the genetic diagnosis of the 
disease. Also consistent with MAX acting as a TSG in cancers with neuroendocrinal features is the recent 
finding of tumor-specific inactivation of MAX in small cell lung cancer [20]. 
MAX is a ubiquitously expressed and highly conserved transcription factor, which plays a central 
role in the regulation of the MYC/MAX/MXD network of basic helix-loop-helix leucine zipper (bHLHZip) 
transcription factors involved in cell proliferation, differentiation and apoptosis [21]. MYC, via 
heterodimerization with MAX, activates the transcription at target promoters by binding hexameric DNA 
consensus sequences “CANNTG” (E-boxes) [22]. In addition, MAX antagonizes MYC-dependent cell 
transformation by transcriptional repression of the same E-boxes through its interaction with several 
repressors (MXD, MNT, and MGA) [23]. The repression of MYC's transforming ability depends on the 
balance between MYC–MAX and MXD/MNT/MGA–MAX complexes [23]. Moreover, MAX homodimers 
can also repress the transcription of genes activated by MYC-MAX heterodimers by reducing the 
population of free MAX monomers and by binding to E-box DNA sequences [24]. The fact that MYC can 
maintain its function in the absence of normally functioning MAX protein [25] suggests that the pivotal 
role of MAX in the network can be related more to repression than to activation [26]. 
To date, twenty-six MAX variants have been reported to be associated with PCC/PGL, and almost 
half of these are missense alterations [18, 19, 27]. While truncating mutations in TSGs are usually 
considered deleterious, establishing the pathogenicity of a missense variant requires further analysis (e.g. 
identifying the presence of a second hit or loss of heterozygosity). In silico algorithms are widely used to 
predict the biological consequences of variants of unknown significance (VUS); however, in the absence 
of other biological evidence they are insufficient to conclude whether a variant is causal. Therefore, in 
order to improve the genetic counseling and clinical follow-up of variant carriers it is necessary to develop 
functional systems to clarify the role that an individual VUS may have in tumor development. The 
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characterization of MAX VUS described herein is based on three consecutive approaches: (i) modeling the 
affected residue in the protein structure in order to predict the effect of the alterations at the molecular 
level (ii) using five algorithms (SIFT, Polyphen, MutPred, SNPs&GO and PON-P2) to obtain a consensus 
prediction of plausible functional effects caused by the variants and (iii) implementing a luciferase-
reporter assay in PC12 cells to assess disruptions in MYC regulation.  
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MATERIALS AND METHODS 
Variants  
 Twelve non-truncating missense variants in MAX, eleven of which had been previously reported 
[18, 19] were included in the present analyses: p.V9L, p.D14N, p.R16W, p.R26C, p.R51W, p.I62S, p.M65V, 
p.R81P, p.L85P, p.L93P, p.N105T and p.S133L (Table 1). The numbering of variants was based upon the 
MAX transcript of 151 amino acids (NM_145112.1), though to avoid confusion with the previously 
reported numbering of MAX mutations (based on the transcript of 160 amino acids, NM_002382.3) we 
provide the correspondence of the variants in Table 1. None of the variants assessed were found in 
controls or reported in public databases of SNPs (http://www.1000genomes.org/ and 
http://evs.gs.washington.edu/EVS/), with the exception of p.V9L which appears in 1 of 470 exomes from 
the ClinSeq project (http://www.genome.gov/20519355). Three somatic missense variants affecting 
amino acids R26, R51 and M65 were reported in the COSMIC 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) database, but the changes were different 
from those considered in the present study. 
 
In silico prediction 
 We used the SIFT algorithm [28] and the programs PolyPhen-2 [29], MutPred [30], SNPs&GO [31] 
and PON-P2 (http://structure.bmc.lu.se/PON-P2/) to predict the impact of each of the twelve MAX VUS 
on protein structure/function. SIFT uses multiple alignment information to predict tolerated and not 
tolerated (deleterious) substitutions for every position of a given query sequence. PolyPhen-2 categorizes 
variants as benign, possibly damaging, or probably damaging based on a sequence-based characterization 
of the substitution site, profile analysis of homologous sequences, and mapping of the substitution site to 
a known protein’s 3-dimentional structure. MutPred uses multiple alignment information, but also 
includes information on the gain/loss of 14 different structural and functional properties to assign a 
pathogenicity score; we considered scores greater than 0.5 to define pathogenicity. SNPs&GO predicts 
whether a variant is disease-related or neutral by exploiting the functional annotation of the protein. 
Finally, PON-P2 predicts the pathogenicity of amino acid substitutions based on amino acid features, 
Gene Ontology (GO) annotations, evolutionary conservation, and if available, annotations of functional 
sites. PON-P2 estimates the reliability of predictions and groups variants into pathogenic, neutral and 
unknown classes. In addition, we used the metaservers PredictSNP [32] and Meta-SNP [33] to validate the 
results obtained by our consensus prediction. These programs use a compendium of in silico algorithms 
to establish a consensus prediction. The consensus prediction given by PredictSNP is based on MAPP, 
PhD-SNP, PolyPhen-1, Polyphen-2, SIFT, SNAP nsSNPAnalyzer and PANTHER. Meta-SNP consensus 
prediction is based on PANTHER, PhD-SNP, SIFT and SNAP.  
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 To assess for the concordance between the in silico predictions and the results of the functional 
assays, a one-sided binomial test was applied. 
 
Structural mapping 
 The coordinates of the MAX-MAX-DNA (1HLO) and MAX-MYC-DNA (1NKP) crystal structures were 
downloaded from the Protein Data Bank and superimposed using the secondary structure alignment 
algorithm implemented in Coot [34]. The variations were then modeled using the “mutate replace” 
routine in the same program. Figures were generated using PyMol (The PyMOL Molecular Graphics 
System, Version 1.2r3pre, Schrödinger, LLC.) 
 
cDNA cloning and mutagenesis 
 A full length sequence of the MAX transcript of 151 amino acids (NM_145112.1) was amplified 
from human peripheral lymphocyte cDNA and cloned into the expression vector pcDNA3.1 (+) 
(Invitrogen, Eugene, OR). The twelve MAX missense variants were generated by mutagenesis using the 
QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), according to the 
manufacturer’s instructions. The designed primers used to generate all mutated alleles are described in 
the Online Resource (Online Resource, Table S1). Both wild-type and mutagenized inserts were verified 
by sequencing both strands.  
 
Cell culture and luciferase assays 
 PC12 cells were cultured in Dulbecco’s modified Eagle medium Gluta MAX (DMEM; Invitrogen), 
supplemented with 10% (v/v) foetal bovine serum (FBS, PAA laboratories, Westborough, MA, USA), 5% 
horse serum (Gibco, Grand Island, NY, USA), 1% (v/v) penicillin/streptomycin and 0.6% (v/v) Fungizone 
(Gibco). Cells were routinely tested for mycoplasma and transfected with Lipofectamine 2000 
(Invitrogen), following the manufacturer’s instructions. PC12 cells were seeded at 200,000 cells per well 
on 24-well plates for 72h before transfection. pBV-Luc wt MBS1-4 (luciferase reporter; Addgene, 
Cambridge, MA, USA), containing four tandem DNA binding sites for the MYC/MAX heterodimer was used 
as a reporter plasmid. Each well of a 24-well plate was transfected with 0.3 μg of pcDNA3.1 (EV), 
pcDNA3.1-MAXwt or pcDNA3.1-MAXmut constructs, pRL-SV40 (Renilla reporter; Promega, Madison, WI, 
USA) (10ng) and pBV-Luc wt MBS1-4 (0.6μg). After 48h, cells were washed and lysed in 100μl of Passive 
Lysis Buffer (Promega) and luminescence recorded using the Dual-Luciferase assay system (Promega), 
according to manufacturer’s instructions. The plate was read on a Turner Biosystems Veritas Microplate 
Luminometer (Promega). We present as results the mean and standard error of at least three 
independent transfections. To explore potential dominant negative mechanisms occurring variants for 
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which LOH was not or could not be observed, we transfected PC12 cells with equal amounts (0.3 µg) of 
MAX-wt and each of these variants, as well as MAX-wt and a nonsense truncating mutation used as 
control (p.R24X), (Online Resource, Fig S2). We expected that if a dominant negative effect were present, 
the mutant MAX proteins would interfere with the wt MAX, leading to differences in the functional assay, 
compared with a truncated (null) MAX protein or the wt MAX alone. 
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RESULTS 
VUS introduce structural alterations in the MAX protein 
 The twelve non-truncating missense variants in MAX described so far were included in the 
present analyses: p.V9L, p.D14N, p.R16W, p.R26C, p.R51W, p.I62S, p.M65V, p.R81P, p.L85P, p.L93P, 
p.N105T and p.S133L. Nine of the twelve VUS affect conserved or highly conserved amino acids located 
within the basic helix-loop-helix leucine zipper (bHLH-Zip) domain of the MAX protein (Online Resource, 
Fig S1). The other three variants, p.V9L, p.N105T and p.S133L, are also conserved but are located outside 
this region. Table 1 summarizes their predicted structural effects. Four variants (p.D14N, p.R16W, p.R26C 
and p.R51W) were predicted to affect DNA-binding, based on the interaction of each of these residues 
with DNA in the wild-type protein (Figure 1). Two variants (p.I62S and p.M65V) probably affect the 
homodimerization of MAX and its heterodimerization with MYC, and three variants (p.R81P, p.L85P and 
p.L93P) introduce proline, a residue that produces substantial kinks in α-helices affecting the structure of 
the protein. The amino acids V9, N105 and S133 are not observed in the reported protein structures [35, 
36], probably due to the intrinsic disorder of these regions, located in the N- and C-termini of the protein.  
 
In-silico prediction algorithms show high discrepancy in predicting the pathogenicity of MAX VUS 
 Only four variants (p.R16W, p.R26C, p.R51W and p.I62S) were classified as pathogenic by the five 
prediction algorithms considered. Three variants were considered disease-causing by four programs 
(p.R81P, p.L85P and p.L93P), one by two (p.M65V), and two variants by just one program (p.D14N and 
p.S133L). Only two variants were predicted to be non-pathogenic by all the prediction methods (p.V9L 
and p.N105T). Thus, a consensus prediction based on the agreement of at least three programs was 
available for 11 of the twelve VUS analyzed. These results are shown in Table 1. Furthermore, the four 
MAX polymorphic missense variants present in the Exome Variant Server (EVS) database (p.D5G, p.D12E, 
p.Y115H and p.G136R) were classified as non-pathogenic by this consensus prediction (data not shown). 
To assess the reliability of our consensus prediction, all variants were tested using two different online 
available metasevers, PredictSNP and Meta-SNP. The consensus established by each of these for the 
twelve variants studied were in agreement with the consensus prediction proposed herein except for the 
variant p.S133L, which was classified as pathogenic by the two metaservers. On the other hand, the 
unique variant unclassified by our consensus prediction (p.M65V) was classified as non pathogenic. The 
four MAX polymorphic missense variants described in the EVS database were also predicted to be non 
pathogenic.  
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Pathogenic MAX variants repress to a lesser extent MYC’s E-box binding ability  
 PC12 cells carry a homozygous chromosomal alteration involving the MAX gene which gives rise 
to a protein incapable of repressing MYC–dependent transcription from E-box elements [26]. To 
determine whether each non-truncating variant had an effect on the regulation of MYC by MAX, we co-
transfected PC12 cells with a reporter plasmid containing four E-boxes and expression vectors containing 
either MAX wild-type cDNA, the empty vector (EV) or the VUS in question. Significantly higher luciferase 
activity relative to wild-type MAX (p<0.05) was observed for all variants, with the exception of p.D14N, 
p.N105T and p.S133L (Figure 2). The concordance of the results of the functional assays with the 
consensus prediction was highly statistically significant (p=1.1x10-19), and higher than the concordance 
with each of the in silico prediction algorithms. Thus, all the variants predicted by at least three in silico 
algorithms as deleterious were found to significantly alter the ability of MAX to regulate MYC. 
Furthermore, three of the four missense variants predicted to be non-pathogenic, p.D14N, p.N105T and 
p.S133L, showed luciferase activities similar to wild-type MAX, while cells transfected with the p.M65V 
variant (the only unclassified change in the consensus prediction), exhibited significant differences 
compared to the control. The p.V9L alteration, predicted by all the methods to be benign and tolerated, 
was found to substantially affect MYC’s E-box transcriptional activation. 
 As expected, transfection of PC12 cells with EV led to significantly higher luciferase levels than 
transfection with wild-type MAX (Figure 2). The absence of LOH in the tumor carrying the p.V9L variation 
suggested that a dominant negative mechanism could be acting in this particular case. Moreover, three 
additional variations (p.R25W, p.R60W, and p.L102P) were not analyzed for LOH. To explore possible 
dominant negative mechanims we transfected PC12 cells with wild-type MAX alone and in combination 
with: a nonsense truncating mutation (p.R24X) and the p.V9L, p.R25W, p.R60W, and p.L102P variations 
(Online Resource, Fig S2). There was no difference in luciferase levels, compared to the control, 
associated with either the p.V9L or the other three variations tested, which suggests that a dominant 
negative effect does not occur for these alterations. 
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DISCUSSION 
 In the absence of informative pedigrees to assess the co-segregation of a novel amino acid 
substitution with a hereditary disease, other indicators, such as the presence of the variant in other 
patients, its absence in controls, and/or the finding of other distinctive syndromic clinical features in the 
patient are widely used to classify its pathogenicity. When all the above methods fail to classify VUS, 
prediction algorithms can be used. Many of these in silico methods have been specifically created to 
evaluate whether a given alteration may have a biological consequence. However, the different 
algorithms often give discrepant results, and this makes the establishment of the clinical relevance of a 
new variant a challenge. MAX is one of the major susceptibility genes that have most recently 
incorporated into the picture of hereditary predisposition to PCC/PGL. Half of all reported MAX variants 
are missense alterations, each found only once (with the exception of p.S133L) [27] and mostly in 
patients without familial antecedents (probably due to a paternal transmission effect) [18, 19], so the 
development of a reliable method to determine their role in the disease is especially important. In the 
present study, we proposed a PC12-based model for classifying non-truncating MAX variants according to 
their potential functional effect. The proposed functional approach showed high concordance with the 
results from a consensus in silico prediction obtained from five “state of the art” prediction algorithms. 
No prediction of changes in MAX protein structural properties could be made for the variants 
p.V9L, p.N105T and p.S133L since they were not observed in the crystal structures. However, we were 
able to classify the other nine variants into three groups. The first comprised residues that are involved in 
protein-DNA interactions. Three of these missense variants consist of a change from arginine to 
hydrophobic tryptophan or cysteine. These variants alter the DNA binding properties of the protein to a 
different extent depending on each protein-DNA interaction, but all imply the loss of a residue commonly 
found in specific protein-DNA interactions. The p.D14N variant is an exception, involving the exchange of 
an acidic side chain for a polar one, which is also able to interact with the nucleic acid, indicating, as 
suggested by our data (Figure 2; Table 1), that this variation may not produce drastic consequences in the 
protein-DNA interaction. The second group of variants involved changes in the dimerization region of the 
protein. These variants strongly affect the MAX homodimer and therefore the assembly of monomers. 
The lack of MAX homodimers may make accessible for the transcription machinery the promoter regions 
of certain genes, which are normally repressed by MAX, thus facilitating their expression. The third group 
of variants involved the change from the wild-type residue to proline, a residue that alters the helical 
structure and may again lead to alterations in the hetero- or homo-dimerization capabilities of the 
mutated protein.  
When we classified variants according to the consensus of different combinations of five in silico 
predictors, the result differed from the functional classification for at least two variants (range: 2-5). This 
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improved on considering the consensus of at least three algorithms, and was further supported by the 
prediction specifically obtained for the four polymorphic missense MAX variants present in the EVS 
database. Though most computational methods used to investigate the disease association of coding 
variants take into consideration the protein sequence, structure, and conservation across species, recent 
studies have demonstrated that they give discrepant results [37]. It has previously been suggested that 
more reliable results may be obtained by integrating the predictions of several algorithms [38, 39]. The 
consistent results obtained in the present study between the consensus prediction and the functional 
assay further supports the validity of this approach. 
The presence of germline-inactivating MAX mutations in patients with hereditary PCC was the 
definitive evidence of the predominant role of MAX as a negative regulator of the MYC/MAX/MXD1 
network [26]. The luciferase-reporter assay described herein further supports this pivotal role of MAX in 
MYC regulation. Thus, transient expression of wild-type MAX protein in PC12 cells significantly decreases 
MYC’s ability to bind to canonical E-boxes (Figure 2). On the other hand, MAX mutant proteins less 
extensively repress MYC activity, thereby increasing luciferase activity, compared to wild-type MAX. Of 
note, the only variant that could not be classified by the consensus prediction (p.M65V) had an effect 
according to the assay. A different somatic change in the amino acid position 65 (to isoleucine) has been 
found in a prostate carcinoma, supporting its potential role in tumor development. Interestingly, the 
p.I62S variation that showed the most significant difference in the luciferase-reporter assay relative to 
the wild-type MAX, was the only variant predicted by MutPred to cause a gain of disorder in the MAX 
protein (p=0.0051). 
For the nine variants predicted to be pathogenic via our functional assays, other features 
corroborated these results. These included the presence of familial antecedents, segregation with disease 
in the pedigree, the development of multiple or bilateral tumors in the carrier, and the presence of the 
previously described MAX-associated secretion phenotype (norepinephrine and epinephrine) [19] and/or 
the detection of LOH in the tumor (Table 1). On the other hand, the three VUS with no functional effect 
on MYC regulation (p.D14N, p.N105T and p.S133L) were found in patients with isolated tumors and no 
clinical features of hereditary disease. Two additional variants (p.R26C and p.R81P) were also found in 
patients with unilateral PCC but the first was somatic, and in both cases LOH affecting the wild-type allele 
was detected in the tumor. The only contradictory result between the consensus prediction and the 
functional assays occurred for variant p.V9L, a controversial change found both in a patient (1/1,694 
cases) [19] who developed two sympathoadrenal tumors, and in 1/470 unaffected individuals (ClinSeq 
project). It has been recently suggested that even in the context of rare Mendelian disorders, the 
potential pathogenicity of variants reported by public databases should not be overlooked [40]. Although 
LOH was not observed in the tumor from the p.V9L variant carrier, the presence of both adrenal and 
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extra-adrenal tumors in this patient, as well as the intermediate norepinephrine/epinephrine secretion 
phenotype observed, suggest that this variation may be pathogenic. Overall, while this patient does not 
carry any other pathogenic variation in the known susceptibility PCC genes, the inconsistent data 
available do not allow us to reach a conclusion regarding the pathogenicity of this variant. 
 The appropriate management of relevant clinical information is one of the most effective tools 
used to decipher whether a germline VUS is causative. Nevertheless, the absence of clinical signs 
suggestive of heritability does not necessarily rule out that the variant is involved in the disease. In fact, 
MAX-associated tumor susceptibility exhibits paternal transmission of unknown origin, which makes the 
characterization of VUS even more complicated. In the present study, results from the clinical revision of 
cases and further molecular evaluation of both pathogenic and non-pathogenic alterations were 
consistent with the results obtained with our functional assays. 
Understanding the possible effects of VUS and elucidating a disease association is a pivotal 
research challenge. The assay proposed in the present study efficiently categorizes the vast majority of 
MAX VUS as pathogenic or non-pathogenic, based on the function disruption of the protein. In addition, 
the consensus prediction obtained from proven computational methods offers a useful tool that 
complements more direct functional tests. 
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 Table 1. Missense variants of unknown significance (VUS) investigated and results obtained from the analyses performed 
a
: numbering of variants is based on MAX transcript NM_145112.1; *: somatic mutation; 
b
: amino acid mutated in other tumors and reported in the COSMIC database 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/); 
§
: variant not reported; 
c
: amino acid not observed in the reported protein structures; 
¥
: variants with MutPred scores over 0.5 
were considered probably pathogenic; 
#
: the consensus prediction is based on the agreement of at least three predictors; U: unilateral PCC; P: paraganglioma; LOH: loss of 
heterozygosity detected in the tumor; n.a.: data not available; B: bilateral PCC; M: multiple PGLs, number of tumors is specified in parenthesis; FA: familial antecedents of PCC; NE: 
norepinephrine secretion; E: epinephrine secretion. Variants for which a likely pathogenic effect was predicted by each in silico algorithm are denoted in bold type. 
Protein varianta 
(original notation) 
Predicted structural 
alteration 
Polyphen-2 
prediction 
SIFT 
prediction 
MutPred 
prediction¥ 
SNPs&GO 
prediction 
PON-P2 
prediction 
Consensus 
prediction# 
Functional 
testing result 
Relevant clinical 
and/or molecular 
data 
p.V9L None observedc Benign Tolerated Non pathogenic Neutral Neutral Non pathogenic Alteration 
U, P, no LOH, 
NE+E 
p.D14N (p.D23N) DNA-binding Benign Not tolerated Non pathogenic Neutral Unknown Non pathogenic No effect U, LOH n.a. 
p.R16W (p.R25W) DNA-binding Probably damaging Not tolerated Pathogenic Disease-related Pathogenic Pathogenic Alteration 
B, M [4], LOH 
n.a., NE 
p.R26C (p.R35C*b) DNA-binding Probably damaging Not tolerated Pathogenic Disease-related Pathogenic Pathogenic Alteration U, LOH, NE+E 
p.R51W (p.R60Wb) DNA-binding Probably damaging Not tolerated Pathogenic Disease-related Pathogenic Pathogenic Alteration 
B, LOH n.a., 
NE+E 
p.I62S (p.I71S) Heterodimerization Probably damaging Not tolerated Pathogenic Disease-related Pathogenic Pathogenic Alteration B, LOH, NE+E 
p.M65V (p.M74Vb) Heterodimerization Benign Not tolerated Pathogenic Neutral Unknown Unclassified Alteration B, LOH, NE+E 
p.R81P (p.R90P) 
Helical properties 
affected 
Possibly damaging Not tolerated Non pathogenic Disease-related Pathogenic Pathogenic Alteration U, LOH 
p.L85P (p.L94P) 
Helical properties 
affected 
Possibly damaging Not tolerated Non pathogenic Disease-related Pathogenic Pathogenic Alteration U, FA, LOH 
p.L93P (p.L102P) 
Helical properties 
affected 
Probably damaging Not tolerated Pathogenic Neutral Pathogenic Pathogenic Alteration U, FA, LOH n.a. 
p.N105T (p.N114T)§ None observedc Benign Tolerated Non pathogenic Neutral Unknown Non pathogenic No effect P, LOH n.a. 
p.S133L (p.S142L) None observedc Possibly damaging Tolerated Non pathogenic Neutral Unknown Non pathogenic No effect 
U, LOH n.a., 
NE+E 
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 FIGURES 
 
 
Figure 1. Mapping of the twelve variants in the MAX-MAX-DNA (PDB file 1HLO) and MYC-MAX-DNA (PDB 
file 1NKP) crystallographic structures: A) Ribbon diagram of the MAX homodimer; B) Ribbon diagram of 
the MAX (green-colored chain)-MYC (flesh-colored chain) heterodimer bound to DNA (blue-colored 
chains); C) Structure guided sequence alignment of MAX. In A and B, the side chains of the amino acids in 
the mutated positions are colored in red. In C, the sequence common to both structures and the full-
length protein is shown with a red background, the positions of the mutations are depicted with an 
asterisk and the upper and lower lines of the alignment display the secondary structure of MAX in each 
PDB file; the alignment was generated with ESPRIPT.[41] 
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Figure 2. Luciferase-reporter assays performed in PC12 cells. pBV-Luc wt MBS1-4 luciferase construct was 
co-transfected in PC12 cells with pcDNA3.1 including either the wild-type MAX cDNA or one of the MAX 
VUS . The relative luciferase activity was calculated as the ratio of the firefly luciferase activity to the 
Renilla luciferase activity and expressed as mean±s.d. (n≥3). *: p-value <0.05; **: p-value <0.0001 
(compared in each case to the luciferase relative activity detected for the wild-type MAX cDNA). 
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Fig. S1. Sequence alignment of multiple amino acids from MAX proteins across various species. 
The conservation of the studied amino acids (marked with a vertical red bar) is shown at the 
bottom of the alignment. Conserved and similar residues are indicated with asterisks and dots 
below the alignment, respectively. Protein sequences were aligned using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). The following protein accession numbers were used 
in the alignment: Homo sapiens (GI:21704263), Macaca mulatta (GI:386780834), Rattus 
norvegicus (GI:485399), Mus musculus (GI:226051848), Sus scrofa (F2Z5K0), Felis catus 
(GI:57619109), Monodelphis domestica (GI:126282606), Danio rerio (GI:56207613), Tetraodon 
nigroviridis (H3BWK6), and Takifugu rubripes (GI:410898003). 
 
 
Fig. S2. Luciferase-reporter assays performed to explore dominant negative effects of MAX VUS. 
pBV-Luc wt MBS1-4 luciferase construct was co-transfected in PC12 cells with pcDNA3.1 including 
either the wild-type MAX cDNA, a control truncating mutation (p.R24X) or the four MAX VUS 
without demonstrated LOH . The relative luciferase activity was calculated as the ratio of the 
firefly luciferase activity to the Renilla luciferase activity and expressed as mean±s.d. (n≥3). 
 
 
 
 
 
 
Table S1. Primer sequences used in the mutagenesis experiments  
 
Variant Primer name Sequence (5' to 3') 
p.V9L 
p.V9L _S 5'-aacgatgacatcgagttggagagcgacgctg-3' 
p.V9L _AS 5'-cagcgtcgctctccaactcgatgtcatcgtt-3' 
p.D14N 
p.D14N_S 5'-ggtggagagcgacgctaacaaacgggctc-3' 
p.D14N_AS 5'-ggtggagagcgacgctaacaaacgggctc-3' 
p.R16W 
p.R16W_S 5'-ggagagcgacgctgacaaatgggctcatca-3' 
p.R16W_AS 5'-tgatgagcccatttgtcagcgtcgctctcc-3' 
p.R24X 
p.R24X_S 5'-catcataatgcactggaatgaaaacgtagggaccaca-3' 
p.R24X_AS 5'-tgtggtccctacgttttcattccagtgcattatgatg-3' 
p.R26C 
p.R26C_S 5'-tcatcataatgcactggaacgaaaatgtagggaccacatc-3' 
p.R26C_AS 5'-gatgtggtccctacattttcgttccagtgcattatgatga-3' 
p.R51W 
p.R51W_S 5'-ggagagaaggcatcctgggcccaaatcctag-3' 
p.R51W_AS 5'-ctaggatttgggcccaggatgccttctctcc-3' 
p.I62S 
p.I62S_S 5'-cctagacaaagccacagaatatagccagtatatgcgaag-3' 
p.I62S_AS 5'-cttcgcatatactggctatattctgtggctttgtctagg-3' 
p.M65V 
p.M65V_S 5'-agacaaagccacagaatatatccagtatgtgcgaaggaaaaacc-3' 
p.M65V_AS 5'-ggtttttccttcgcacatactggatatattctgtggctttgtct-3' 
p.R81P 
p.R81P_S 5'-attgacgacctcaagccgcagaatgctcttctg-3' 
p.R81P_AS 5'-cagaagagcattctgcggcttgaggtcgtcaat-3' 
p.L85P 
p.L85P_S 5'-tcaagcggcagaatgctcctctggagcag–3’ 
p.L85P_AS 5’-gagcattctgccgcttgagcagcagttatag-3’     
p.L93P 
p.L93P_S 5'-caagtccgtgcaccggagaaggcgagg-3' 
p.L93P_AS 5'-cctcgccttctccggtgcacggacttg-3' 
p.N105T 
p.N105t_S 5'-ccaactgcagaccacctacccctcctcag-3' 
p.N105t_AS 5'-ctgaggaggggtaggtggtctgcagttgg-3' 
p.S129S 
p.S129L_S 5'-cgatgggggctcagactccagctcg-3' 
p.S129L_AS 5'-cgagctggagtctgagcccccatcg-3' 
p.S133L 
p.S133L_S 5'-ctcggactccagcttggagtctgagcc-3' 
p.S133L_AS 5'-ggctcagactccaagctggagtccgag-3' 
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ABSTRACT 
 As previously mentioned, sequencing multiple trios (a patient and their unaffected parents) in 
which affected individuals share similar clinical characteristics is a suitable approach to find a causal gene, 
especially for genes harboring de novo mutations or following a recessive inheritance model. 
 In a second NGS project we applied WES to the germline DNA of three trios selected because the 
probands showed a very unusual clinical presentation: idiopathic polycythemia and multiple PCCs/PGLs. 
During the analysis of the WES data, Pacak’s group in USA (Zhuang et al., 2012) published their discovery 
of somatic post-zygotic HIF2A gain-of-function mutations in patients with PGLs and congenital 
polycythemia. Subsequent analysis of HIF2A in our three selected probands revealed that all of them 
carried somatic post-zygotic mutations in the gene. The inheritance model underlying HIF2A mutations in 
PCC/PGL, despite being very uncommon, presents a challenge to non-agnostic approaches, and highlights 
the importance of performing WES in tumor-blood matched samples in order to cover as many genetic 
models as possible. 
 In this study we assessed 41 PCCs/ PGLs for mutations in HIF2A and described the clinical, 
molecular and genetic characteristics of the seven patients found to carry somatic HIF2A mutations; four 
presented with multiple PGLs (three of them were the initially sequenced tumors and also had congenital 
polycythemia), whereas three were single sporadic PCC/PGL cases.  After excluding the three probands 
with multiple tumors and polycythemia, somatic mutations affecting HIF2A accounted for 10% of the 
tumors analyzed in this series, suggesting that this alteration is a relevant somatic oncogenic event in 
PCC/PGL development. All the tumors were also screened for HIF1A mutations, however none were 
found. The gene expression analysis of HIF2A-mutated tumors revealed similar mRNA HIF2A levels to 
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those found in SDH-gene- and VHL-mutated cases and a significant up-regulation of two hypoxia-induced 
genes (PCSK6 and GNA14). Interestingly, single nucleotide polymorphism (SNP) array analysis revealed an 
exclusive gain of chromosome 2p in three HIF2A-mutated tumors. Furthermore, multiplex-PCR screening 
for small rearrangements detected a specific HIF2A gain in another HIF2A-mutated tumor and in three 
non-mutated cases suggesting that the gain of the gene is an important oncogenic event in the 
development of the disease.  
 The finding that HIF2A is involved in the sporadic presentation of the disease not only increases 
the percentage of PCCs/PGLs with known driver mutations, but also highlights the relevance of studying 
other hypoxia-related genes in apparently sporadic tumors. Finally, the detection of a specific copy 
number alteration affecting chromosome 2p in HIF2A-mutated tumors may guide the genetic diagnosis of 
patients with this disease. 
 
Personal contribution: I participated in the conception and design of the study and the acquisition of the 
samples and data. Besides, I was actively involved in the genetic screening for mutations in HIF2A and 
HIF1A in our selected series of tumors by means of Denaturing High-Performance Liquid Chromatography 
(dHPLC) and Sanger sequencing. I also participated in the analysis of the tumors, testing for gains in the 
gene using a multiplex PCR-based method and SNP array. Finally I was involved in the analysis of the 
expression data, the discussion of the results and the drafting of the paper. 
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Pheochromocytomas (PCCs) and paragangliomas (PGLs) are chromaffin-cell tumors that arise from the ad-
renal medulla and extra-adrenal paraganglia, respectively. The dysfunction of genes involved in the cellular
response to hypoxia, such as VHL, EGL nine homolog 1, and the succinate dehydrogenase (SDH) genes,
leads to a direct abrogation of hypoxia inducible factor (HIF) degradation, resulting in a pseudo-hypoxic
state implicated in PCC/PGL development. Recently, somatic post-zygotic mutations in EPAS1 (HIF2A)
have been found in patients with multiple PGLs and congenital erythrocytosis. We assessed 41 PCCs/
PGLs for mutations in EPAS1 and herein describe the clinical, molecular and genetic characteristics of the
7 patients found to carry somatic EPAS1 mutations; 4 presented with multiple PGLs (3 of them also had con-
genital erythrocytosis), whereas 3 were single sporadic PCC/PGL cases. Gene expression analysis of EPAS1-
mutated tumors revealed similar mRNA EPAS1 levels to those found in SDH-gene- and VHL-mutated cases
and a significant up-regulation of two hypoxia-induced genes (PCSK6 and GNA14). Interestingly, single nu-
cleotide polymorphism array analysis revealed an exclusive gain of chromosome 2p in three EPAS1-mutated
tumors. Furthermore, multiplex-PCR screening for small rearrangements detected a specific EPAS1 gain in
another EPAS1-mutated tumor and in three non-EPAS1-mutated cases. The finding that EPAS1 is involved
in the sporadic presentation of the disease not only increases the percentage of PCCs/PGLs with known
driver mutations, but also highlights the relevance of studying other hypoxia-related genes in apparently
sporadic tumors. Finally, the detection of a specific copy number alteration affecting chromosome 2p in
EPAS1-mutated tumors may guide the genetic diagnosis of patients with this disease.
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INTRODUCTION
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are
rare neural crest tumors that arise from the adrenal medulla
and from the extra-adrenal sympathetic and parasympathetic
paraganglia, respectively. The genetics of PCCs/PGLs is ex-
tremely puzzling, with up to 40% of patients carrying a germ-
line mutation that affects 1 of 10 major susceptibility genes
(1–10). Depending to a great extent on the gene mutated,
the clinical phenotype of mutation carriers can vary dramatic-
ally (e.g. patients carrying germline mutations in VHL versus
RET) as can risk of malignancy or age-related penetrance
(e.g. patients carrying germline mutations in SDHB versus
SDHD). Furthermore, some of the genes (i.e. SDHD,
SDHAF2 and MAX) are affected by maternal imprinting or pa-
ternal transmission. In addition to this high and heterogeneous
genetic predisposition, there is also a substantive percentage of
hereditary cases, either with familial antecedents of PCC/PGL
or with other clinical characteristics suggestive of hereditary
disease, that do not harbor mutations in any of the susceptibil-
ity genes mentioned above. The sporadic presentation of the
disease appears to also have a complex genetic etiology;
NF1 that, of the known susceptibility genes, has one of the
lowest associated incidences of PCC/PGL has recently been
found to play a very important role in the sporadic presenta-
tion of the disease (11). For all these reasons, the genetic diag-
nosis, genetic counseling and clinical follow-up of patients
with PCC/PGL syndromes are major challenges.
The most recent addition to the growing list of PCC/
PGL-associated genes is endothelial PAS domain-containing
protein 1 (EPAS1) (12). EPAS1, also known as HIF2A,
encodes one of the members of the hypoxia inducible factor
(HIF) family of transcriptional regulators involved in
hypoxic response (13). Zhuang et al. (12) described somatic
mutations in EPAS1 in two unrelated patients presenting
with multiple PGLs. The mutations seemed to occur during
early embryogenesis because both patients also had congenital
erythrocytosis and one of them developed multiple somatosta-
tinomas. Despite the fact that germline gain-of-function muta-
tions affecting this gene are associated with increased
erythropoietin and familial erythrocytosis (14–16), and unlike
what happens with mutations in other polycythemia-related
genes such as VHL and EGL nine homolog 1 (17), none of
EPAS1 mutation carriers developed cancer. The discovery of
somatic mutations affecting EPAS1 in PCC/PGL not only
once again links polycythemia and cancer, but it also adds
further weight to the hypothesis that the stabilization of
HIF-alpha is important in chromaffin tumor development.
This process, known as pseudo-hypoxia, has been described in
PCC/PGL harboring mutations in VHL or in the succinate de-
hydrogenase (SDH) genes (18). LikeEPAS1mutations, pseudo-
hypoxia prolongs the half-life of HIF-alpha and triggers the ac-
tivation of the cellular adaptation to hypoxia in VHL- and
SDH-related tumors (19), which seems to be of pivotal import-
ance in the development of other neural crest tumors (20).
In the present study, we tested for EPAS1 mutations in three
patients with multiple PCC/PGLs and erythrocytosis, as well
as an additional series of 38 PCCs/PGLs, and described the
clinical, molecular and genetic features of seven patients car-
rying somatic EPAS1 mutations. Of note, only three of these
seven patients with EPAS1-mutated tumors presented with
congenital erythrocytosis and three had a single sporadic
PCC/PGL.
RESULTS
Somatic EPAS1 mutations are frequently found
in PCC/PGL
We first genotyped exon 12 of EPAS1 in three tumors from
three unrelated individuals who had developed multiple
PCC/PGLs and congenital erythrocytosis. Three missense
mutations, p.Ala530Thr, p.Pro531Ser and p.Pro531Leu,
were found in three tumors (Table 1). To assess the invol-
vement of EPAS1 mutations in PCC/PGL development, geno-
typing of exon 12 was also performed in 38 apparently
sporadic tumors. Four non-truncating mutations were identi-
fied in four independent tumors: two were missense variants
(p.Ala530Val and p.Asp539Tyr) and two were in-frame
deletions (p.Ile533_Pro534del and p.Pro534_Asp536del)
(Table 1). The p.Pro531Ser and pPro531Leu mutations
affect the primary prolyl hydroxylation site, Pro-531, in
EPAS1, whereas the remaining variants affect amino acids in
proximity to this site. The two mutations involving Ala-530
had been previously reported (12); the other five were novel
variants. None of the mutations were found in the correspond-
ing patients’ germline DNA. The subsequent analysis of add-
itional tumors developed by cases 1, 3 and 4 (Table 1)
confirmed the presence of the same mutations (p.Ala530Thr,
p.Pro531Ser and p.Pro531Leu, respectively), suggesting that
the mutations occurred in a chromaffin precursor cell in
these three cases. Moreover, the mutations found in tumors
were neither present in extra-adrenal normal tissue (cases 2
and 3) nor in a non-neural-crest tumor obtained from case 2,
supporting that a genetic mosaicism occurred in these patients.
The analysis of normal adrenal tissue adjacent to the tumor
obtained from one of the patients who developed a single
tumor (case 7, Table 1) revealed the absence of the mutated
allele, demonstrating that, at least in this case, the somatic mu-
tation occurred only in the tumor.
The screening for mutations in exon 12 of the EPAS1 gene
carried out in germline DNA from 186 patients without muta-
tions in the known susceptibility genes revealed a missense
variant (c.1700T . C; p.Met567Thr) in two apparently spor-
adic cases (Table 1). Alamut software predicts that the
variant is not deleterious because it affects a moderately con-
served residue, and the change to threonine is not physico-
chemically relevant. Furthermore, this variant was found in
1 of 4300 European individuals in the NHLBI Exome Sequen-
cing Project and in 3 of 254 Spanish controls included in the
present study. Based on these findings and the mild phenotype
of the corresponding patients, we concluded that this variant is
not disease causing.
Gain of 2p is an alteration exclusive to tumors harboring
EPAS1 mutations
High-density single nucleotide polymorphism (SNP) genotyp-
ing performed in four EPAS1-mutated tumors revealed that
three carried a gain of the short arm of chromosome 2 that
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includes EPAS1 (Fig. 1A; Table 1). To investigate whether
this somatic mechanism could be exclusive to tumors carrying
EPAS1 mutations, we interrogated SNP array data from a
further 94 PCC/PGLs with or without mutations in other
PCC/PGL susceptibility genes (Data not shown), 34 of
which had no somatic mutations in EPAS1, and found that
none presented a gain of chromosome 2p (P ¼ 4.7 × 1024).
We found by allele-specific PCR that the duplication of 2p
detected in the EPAS1-mutated cases affected the mutated
allele in one tumor and the non-mutated allele in the other
two (Supplementary Material, Fig. S1A and B). Using a
multiplex-PCR assay for the detection of chromosomal rear-
rangements under SNP-array detection limits, we identified
the specific gain of EPAS1 in one of the EPAS1-mutated
cases and in three additional EPAS1-mutation-negative
tumors (Supplementary Material, Fig. S1C). Genotyping of
the two additional EPAS1 prolyl hydroxylation sites
(Pro-405 and Asn-847) revealed no mutations in the three
tumors with specific EPAS1 gain, or in the remaining 31
EPAS1-mutation-negative tumors. The same negative result
was obtained when exon 12 of both HIF1A and HIF3A was
analyzed in the 34 EPAS1-mutation-negative tumors.
EPAS1-mutated tumors showed overexpression of several
hypoxia-induced genes
It has been reported that gain-of-function mutations in EPAS1
lead to the up-regulation of hypoxia-related genes (12). To
assess whether the tumors carrying EPAS1 mutations exhib-
ited a characteristic pseudo-hypoxic transcriptional profile,
we used previously reported gene expression data from four
of the seven EPAS1-mutated tumors (21). A previous hierarch-
ical cluster analysis had grouped one of the EPAS1-mutated
tumors in ‘cluster 1’, composed primarily of pseudo-hypoxic
PCCs, whereas the remaining three cases were spread across
the Ras/PI3K/mammalian target of rapamycin cluster
(‘cluster 2’) (21). To decipher the particular hypoxic profile
of EPAS1-mutated tumors, we carried out a supervised
cluster analysis of the 4 altered tumors when compared with
22 sporadic tumors negative for mutations in EPAS1 included
in the original expression profile study. This analysis revealed
12 probes (corresponding to 11 genes) significantly
up-regulated in EPAS1 tumors (Fig. 1B) and 3 of these
(TMEM45A, PCSK6 and LMO4) were known hypoxia-induced
genes (22–24). After excluding 6 tumors suspected to carry
NF1 somatic mutations (because they exhibited known
chromosome 17 losses), the up-regulation of 4 of the 11
genes remained significant: PCSK6, GNA14, AMZ1 and
THC2316750 (denoted in red in Fig. 1B). Furthermore, we
found significantly higher levels of EPAS1 mRNA expression
in the EPAS1-mutated tumors when compared with ‘cluster 2’
cases (P ¼ 0.002, Supplementary Material, Fig. S2); no differ-
ences in expression were found when we compared EPAS1-
mutated tumors with pseudo-hypoxic cases (‘cluster 1’, SDH
and VHL). Finally, the sporadic tumor group, which included
cases belonging to both PCC transcriptional clusters, showed
an intermediate level of expression, suggesting that it includes
both pseudo-hypoxic and non-pseudo-hypoxic cases. When
we subclassified these cases depending on the transcriptional
cluster they belonged to, we found significant differences
with the EPAS1-mutated tumors within each subgroup, con-
firming that ‘cluster 1’ sporadic cases are even more pseudo-
Table 1. Clinical presentation and genetic data for patients carrying variants in exon 12 of EPAS1
ID Age
at
onset
Sex Tumor
(n)
Congenital
erythrocytosis
(age at onset)
Secretion Other tumors
(age at onset)
Tumor variant Germline
variant
2p
gaina
EPAS1
gainbcDNA Protein
1 18,
22,
26
F PCC, TA
PGLs
(6)
Yes (1 year) EPO, NE,
DA
No c.1588G. A p.Ala530Thr No Yes –
2 40 F bPCC,
TA
PGLs
(3)
No E, NE Basal cell
carcinoma
(75 years)
c.1589C. T p.Ala530Val No ND ND
3 13,
22,
23
M PCC, TA
PGL
(3)
Yes (7 years) EPO Parotid
adenoma
(21 years)
c.1591C. T p.Pro531Ser No ND ND
4 18, 20 F PCC, TA
PGLs
(5)
Yes (1 year) EPO No c.1592C. T p.Pro531Leu No ND ND
5 46 F PCC No n.a. No c.1599_1604del p.Ile533_Pro534del No Yes –
6 43 F PCC No E, NE Uterine
myoma (41
years)
c.1600_1608del p.Pro534_Asp536del No Yes –
7 78 F TA PGL No n.a. No c.1615G. T p.Asp539Tyr No No Yes
8 73 F PCC No n.a. No – – c.1700T. C – –
9 46 F PCC No NE, DA No – – c.1700T. C – –
F, female; M, male; PCC, pheochromocytoma; PGL, paraganglioma; bPCC, bilateral PCC; TA, thoracic-abdominal; NE, norepinephrine; E, epinephrine, EPO,
erythropoietin; DA, dopamine; n.a., not available; ND, not done due to poor DNA quality.
aGain detected by SNP-array analysis.
bGain detected by multiplex-PCR analysis.
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hypoxic and that ‘cluster 2’ sporadic tumors exhibit a non-
hypoxic expression profile similar to the mutated tumors
from this cluster
(P ¼ 0.038 and P ¼ 0.029, respectively).
DISCUSSION
The presence of known germline mutations in almost 40% of
patients means that PCC/PGL is one of the human tumor en-
tities with the highest explained heritability worldwide. In
addition, the demonstrated relevance of somatic mutations
affecting some of the susceptibility genes (especially NF1)
in the sporadic forms of the disease has rapidly increased
during recent years to 24–35% of cases (11,25). The discovery
of somatic post-zygotic EPAS1 mutations in patients develop-
ing multiple PCC/PGLs represents a new twist in the genetics
of the disease and means that some patients who apparently
exhibit a familial phenotype are really non-hereditary. In the
present study, we found somatic EPAS1 mutations not only
in three additional patients with multiple PCC/PGLs, but
also in three cases presenting with single tumors, the latter
result revealing EPAS1 as a new gene involved in the sporadic
presentation of the disease. Overall, after excluding the three
selected cases with multiple tumors and erythrocytosis, muta-
tions affecting the EPAS1 gene accounted for 10% of the con-
secutive tumors analyzed in this study which suggests that this
somatic oncogenic event is one of the most relevant in the de-
velopment of sporadic PCC/PGL, together with NF1, VHL and
RET alterations.
The Pro-531 mutations constitute the first example of var-
iants causing the direct abrogation of prolyl hydroxylation in
EPAS1. In addition, as occurs with mutations found in patients
with familial erythrocytosis, the remaining EPAS1 variants
identified in the present study affect amino acids in proximity
to the primary prolyl hydroxylation site (Fig. 2) and could,
therefore, affect the conformation of the hydroxylation
domain interfering with prolyl hydroxylase recognition, as
Figure 1. (A) SNP-array analysis of chromosome 2 performed with tumor DNA from the patient carrying the p.Ile533_Pro534del mutation reveals a gain of the
short arm. The lower panel shows the genomic plots of the log R ratio [log2(Rpatient/Rreference)], indicating the presence of three alleles along the short arm.
The upper panel gives the allele frequency parameters along chromosome 2, showing that the heterozygous state splits into two clusters. The chromosomal lo-
cation of EPAS1 is also indicated; (B) Heat map showing the 11 genes (represented in the rows) differentially up-regulated (FDR, 0.15) in the supervised
cluster analysis of EPAS1-mutated and EPAS1-non-mutated tumors (represented in the columns). Significantly up-regulated genes after ruling out tumors po-
tentially NF1 mutated are highlighted in red. Color bar: green and red colors represent ≥2-fold relative under- and over-expression, respectively.
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demonstrated for the Ala-530 substitutions (12). The identifi-
cation of two new cases harboring mutations in Ala-530,
and another one involving Asp-539, a residue mutated in a
patient with erythrocytosis (26), suggests that these two
amino acids could be hotspots for both erythrocytosis and
PCC/PGL. On the other hand, the absence of PCCs and
PGLs in the reported cases of familial erythrocytosis carrying
EPAS1 germline mutations suggests that, as occurs with muta-
tions in the VHL gene, different mutations in EPAS1 predis-
pose to different diseases. Nevertheless, we cannot rule out
that additional genetic factors modulate the clinical phenotype
of EPAS1 mutation carriers. In the case of the patient with
multiple tumors found to carry one of the Ala-530 mutations
(previously reported in a patient with erythrocytosis and
PGLs) (12), the absence of erythrocytosis could be related
to the time at which the mutation occurs. Studying a larger
number of patients with erythrocytosis and/or PCC/PGL
who carry EPAS1 mutations could help to solve this new
phenotypic puzzle.
As recently reported for PCCs carrying somatic mutations
in NF1, the detection of a specific copy number alteration
may guide the genetic diagnosis of the disease. Indeed, it is
nowadays accepted that negative immunostaining for SDHB,
partially due to the somatic loss of chromosome 1p, almost
guarantees the detection of a mutation in one of the SDH
genes (27). The exclusive gain of chromosome 2p identified
in three of the four EPAS1-mutated tumors analyzed, and
the specific gain of the gene detected in another mutated
case, could, therefore, be used to select candidate tumors to
be analyzed for mutations in this particular gene, avoiding un-
necessary expenses. Unexpectedly, we found that the chromo-
somal gain of 2p affected both the wild-type and the mutated
alleles alike (Supplementary Material, Fig. S1A and B). There
are three well-known genetic mechanisms to activate onco-
genes in human neoplasm: activating mutations, gene amplifi-
cations and chromosomal rearrangements. Although it is
widely accepted that a single altered copy of an oncogene is
sufficient to cause alterations in cell growth, it has been
reported that PCCs in patients carrying germline activating
mutations in RET may harbor either somatic duplications of
the mutated allele or loss of the wild-type RET allele (28). Al-
though duplication of the mutated allele would lead to higher
amount of stabilized EPAS1 protein, somatic gain of an extra
copy of the wild-type allele can also activate the hypoxic re-
sponse in the tumor. This is because, in the case of a mono-
meric protein such as EPAS1, a dominant negative effect is
not required. Finally, the detection of the specific gain of the
gene in three EPAS1-mutation-negative cases strongly sug-
gests that somatic gain of EPAS1 could be a driving oncogenic
event in some PCCs/PGLs.
A hierarchical cluster analysis suggested that EPAS1-
mutated tumors do not exhibit the classical pseudo-hypoxic
profile of VHL and SDH cases. Nevertheless, we found two
hypoxia-related genes that were up-regulated in EPAS1-
mutated cases when compared with sporadic tumors without
EPAS1 mutations: PCSK6 and GNA14. Although the latter
has not been reported as a hypoxia-related gene, it seems
that it has an oxygen concentration-dependent expression
and may play an important role in placental and fetal vascular
endothelial functions, especially under chronic hypoxia (http://
www.erp.wisc.edu/symposium/2012_abstracts.pdf). In add-
ition, it has been reported that activation of the GNA14
protein can lead to STAT3 stimulation that plays a critical
role in the development and function of normal hematopoietic
cells (29). On the other hand, it is known that PCSK6 overex-
pression resulted in enhanced susceptibility to carcinogenesis
and tumor progression (30), and it has been proposed as an
invasion-associated gene in malignant gliomas (31). The low
number of hypoxia-related genes significantly up-regulated
in EPAS1-mutated cases suggested that some of the sporadic
tumors could harbor alterations in other hypoxia-related
genes. That we found high EPAS1 mRNA levels in ‘cluster
1’ sporadic tumors (Supplementary Material, Fig. S2) is con-
sistent with this hypothesis. Interestingly, for two of these
samples, the high mRNA expression of EPAS1 was associated
with the gain of the specific gene. Further studies are needed to
assess the involvement of still unknown pseudo-hypoxic
alterations in the development of sporadic tumors. Whereas
HIF1A is ubiquitously expressed, EPAS1 is encountered
only in a limited number of cell types, with particularly ele-
vated mRNA levels found in catecholamine-producing cells
of the sympathetic nervous system (32). Interestingly, it has
been proposed that the pattern of EPAS1 abundance may be
responsible for the observed organ specificity of the VHL syn-
drome (33). Thus, considering that other organs affected in
this syndrome, such as the retina, the kidney and the pancreas,
also have high EPAS1 expression levels, it is plausible that
EPAS1 driver mutations would be found in non-VHL heman-
gioblastomas, clear cell renal cell carcinomas or pancreatic
neuroendocrine tumors. Indeed, the EPAS1 locus has been re-
cently identified as a new genomic region associated with
renal cell carcinoma risk (34).
In summary, the finding of somatic post-zygotic mutations
affecting EPAS1 in PCC/PGL patients suggests an alternative
genetic explanation for the etiology of the disease in patients
with multiple tumors, but not germline mutations. In addition,
the discovery of the involvement of this gene in the sporadic
presentation of the disease (i.e. one single tumor) not only
increases the percentage of tumors with known driver muta-
tions, but also highlights the relevance of studying other
Figure 2. Schematic representation of EPAS1 domains and the location of
mutations (in bold letters) along the N-TAD. N-TAD, N-terminal transcrip-
tional activation domain; bHLH, basic helix-loop-helix domain; PAS,
per-ARNT-Sim domains; ODD, oxygen-dependent degradation domain;
C-TAD, C-terminal transcriptional activation domain; FE, familial erythrocy-
tosis; NFP, non-familial paraganglioma/PCC; ∗: primary site of prolyl hydrox-
ylation. In square brackets are the residues affected by the two in-frame
deletions. Numbers denote more than one case found carrying a mutation in
the specified amino acid.
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hypoxia-related genes in apparently sporadic PCC/PGLs.
Finally, the detection of a specific copy number alteration
affecting EPAS1 may guide the genetic diagnosis of the
disease in these patients.
MATERIALS AND METHODS
Tumors and patients
Three tumors, one frozen and two formalin-fixed paraffin-
embedded (FFPE), were obtained from patients with multiple
PGLs/PCCs and congenital erythrocytosis. In addition, frozen
tumors were obtained through the Spanish National Tumor
Bank Network in Madrid (Spain) for a total of 38 unrelated
consecutive patients with PCC/PGL who were tested negative
for germline and somatic mutations in the major susceptibility
genes VHL, RET, SDHB, SDHC, SDHD, TMEM127 and MAX.
Additional FFPE PCCs/PGLs were obtained from three of the
four cases with somatic EPAS1 mutations who developed mul-
tiple tumors (a second tumor from cases 1 and 3 and the five
additional tumors from case 4; Table 1); other tissue speci-
mens were obtained from case 2 (bone and basal cell carcin-
oma), case 4 (lymphatic ganglia and intestine) and case 7
(normal adrenal medulla). A further 186 consecutive non-
related index patients without germline mutations in VHL,
RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127
and MAX were also included in the study. All patients were
clinically diagnosed in public Spanish hospitals with function-
ing or non-functioning PCC/PGL. Genomic DNA was
obtained from tumor tissue using the DNAeasy (Qiagen Inc.,
Valencia, CA, USA) kit and from blood samples using a stand-
ard procedure (35). Clinical data were collected for all patients
by means of detailed questionnaires, and written informed
consent was obtained from each patient. We used DNA
from 254 unrelated unaffected individuals as a control
sample for the study of the variant of unknown significance
detected in the germline genetic screening.
Mutational and molecular analyses
Analysis of point mutations affecting exon 12 of EPAS1
(ENST00000263734, NM_001430.4), which contains the
primary hydroxylation site of the protein, was performed
both in tumor and germline DNA, as well as in the non-
paraganglionic tissue samples, using a standard PCR amplifi-
cation protocol. Additional analysis of the 2 remaining
EPAS1 hydroxylation sites (i.e. Pro-405 and Asn-847 located
in exons 9 and 16, respectively), and exon 12 of
HIF1A (ENST00000337138, NM_001530.3) and HIF3A
(ENST00000377670, NM_152795.3), was performed in the
34 frozen tumors without mutations at the primary site. PCR
conditions and primers are available on request. The
Alamutw mutation interpretation software (http://www.intera
ctivebiosoftware.com/software.html) was used to assess the
pathogenicity of the germline variants identified.
SNP-array and multiplex-PCR analyses
To investigate the presence of chromosomal rearrangements in
the tumors, we performed high-density SNP-array analysis in
four EPAS1-mutated cases (three of the tumors were not ana-
lyzed due to poor DNA quality). A genome-wide scan of
616 795 markers was conducted on 250 ng of tumor DNA,
using the Illumina Human610-Quad BeadChip according to
the manufacturer’s specifications. Image data were analyzed
using the Chromosome Viewer tool contained in GenomeStu-
dio 2010.2 (Illumina). The metric used was the log-R ratio that
is the binary logarithm of the ratio of the observed to expected
normalized R values for a given SNP (36). The allele fre-
quency was also estimated for all SNPs. EPAS1 genomic
gains were assessed in the 40 tumors by multiplex-PCR, in-
cluding 2 pairs of primers for exons 12 and 14, as previously
described for other genes (37). A similar semi-quantitative
multiplex-PCR method was used to investigate which allele
was duplicated in the three tumors exhibiting chromosome
2p gain in the array-SNP analysis. Briefly, we first designed
and labeled (5′ 6-FAM) two pairs of primers for each mutation
that discriminated the wild-type allele from the mutated allele.
Following that, three cocktails containing each specific pair of
primers mixed with three control-labeled pairs of primers for
chromosomes 5 and 16 (as internal controls) were prepared
and used to amplify the corresponding tumor DNA by
multiplex-PCR. The subsequent normalization was performed
for each PCR product by overlapping each tumor sample with
a control sample using the Peak ScannerTM software (Applied
Biosystems, Foster City, CA, USA), as previously described
for other genes (37).
Gene expression analysis
To identify specific transcripts related to EPAS1 deregulation,
we used gene expression data for four of the 7 mutated tumors
and for 22 sporadic cases negative for mutations affecting
EPAS1 exon 12, as deposited in the National Center for Bio-
technology Information GEO database under the accession
number GSE19422 (21). A t-test was applied using POME-
LOII (http://pomelo2.bioinfo.cnio.es/) to compare the expres-
sion of individual genes between the two groups (38).
Benjamini’s false discovery rate (FDR) correction was used
to account for multiple testing (39); genes up-regulated in
the mutated tumors with an FDR , 0.15 were selected as dif-
ferentially expressed. In addition, we assessed the mRNA ex-
pression of EPAS1 in the whole series of PCC/PGLs (21), by
the gene mutated. Considering that some of the sporadic cases
included in the present study could have NF1-mutated tumors,
we performed a second analysis excluding the six that exhib-
ited chromosome 17 losses, based on the report that 84–90%
of tumors with these losses harbor mutations in NF1 (11,25).
Statistical analysis
Difference in frequency of 2p gain between EPAS1-mutation-
positive and -negative cases was assessed by Fisher’s exact
test, using the SPSS software, version 17.0 (SPSS Inc.,
Chicago, IL, USA).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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SUPPLEMENTARY MATERIAL 
 
Supplementary Figure 1. Peak Scanner analysis of amplified PCR fragments, using wild-type allele-specific 
primers, of a control tumor sample (blue) overlapped with patient tumor samples (red): A, tumor sample 
carrying the mutation p.Ile533_Pro534del; B, tumor sample carrying the mutation p.Ala530Thr; C, tumor 
sample (red) negative for chromosome 2p gain by SNParray exhibiting specific EPAS1 gain affecting exons 
12 and 14, compared with a control sample (blue). Fragments MP-C1, MP-C2, and MP-C3 were used as 
internal controls for these assays. 
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Supplementary Figure 2. n-fold EPAS1 mRNA expression relative to reference RNA. Black rectangles 
represent “cluster 1” tumors, white rectangles, “cluster 2” tumors and grey rectangles mixed cluster 1 
and 2 tumors; VHL, SDH, EPAS1, RET, NF1, TMEM127, and MAX: tumors carrying mutations in the 
corresponding pheochromocytoma/paraganglioma susceptibility gene; SP1: sporadic tumors belonging to 
cluster 1; SP2: sporadic tumors belonging to cluster 2.  
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ABSTRACT 
 
 This study started with the design of a WES project focused on patients presenting with multiple 
tumors and therefore candidates to be hereditary. After filtering known polymorphisms and variants 
causing low or moderate impact in the protein, we found a variant affecting the donor splice-site of 
MDH2 in tumor DNA from one of the selected patients. MDH2 encodes the mitochondrial malate 
dehydrogenase enzyme involved in the Krebs cycle. Disruption of Krebs cycle is a hallmark of cancer, and 
especially of PCC/PGL in which mutations affecting the SDH- or FH genes are involved in the susceptibility 
to the disease. 
 We first demonstrated the deleterious effect of the splice-site mutation, the presence of LOH in 
some tumors, and the absence of the protein in all available tumors. MDH2 enzymatic activity was almost 
abolished in the mutant tumors, and a high fumarate:succinate ratio suggested the accumulation of 
fumarate. Depletion of MDH2 in HeLa cells showed an accumulation of both fumarate and malate, that 
was partially restored upon reintroduction of wild-type MDH2. Gene expression analysis, as well as 5-
hmC and H3K27me3 immunohistochemistry, of MDH2-mutated tumors showed a CpG island methylator 
phenotype typical of tumors harboring Krebs cycle alterations. Finally, segregation of the variant with the 
disease in the family further demonstrated the implication of the MDH2 mutation in the disease, and 
suggested that it behaves as a classical tumor suppressor gene. 
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 Overall, our finding of a novel PCC/PGL susceptibility gene once again links the disruption of the 
Krebs cycle with tumor development, and also suggests that alterations in other Krebs cycle genes may 
be involved in PCC/PGL susceptibility.  
 
Personal contribution: I actively participated in the conception of the project, the preparation of the 
samples, the WES data analysis, the validation, and the mRNA and protein expression studies. I carried 
out the silencing of the gene in HeLa cells, and performed additional experiments and statistical analyses. 
Finally, I participated in the discussion and writing of the manuscript. 
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ABSTRACT 
Disruption of the Krebs cycle is a hallmark of cancer. IDH1 and IDH2 mutations are found in many 
neoplasms, and germline alterations in SDH genes and FH predispose to 
pheochromocytoma/paraganglioma and other cancers. We describe a paraganglioma family carrying a 
germline mutation in MDH2, which encodes a Krebs cycle enzyme. Whole-exome sequencing was applied 
to tumor DNA obtained from a 55 year-old man diagnosed with multiple malignant paragangliomas. Data 
were analyzed with the Student t and two-sided Mann-Whitney U tests with Bonferroni correction for 
multiple comparisons. Between 6- and 14-fold lower levels of MDH2 expression was observed in MDH2-
mutated tumors compared to controls. Knockdown (KD) of MDH2 in HeLa cells by shRNA triggered the 
accumulation of both malate (mean±SD: 1±0.18 [WT] vs 2.24±0.17 [KD]; P=.043) and fumarate (1±0.06 
[WT] vs 2.6±0.25 [KD]; P=.033), which was reverted by transient introduction of WT MDH2 cDNA. 
Segregation of the mutation with disease and absence of MDH2 in mutated tumors reveal MDH2 as a 
novel pheochromocytoma/paraganglioma susceptibility gene. 
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Pheochromocytomas and paragangliomas are tumors that mainly arise from the adrenal medulla and the 
sympathetic nervous system paraganglia, respectively. Since 1990, eleven major susceptibility genes have 
been identified: NF1, RET, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, MAX and FH1. However, 
there are still some patients with clinical indicators of hereditary disease (i.e. family history, multiple 
tumors and/or young age) that are not explained by mutations in these genes. 
 
Whole-exome sequencing was applied to tumor DNA obtained from a 55 year-old man diagnosed 
with multiple malignant paragangliomas. Five single nucleotide substitutions and eleven INDELs 
(insertions or deletions) passed the filtering process (Supplementary Table 1, available online). These 
included a heterozygous variant, c.429+1G>T, affecting a canonical donor splice site on exon 4 of MDH2, 
the gene that encodes the mitochondrial malate dehydrogenase enzyme involved in the Krebs cycle. After 
confirming the presence of the variant in the sequenced tumor and in peripheral blood lymphocytes from 
the patient, Sanger sequencing of the available primary tumors from the patient (n=4) revealed loss of the 
MDH2 wild type allele in 2 tumors, indicating loss of heterozygosity (Figure 1A). Direct sequencing of the 
cDNA regions flanking the mutation demonstrated that c.429+1G>T gave rise to an altered transcript that 
incorporated 20 additional amino-acids into the exon as well as to a premature stop codon. Since the stop 
codon is followed by more than 50 nucleotides, it was considered potentially involved in nonsense-
mediated decay2 (Figure 1B). MDH2 mRNA expression analysis revealed 6- to 14-fold lower levels of 
MDH2 expression in the four tumors carrying the c.429+1G>T mutation, compared to controls (Figure 1C). 
In addition, substantially lower levels of MDH2 protein were detected in the MDH2-related tumors 
compared to controls (Figure 1D), suggesting that nonsense-mediated decay was occurring and 
confirming loss of expression of the wild-type allele in all mutated tumors. The MDH2-mutated tumor 
displayed statistically significantly lower MDH2 activity than that of control tumors (median [range]: 
275.78 [181.69-882.43] vs 966.64 [221.07 - 3551.0]; P=.006) (Figure 1E), suggesting severe malate 
dehydrogenase deficiency. Krebs cycle metabolite analysis did not detect accumulation of malate in the 
MDH2-mutated tumor. However, a much higher fumarate:succinate ratio was observed in the MDH2-
mutated tumor (mean±SD: 0.34±0.02) in comparison to succinate dehydrogenase (SDH) gene-mutated 
(mean±SD: 0.01±0.02; P=.044) and non-mutated (mean±SD: 0.06±0.10; P=.006) tumors (Supplementary 
Figure 1), suggesting that fumarate could be accumulated in MDH2-mutated cells. Knockdown of MDH2 
expression in HeLa cells by shRNA (Supplementary Figure 2A-C) triggered the accumulation of both 
malate (mean±SD: 1±0.18 [WT] vs 2.24±0.17 [KD]; P=.043) and fumarate (mean±SD:1±0.06 [WT] vs 
2.6±0.25 [KD]; P=.033) which was reverted by transient introduction of wild-type MDH2 cDNA (Figure 1F-
H). Additional malate-utilizing enzymes (MDH1 and malic enzymes 1-3) could be responsible for the 
absence of malate accumulation in MDH2-mutated tumors. However, neither the observed MDH1 activity 
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(Supplementary Table 2) nor the expression of malic enzymes 1-3 (data not shown) in the MDH2-mutated 
tumors explain the absence of malate accumulation, suggesting that an unknown mechanism is 
accounting for this controversial result. 
Several studies have demonstrated that the accumulation of succinate and fumarate, caused by 
SDH gene mutations and FH mutations, respectively, and the production of 2-hydroxyglutarate (2HG), 
associated with IDH1 and IDH2 alterations, lead to the enzymatic inhibition of multiple α-KG-dependent 
dioxygenases5, 6. This inhibition causes impaired histone demethylation and 5-mC hydroxylation (5-hmC), 
and, consequently, genome-wide histone and DNA methylation alterations. This in turn leads to a 
characteristic CpG island methylator phenotype (CIMP)7, and provides a rationale for tumor development 
caused by Krebs cycle disruption. Expression profiling analysis based on genes that were hypermethylated 
and downregulated in SDH gene- and FH-mutated tumors and associated with the characteristic CIMP7, 
revealed that the MDH2-mutated tumor and three apparently sporadic cases all clustered with SDH gene-
mutated tumors, suggesting a similar CIMP (CIMP-like) profile (Figure 2A). Immunohistochemical 
evaluation of 5-hmC (Figure 2B) and trimethylation of histone H3 lysine 27 (H3K27me3) (Supplementary 
Figure 3A) were also consistent with the MDH2-mutated tumor having a CIMP-like profile. In addition, 
classification by retinol binding protein 1 (RBP1) expression, which is an exclusive biomarker for IDH 
mutations in gliomas8, segregated the MDH2- with the SDH-mutated tumors (Figure 2C and 
Supplementary Figure 3B), providing further evidence that MDH2 mutations are associated with a 
methylator phenotype. Finally, methylation analysis based on pyrosequencing of CpG sites in seven 
selected genes (including RBP1) (Supplementary Figure 3C) demonstrated that the genome-wide 
downregulation observed for the MDH2-mutated tumors was due to CpG island methylation. 
A genetic study of five asymptomatic relatives of the patient found that two of them carried the 
MDH2 c.429+1G>T mutation. MDH2 mRNA and protein expression in blood cells were statistically 
significantly lower in the two carriers compared to controls (median±SD: 0.33±0.07 [P=.0001] and 
0.53±0.05 [P=.0001] vs 1.08±0.08, respectively), confirming that the splicing mutation has a deleterious 
effect (Supplementary Figure 4). Subsequent clinical testing detected high levels of normetanephrine for 
one of the carriers (II-2), thus confirming the presence of the disease. Neither the three apparently 
sporadic cases with tumors that grouped within the CIMP-like cluster nor a selected series of cases with 
clinical features of a hereditary disease (Supplementary Table 3) had alterations in the MDH2 gene. 
During the last ten years, germline and acquired alterations affecting some of the enzymes involved 
in the Krebs cycle have been recognized as one of the hallmarks of cancer, and, more specifically, of 
pheochromocytoma/paraganglioma development. It is well known that germline mutations in the genes 
encoding the four structural subunits of the Krebs cycle enzyme SDH9-12, or in the regulatory enzyme 
SDHAF213, predispose to hereditary pheochromocytoma/paraganglioma. In addition, inactivating 
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mutations in FH predispose to hereditary leiomyomatosis and renal cell cancer (HLRCC)14, and have 
recently been identified in patients with pheochromocytoma/paraganglioma7, 15. Finally, IDH1 and IDH2 
are frequently mutated in multiple types of human cancer, including one paraganglioma16. In the present 
study, we have demonstrated the deleterious effect of a germline MDH2 mutation identified by whole-
exome sequencing. We have also confirmed the absence of MDH2 protein in tumors carrying the variant, 
as well as the segregation of the c.429+1G>T mutation with the disease, suggesting that MDH2 behaves as 
a classic tumor suppressor gene. 
The MDH2-mutated tumor had not only a global transcriptional profile similar to SDH gene-
mutated tumors, but also a CIMP-like signature consistent with Krebs cycle disruption. Mdh2 function 
abrogation in Drosophila pupae results in a severe energy deficit and accumulation of late-stage Krebs 
cycle intermediates such as malate, succinate, and fumarate17. A similar mechanism occurs in Fh1-
deficient cells which accumulate fumarate and succinate18. In the present study we have demonstrated 
that stable silencing of MDH2 expression in HeLa cells also leads to malate and fumarate accumulation. 
Like succinate and fumarate, malate inhibits hypoxia inducible factor alpha (HIF-α) prolyl hydroxylation19, 
20. Though no malate accumulation was found in the MDH2-mutated tumor, the high fumarate:succinate 
ratio detected suggests that fumarate accumulation may have been present, which would explain the 
CIMP-like profile observed. The finding of three SDH gene-, FH- and MDH2-negative tumors exhibiting the 
CIMP-like signature, points to the possibility that other, still hidden, molecular alterations in the Krebs 
cycle account for these cases, and for an unknown proportion of additional patients. The absence of 
paraganglioma in one of the three c.429+1G>T carriers suggests that the penetrance of mutations in this 
gene is incomplete, as is the case for SDHB mutations21. Interestingly, none of the seven FH mutation 
carriers described so far with pheochromocytoma/paraganglioma has a family history of the disease22. 
Moreover, mutations in the more recently discovered pheochromocytoma/paraganglioma susceptibility 
genes (MAX, TMEM127 and FH) are present in less than 2% of cases without mutations in known genes1, 
15, and in fact none of the 239 Spanish patients screened for mutations was found to be carrier of an FH 
mutation. Finding additional MDH2 mutation carriers will presumably require genetic screening of large 
cohorts of patients. Finally, only one truncating mutation (p.E153*) in MDH2 is recorded in The Catalogue 
of Somatic Mutations in Cancer (COSMIC; http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). 
The mutation was found in a neuroblastoma, a highly metastatic malignancy of the sympathetic nervous 
system that is genetically related to pheochromocytoma23 and that also originates primarily in the adrenal 
gland.  
This study is limited by the number of mutation carriers in the pedigree and the incomplete 
penetrance observed for the MDH2 alteration. The identification of additional disease-causing mutations 
in MDH2 will provide further information about the clinical relevance of this gene. Though we have no 
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explanation for the absence of malate accumulation in the MDH2-mutated tumor, we have demonstrated 
using HeLa cells that MDH2 abrogation leads to increased levels of malate and the oncometabolite 
fumarate. 
In summary, whole-exome sequencing has identified a novel tumor suppressor gene, MDH2, 
associated with paraganglioma development. This finding further links the disruption of the Krebs cycle to 
cancer etiology and highlights that alterations in this major metabolic pathway may explain additional 
pheochromocytoma/paraganglioma cases. 
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Accession code. A full listing of the exome sequencing results and microarray results has been deposited 
in the ArrayExpress database (accession code: E-MTAB-2422) and the National Center for Biotechnology 
Information GEO database (accession number: GSE56573), respectively. 
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FIGURES 
 
Figure 1. Characterization of MDH2-mutated tumors. (A) MDH2 mutation in germline DNA from the 
patient and loss of the wild-type (WT) allele in two tumors of the patient. (B) Sequence of the aberrant 
transcript caused by the MDH2 mutation. (C) MDH2 mRNA expression in the four MDH2-mutated 
paragangliomas available from the index patient and genetically characterized 
pheochromocytoma/paraganglioma. Expression level was normalized to β-actin (ACTB) and presented as 
mean and standard deviation (n≥3). Error bars represent standard deviation. (D) MDH2 western blot of 
mutated tumors and controls. ACTB was used as a loading control. (E) Representation of MDH2 activity 
measured in MDH2-mutated and control tumors. The black line at the middle of the box represents the 
median. Whiskers represent Minimun-Q1, Q3-maximum ranges. P-value based on a two-sided Mann-
Whitney U test. (F) Western blot of MDH2 KD HeLa cells transfected with a plasmid containing the full 
cDNA sequence of the human MDH2 gene (pCMV6-AC-MDH2; Origene), compared to MDH2 KD cells 
transfected with empty vector (EV), and to untransfected WT HeLa cells. ACTB was used as a loading 
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control. (G) Metabolite ratios assessed by liquid chromatographic tandem-mass spectrometry in MDH2 
KD (blue bars) compared to WT (grey bars) HeLa cells. The ratios were normalized relative to WT control 
values and reported as mean and standard deviation (n=3). A two-sided t-test for independent samples 
was applied to test for differences. *: P<.05. Error bars represent standard deviations. (H) Metabolite 
ratios for MDH2 KD cells transfected with pCMV6-AC-MDH2 (black bars) compared to MDH2 KD cells 
transfected with EV (blue bars). The ratios were normalized relative to control (EV) values and reported as 
mean+s.d. (n=3). A two-sided t-test for independent samples was applied to test for differences. Error 
bars represent standard deviations. MDH2: malate dehydrogenase 2.
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Figure 2. Expression analyses carried out in the MDH2-mutated tumors. (A) Hierarchical clustering of 91 
genetically characterized pheochromocytomas/paragangliomas based on expression data for genes 
hypermethylated and down-regulated in SDH/FH-mutated pheochromocytomas7. Three clusters, 
mimicking those previously obtained using methylation data, were observed and named M1 (CIMP-like), 
enriched with SDH gene-mutated tumors, M2 with VHL-mutated tumors, and M3 with 
RET/NF1/MAX/TMEM127-mutated tumors. Tumors with no color are apparently sporadic cases. Asterisks 
denote three CIMP-like tumors with no identified mutations in the SDH genes, FH or MDH2. (B) 
Immunohistochemical staining of 5-hmC in MDH2-, RET- and SDHB-mutated tumors. Nuclear 5-hmC was 
almost undetectable in MDH2- and SDHB-mutated tumor cells; it was observed only in sustentacular and 
some stromal cells. The scale bar represents 50µm. (C) mRNA expression of RBP1 in the MDH2-mutated 
tumor, SDH gene-mutated tumors, the CIMP-like apparently sporadic tumors clustered in M1 (see Panel 
A) and tumors clustered in the M2 and M3 groups (see Panel A), defined based on gene expression. P-
value based on a two-sided exact Mann-Whitney U test. The horizontal black line represents the median. 
Filled squares and triangles represent individual datapoints. MDH2: malate dehydrogenase 2; SDH: 
succinate dehydrogenase; FH: fumarate hydratase; RET: ret proto-oncogene; NF1: neurofibromin 1; MAX: 
MYC associated factor X; TMEM127: transmembrane protein 127; RBP1: retinol binding protein 1.  
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Supplementary Figure 1. Fumarate:succinate ratio for the MDH2-mutated tumor (in duplicate), and SDH 
and non-SDH gene-mutated cases. P-values based on a two-sided exact Mann-Whitney U test.*: 
statistically significant after applying a Bonferroni correction for multiple testing. The horizontal black line 
represents the median. Filled squares and triangles represent individual datapoints. MDH2: malate 
dehydrogenase 2; SDH: succinate dehydrogenase.  
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Supplementary Figure 2. Experiments with MDH2-depleted cells. (A) MDH2 western blot of HeLa cells 
stably silenced for MDH2 expression by shRNA transfection (sh8561; Sigma) compared to untransfected 
wild-type (WT) and non-silenced scrambled (Scr) control cells. β-actin was used as a loading control. (B) 
Quantitative real-time PCR analysis of MDH2 mRNA performed in MDH2 knock-down (KO) cells, 
compared to WT and Scr cells. The MDH2 mRNA level was normalized to ACTB and reported as mean+s.d. 
(n≥3). A two-sided t-test for independent samples was applied to test for differences between MDH2 KO 
and WT or Scr HeLa cells. *: p<0.01. Error bars represent standard deviation. (C) Representation of the 
enzymatic activities determined in mitochondrial (MDH2, CS) or cytosolic (MDH1, LDH) fractions, as 
detailed in Methods. Values were expressed in nmols/min/mg and are summarized as mean ± SD of 3 
paired independent experiments in HeLa WT (grey bars), Scr (red bars) or MDH2 KO cells (blue bars). 
MDH2c: MDH2 activity in mitochondrial fractions corrected for residual MDH1. A two-sided t-test for 
independent samples was applied to test for differences between MDH2 KO and WT or Scr HeLa cells. *: 
p<0.05. Error bars represent standard deviations. MDH2: malate dehydrogenase 2; ACTB: β-actin. 
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Supplementary Figure 3. RBP1 and histone methylation analyses. (A) Immunohistochemical staining of 
H3K27me3 in a representative MDH2-mutated tumor. Nuclear staining was high in tumor cells and almost 
undetectable in stromal and endothelial cells. The scale bar represents 50µm. (B) RBP1 mRNA expression 
in the four MDH2-mutated paragangliomas, three SDH-mutated tumors and five 
pheochromocytoma/paragangliomas without mutations in the Krebs cycle genes. Expression was 
normalized to ACTB and reported as mean+s.d. (n≥3).  Error bars represent standard deviations. (C) 
Representative pyrogram from the quantification of the methylation of 6 CpG sites in the RBP1 promoter 
of a MDH2-mutated tumor. The targeted cytosines are enclosed in gray squares. The percentage 
methylation at individual CpG positions is shown at the top of the pyrogram. RBP1: retinol binding 
protein 1; MDH2: malate dehydrogenase 2; ACTB: β-actin. 
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Supplementary Figure 4. Results from genotyping and expression analyses of MDH2 performed in the 
patient’s relatives. (A) Pedigree with the genotype for the c.429+1G>T mutation in MDH2 for the tested 
family members. Squares and circles represent male and female family members, respectively, and lines 
through these indicate deceased individuals. The proband (II-1), diagnosed with multiple paragangliomas, 
is denoted by an arrow. A black circle in carrier II-2 denotes a positive biochemical diagnosis.*: 123I MIBG 
scintigraphy and whole-body magnetic resonance imaging gave negative results. The patient refused PET-
CT. (B) Quantitative real-time PCR analysis of MDH2 mRNA performed in peripheral blood leukocyte 
samples (in triplicate) from the patient’s relatives who were genotyped for the mutation. A t-test for 
independent samples was applied to test for differences between carriers (II-2 and II-3) and non-carriers 
(II-4, II-5, and III-1). *: p<0.01. (C) MDH2 western blot of lymphoblastic cell lines (LCL) derived from two 
carriers (II-2 and II-3) of the c.429+1G>T MDH2 mutation and LCL from unrelated controls (C1-C4). ACTB 
(β-actin) was used as a loading control. MDH2: malate dehydrogenase 2. 
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Patients 
A 55 year-old man was diagnosed with asymptomatic paraganglioma by a computed tomography (CT) 
scan, as part of the clinical staging of a squamous skin cell carcinoma. On hospital admission, the patient 
reported a history of type-2 diabetes since age 35 years, but no personal or familial antecedents of 
neural-crest tumors. Continuous monitoring of ambulatory blood pressure revealed nocturnal 
hypertension. Catecholamine urine testing showed high levels of norepinephrine, and meta-
iodobenzylguanidine (MIBG) scintigraphy revealed the presence of two primary retroperitoneal 
paragangliomas that were surgically removed. Fourteen and fifteen years after the initial diagnosis, MIBG 
scintigraphy showed an additional retroperitoneal paraganglioma and a thoracic vertebral-invading 
paraganglioma, respectively; both were extirpated. Two years later, another thoracic paraganglioma, 
revealed by MIBG scintigraphy and CT scan, was surgically removed, and chemotherapy was initiated, 
with no clinical response. The patient died 2 years later. Three additional patients, whose tumors 
exhibited a CIMP-like profile, and a selected series of 29 patients with clinical features of a hereditary 
disease (i.e. family history and/or multiplicity) (Supplementary Table 3) were also tested for MDH2 
mutations. All patients tested negative for mutations in the ten major pheochromocytoma susceptibility 
genes: VHL, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, MAX and FH. Immunohistochemical 
SDHB analysis of formalin-fixed paraffin-embedded (FFPE) tissue from the index case further ruled out the 
presence of SDH gene mutations1. Genomic DNA was extracted from the patients’ and relatives’ blood 
following a standard method2. Tumor DNA from frozen and FFPE tissue was obtained using the DNeasy kit 
(Qiagen Inc.), following the manufacturer's instructions. The Instituto de Salud Carlos III (ISCIII) ethics 
committee approved the study, and the patients or their relatives provided written informed consent. 
 
Methods 
Whole-exome sequencing analysis 
Whole-exome sequencing was carried out in tumor DNA from the index patient at the National Centre for 
Genomic Analysis (CNAG). Briefly, the covaris S2 System (Covaris) was used for DNA fragmentation and 
exome capture was performed using the SureSelect XT HumanAllExon 50Mb kit (Agilent Technologies). 
Exome sequencing at a mean coverage >50x was performed by 75-bp paired-end technology using a 
HiSeq2000 (Illumina). The GEM and BFAST programs were used to align the reads against the whole 
human genome (hg19 assembly). To identify single nucleotide substitutions and small insertions and 
deletions (INDELs) the SAMtools program was used (http://samtools.sourceforge.net). Variants were 
filtered to rule out those in genome regions with low mappability, with low depth readings, with the 
alternative allele present in <20% of reads, or with alternative alleles present only in forward or reverse 
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reads. Single nucleotide substitutions and INDELs were selected and consecutively filtered by excluding: i) 
variants present in the dbSNP database, the 5400 NHLBI exomes database or in internal exomes; ii) 
variants in intergenic, intronic or UTR regions; iii) variants with <10 reads and <20 genotype quality; iv) 
variants affecting transcripts without an annotated consensus coding sequence (CCDS); v) variants with 
low or moderate impact (i.e. missense or silent variants, respectively). Finally, we used PROVEAN 
software (http://provean.jcvi.org/index.php), manual curating and additional internal exomes as final 
steps in the filtering process, thus identifying fifteen variants. We selected for further analysis a variant in 
MDH2, based on the relevant function of this gene in the Krebs cycle, a well-known pheochromocytoma-
related pathway. 
 
MDH2 Sanger sequencing and loss of heterozygosity analysis 
Primers designed for the amplification of the exon 5 donor site of the MDH2 gene were used for the 
validation of the germline variant found by exome sequencing. In addition, primers spanning the nine 
exons of the most common MDH2 transcript (ENST00000315758) were used to amplify tumor DNA from 
the three patients with tumors exhibiting a CIMP-like profile. Loss of heterozygosity of the MDH2 locus in 
DNA from the four available tumors developed by the index patient was assessed by direct sequencing 
using the same PCR conditions as applied for germline DNA. Tumoral cell-enriched FFPE cores were 
selected to perform the DNA isolation. Primer sequences and PCR conditions are available upon request. 
 
Reverse transcriptase-PCR 
Total RNA was isolated from frozen tumor tissue carrying the MDH2 mutation using the TriReagent kit 
(MRC), following the manufacturer’s instructions. First strand cDNA was synthesized from 0.45 μg of total 
RNA by oligo (dT)14 primer reverse transcription with Superscript II Reverse Transcriptase (Invitrogen) 
following the manufacter’s instructions. A PCR was then performed using a forward primer designed in 
the exon1-exon2 junction and a reverse primer located in intron 4, and the PCR product was purified and 
sequenced. 
 
Quantitative real-time PCR 
Total RNA was isolated from peripheral blood lymphocytes, cells and from FFPE tumor tissues using the 
TriReagent kit (MRC) and the RNeasy FFPE kit (Qiagen), respectively. The quantity and purity of the RNA 
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were determined using NanodropTM 1000 (Thermo Scientific) and cDNA was prepared from 1 µg of total 
RNA using oligo (dT) primers and SuperScript® III RT (Invitrogen). The MDH2 and RBP1 mRNA levels were 
determined by quantitative PCR on a 7500 fast real-time PCR system (Applied Biosystems) using the 
Universal ProbeLibrary set (https://www.roche-applied-science.com) as described by the manufacturer. 
Relative mRNA levels were estimated by the 2-CT method3 and normalized using β-glucuronidase (GUS) 
and β-actin (ACTB) as housekeeping genes. The results are shown as mean+s.d. (n≥3). For the blood 
MDH2 mRNA study we used as controls mRNA from three relatives that tested negative for the MDH2 
mutation. mRNA obtained from FFPE tumors carrying mutations in other known pheochromocytoma 
susceptibility genes were used as controls: three tumors with mutations in RET, one with a mutation in 
TMEM127, one with a MAX mutation, and three tumors with SDH gene mutations (the latter group only 
for RBP1 mRNA assessment). 
 
Western blot 
To demonstrate the absence of full-length MDH2 protein in tumors carrying the c.430G>T mutation, we 
performed western blot analysis using a polyclonal rabbit MDH2 antibody (HPA019716; Sigma-Aldrich) 
that specifically recognizes translated MDH2 transcript 1 (ENST00000315758). Proteins were obtained 
from the four FFPE tissue samples carrying the MDH2 mutation and from five control tissue samples 
carrying other known genetic alterations (three tumors carrying mutations in RET, one with a TMEM127 
mutation, and one with a MAX mutation), using the Qproteome FFPE Tissue kit (Qiagen). Proteins were 
separated by 10% SDS-PAGE and transferred to a polyvinylidene fluoride membrane. The membrane was 
blocked and then incubated with a 1:100 dilution of the antibody following the manufacturer’s 
instructions. Equal protein loading was assessed using a 1:12,000 dilution of monoclonal anti- β-actin 
mouse antibody (A5441, Sigma-Aldrich). Western blot analyses of MDH2 were also performed for 
proteins obtained from lymphoblastic and HeLa cells using standard procedures. 
 
Immunohistochemistry 
Immunohistochemical staining of 5-hmc (Active Motif; 39770) and H3K27me3 (Cell Signaling Technology; 
9756) was performed using 3 μm FFPE sections from the four MDH2-mutated tumors, following standard 
procedures. Two tumors carrying mutations in RET and SDHB were used as controls. 
 
Gene expression analysis 
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To identify the transcriptional profile associated with alterations in MDH2 we used gene expression data 
for the tumor carrying the MDH2 mutation, for 84 pheochromocytomas and paragangliomas deposited in 
the National Center for Biotechnology Information GEO database under the accession number GSE194224, 
and for six additional genetically characterized tumors. Tumor sample processing, hybridization on the 
Agilent Whole Human Genome platform (4x44K) (Agilent Technologies), and data normalization were 
performed as previously described4. Tumor samples were grouped according to their expression profiles 
by unsupervised clustering using GeneCluster 2.05, as previously described4. Hierarchical clustering was 
performed using the 176 genes with expression data available, of the total 191 genes described as 
hypermethylated and downregulated in SDH gene-mutated and FH-mutated pheochromocytomas6. We 
used the clustering average for linkage and uncentered correlation as the distance measure. In addition, 
we assessed the mRNA expression of RBP1 in the whole series of pheochromocytoma/paragangliomas, by 
gene mutated. 
 
Liquid chromatographic tandem-mass spectrometric determination of energy pathway metabolites 
Fresh frozen tumor tissue (5-10 mg), from the index case and from eight SDH gene-mutated and 48 non-
SDH gene-mutated cases, was immersed in 500 μl LC/MS grade methanol containing isotope-labeled 
internal standards. Homogenization was achieved by vortexing with a metal bead for 2 minutes. 
Homogenates were then centrifuged at 2000xg for 5 minutes at 4°C to separate insoluble debris. 
Supernatants were taken to dryness with a speed vac concentrator (Thermo Scientific) and stored at -
80°C. Pellets were resuspended in mobile phase and filtered using a centrifugal tube with a pore size of 
0.2 µm. Analysis of metabolites was carried out using an API QTRAP 5500 (AB Sciex) mass spectrometer 
coupled to an Acquity ultra-high performance liquid chromatographic system (Waters). Chromatographic 
separation was achieved on a Waters Acquity UPLC® HSS T3 column (1.8 μm, 2.1 x 100 mm) with a flow 
rate of 0.459 ml/min, a mobile phase of 0.2% formic acid in water (A) and 0.2% formic acid in acetonitrile 
(B), and a gradient of 0.37min 95% A, 4.87min 70% A, 5.37min 100% B, 5.87min 100% B, 6.37min 95% A, 
7.5min 95% A. The column was maintained at a temperature of 25°C and the sample manager at 5°C. The 
mass spectrometer was operated at 550°C in negative ion electrospray mode. Multiple reaction 
monitoring was used for detection and quantification. For cell line metabolite assessments, the same 
procedure was applied, using 106 cells in each determination. 
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Enzymatic activity analyses 
Cytosolic and mitochondrial fractions were obtained after homogenization of frozen tumor biopsies 
obtained from the MDH2-patient and from 4 controls, by a standard differential centrifugation 
procedure7, 8. Protein concentration was determined by Bradford with BSA as standard. The cytosolic and 
mitochondrial fractions were used to determine the enzymatic activity of MDH1 and MDH2, quantified as 
a decrease in NADH fluorescence, after the addition of OAA, using a BMG plate reader, as previously 
described.7 NADH fluorescence was calibrated based on NADH standards. Control and mutant MDH2 
tumor fractions were used at different dilutions in 5-6 paired independent experiments to correct for 
measurement variability. A similar procedure was carried out for HeLa cell fractions. Lactate 
dehydrogenase (LDH, measured as the increase in NADH caused by lactate addition) and citrate synthase 
(CS, measured as the increase in absorbance of 5,5’-dithiobis-2-nitrobenzoic acid after the addition of 
OAA) were assayed using standard procedures8, 9. Contamination of mitochondrial fraction with cytosol 
(residual LDH activity) was detected in approximately 3% of HeLa extracts, but not in tumor samples. 
MDH2 activity in HeLA cells was thus corrected by subtracting the estimated cytosolic contamination (% 
of LDH present) from the activity measured in the mitochondrial fraction. Contamination with broken 
mitochondria in the cytosolic fraction (residual citrate synthase activity), was approximatley 10% and 50% 
of tumor and HeLa preparations, respectively. 
Cell cultures 
Lymphocytes from the two carriers of the c.429+1G>T MDH2 mutation (II-2 and II-3 in Supplementary 
Figure 4) were immortalized using Epstein-Barr virus, as previously described10. HeLa cells were cultured 
in Dulbecco’s modified Eagle medium GlutaMAX (DMEM; Invitrogen), supplemented with 10% (v/v) foetal 
bovine serum (FBS, PAA laboratories), 1% (v/v) penicillin/streptomycin and 0.6% (v/v) Fungizone (Gibco), 
and maintained at 37°C in a humidified incubator with 5% CO2. MISSION® shRNA lentiviral transduction 
particles (TRCN0000028561; Sigma) were used to specifically knockdown MDH2. Stable gene knockdown 
(KD) was established by cellular resistance to puromycin (3 µg/ml). After one week, selected puromycin-
resistant clones were isolated and cloned for further analysis. Scrambled non-target shRNA control vector 
(Sigma) served as a negative control. To rescue from MDH2 depletion, HeLa MDH2 KD cells were seeded 
at 200,000 cells per well on 24-well plates for 24h. Each well was transiently transfected with 0.15 μg of 
pCMV6-AC-MDH2 (Origene), a plasmid containing the full cDNA sequence (NM_005918) of the human 
MDH2 gene, using Lipofectamine 2000 (Invitrogen), according to the manufacturer's recommendations. 
pCMV6-AC empty vector was used as a control. 
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Pyrosequencing 
Specific sets of primers were designed for PCR amplification and sequencing using a specific software 
package (PyroMark assay design version 2.0.01.15) to interrogate the methylation status of CpG sites 
from seven selected genes: RBP1, SPOCK2, KRT19, ARSG, TMEM45B, HTATIP2, and MAPK13. Single-
stranded DNA templates from the corresponding amplifications of DNA extracted from two MDH2-
mutated tumors were treated to quantify methylation level using the PyroMark Q24 System, version 2.0.6 
(Qiagen), according to the manufacturer’s instructions. Whole-genome amplified DNA from normal 
lymphocytes was used as a control11. 
 
Statistical methods 
The Kolmogorov-Smirnov test was used to assess departure from the normal distribution. When a normal 
distribution could not be assumed, a two-sided exact Mann-Whitney U test was applied to test for 
differences. Otherwise a t-test for independent samples was applied. Nominal two-sided P-values less 
than 0.05 were considered statistically significant. Statistical analyses were performed using SPSS version 
17 (SPSS Inc, Chicago, Illinois), R version 3.0.1 and Graphpad Instat version 3.05. 
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PCC/PGL is the most heritable of all cancers, with 40% of cases explained by known genetic 
factors. Despite this, there are still a substantial number of patients with clinical characteristics suggesting 
heritability in whom no mutations in PCC/PGL susceptibility genes are found. This clearly suggests the 
implication of other genes in the predisposition to this already puzzling genetic disease. Linkage analysis 
and positional cloning have been successfully employed in the past to identify PCC predisposition genes 
such as RET, NF1, VHL, and TMEM127. However, these approaches usually require highly informative 
pedigrees and therefore are not suitable for patients with no, or limited, family history of disease. In 
more recent years, NGS, and more specifically WES, has been demonstrated to be a very powerful tool in 
discovering new genes related to hereditary disorders. Therefore, the purpose of this thesis was to apply 
WES to identify genes involved in hereditary predisposition to PCC/PGL in patients with clinical 
characteristics of heritability but no mutations in any of the susceptibility genes known so far. Taking into 
account the aforementioned genetic heterogeneity of this disease, one of the crucial steps to achieve our 
objective was the adequate selection of patients to be studied. Thus, we used either molecular or clinical 
markers to choose sets of patients that were as homogeneous as possible (Figure 3).  
 
 
A B
C
.... ..
. ....
Figure 3. Schematic representation of the three strategies applied for the selection of cases. A) Molecular 
marker: transcriptional profiles of tumors. B) Approach based on trios: patient/mother/father. C) Clinical 
marker: tumor multiplicity. 
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This approach enabled us to identify for the first time two genes (MAX and MDH2) involved in 
predisposition to develop PCC/PGL. Although WES performed in blood samples from selected trios 
(patient-father-mother) did not identify the now-known EPAS1 somatic mosaic mutations, we were able 
to provide relevant information about the contribution of EPAS1 alterations to the disease in our selected 
series of patients. 
  
• ARTICLE 1: Discovery of germline mutations affecting MAX in patients with PCC. 
One of the most important applications of genome-wide expression profiling is to classify 
tumors182. Thus, since 2000, several studies have applied hierarchical clustering to identify characteristic 
patterns of expression for specific tumor phenotypes183-185. Especially illustrative of the utility of this 
approach is the transcriptional classification of breast tumors that distinguishes based on molecular 
profiles luminal, basal like and ErB2-positive carcinomas184,186-188. In the case of PCCs and PGLs, 
transcriptional profiling has been widely used to cluster tumors according to their genetic background or 
associated biochemical profile52-55. PCCs/PGLs carrying mutations in the same gene have similar 
expression profiles and can therefore be segregated into well-defined transcriptional clusters. Taking 
advantage of a hierarchical clustering performed in our laboratory, we selected three unrelated patients, 
with family history of PCC and no mutations in any of the known susceptibility genes, as candidates for 
WES since their tumors showed a highly homogeneous expression profile55.  
The bioinformatic pipeline and the filtering steps for WES data that we designed and applied 
enabled us to identify in all three individuals germline mutations in two genes. The presence of these 
mutations was confirmed by Sanger sequencing, however only those affecting MAX were found to 
segregate with the disease in the three pedigrees. The truncating effect of the MAX variants identified 
(i.e. alteration of the initiation codon, introduction of a premature stop signal, and frameshift skipping of 
one complete exon), provided strong evidence that MAX loss of function mutations were involved in PCC 
development in these pedigrees.  
Once variants in a gene pass all the filtering steps included in a given WES pipeline, it is highly 
advisable to assess previous evidence or data that might connect the function of the gene to the disease, 
in order to inform subsequent work. In the case of MAX, while there was ample knowledge about the role 
of this protein regulating MYC functions, no association with cancer susceptibility had been reported. 
However, Ribon et al. had demonstrated in 1995 the existence of a homozygous rearrangement affecting 
MAX in PC12 cells, a cell line derived from rat adrenal PCC189. The observed alteration led to the inability 
of the protein to homo- or hetero-dimerized and, therefore, to inefficiency in the repression of the 
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oncogenic properties of MYC190. Further, the authors demonstrated that reintroduction of MAX in PC12 
cells resulted in transcriptional repression and a reduction in growth rate. Thus, the presence of MAX loss 
of function mutations in PCCs was consistent with the suggested role of the protein repressing MYC-
dependent transcriptional activation in PC12 cells. Moreover, the oncogenic, MAX-independent abilities 
of MYC, and the role of MAX acting more like repressor than activator of MYC-target genes, had been 
further demonstrated in Drosophila by Gallant et al145. 
Subsequently, the loss of the wild type allele (LOH), plus the absence of the protein in the tumors 
developed by the three sequenced patients, suggested that the mutations found in MAX were the cause 
of the disease in these families. In the genetic models in which a tumor suppressor gene is implicated, the 
mechanisms producing LOH following the Knudson’s two-hit model191 can be very diverse and sometimes 
do not affect the coding part of the genome, implying other genetic or epigenetic mechanisms. This can 
make the establishment of the implication of a gene in a given disease very difficult. In the tumors 
developed by our three sequenced patients, the LOH was due to paternal uniparental disomy (UPD) 
affecting chromosome 14, were MAX is located. 
Taken together, these findings suggested that MAX germline mutations were the cause of PCC 
susceptibility and that MAX behaved as a classic tumor suppressor gene. This was endorsed by the 
identification of two additional truncating mutations and three missense variants by genetic testing of 
MAX mutations in a selected series of PCC/PGL patients suspected to be hereditary. Despite the fact that 
the missense variants were not found in controls, were predicted to be pathogenic by in-silico prediction 
algorithms, and affected important regions within the protein, we considered them to be VUS, and 
developed functional models to determine whether they have a causal role (see project 1.3). Besides the 
presence of bilateral tumors amongst MAX mutation carriers, and an apparent paternal transmission of 
the disease (a paternal origin of the mutated allele was detected in six families), 25% of cases developed 
metastases. The malignant behavior of tumors with mutations in MAX seemed to be consistent with what 
was known about neuroblastoma, the other tumor derived from neural crest and developed mainly from 
the adrenal medulla. Up to 22% of neuroblastomas show MYC amplification, strongly associated with 
advanced disease stages and rapid tumor progression192, which would support the idea that MAX loss of 
function is related to metastatic potential, since MAX is the main regulator of MYC. Nevertheless, the 
association of MAX mutations with malignancy was not confirmed in a larger series of MAX mutation 
carriers (see Project 1.2). Finally, and as previously described55, tumors carrying mutations in MAX were 
grouped within the PIK3CA-AKT1-mTOR transcriptional cluster 2, along with tumors carrying mutations in 
RET, NF1 and TMEM127. The known crosstalk between the MYC-MAX-MXD1 axis and the PIK3CA-AKT1-
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mTOR pathway explains this particular expression profile of MAX tumors and provides further evidence of 
the implication of the gene in the disease193,194. 
The MYC family of proto-oncogenes is composed of important transcriptional activators 
implicated in the regulation of normal cell proliferation, differentiation and apoptosis142. MAX is a well-
known dimerization partner of MYC which plays a central role in the regulation of the cancer-
predisposing MYC-MAX-MXD1 network100. Deregulation of the MYC-MAX-MXD1 network has been widely 
linked to cancer, especially neuroblastoma for which the amplification and overexpression of MYCN is a 
well-known genetic hallmark195. Thus, ablation of MAX's transcriptional repression of MYC in PCC could 
lead to the same oncogenic deregulation of MYC that occurs in neuroblastoma101. However, a role of 
MAX that is independent of MYC cannot be ruled out as the mechanism behind PCC/PGL development. 
The ubiquitous expression of MAX, plus its central role in the axis, suggests that MAX mutations might be 
implicated in a wider spectrum of neoplasias. Indeed, Romero et al., recently described the implication of 
MAX somatic mutations in small cell lung cancer (SCLC)196, in which the inactivation of MAX occurs in a 
way that is mutually exclusive of MYC amplifications.  
In 2011, MAX became the first cancer predisposition gene identified by WES117, and our next main 
objective was to establish the prevalence and the associated clinical characteristics of MAX mutation 
carriers.  
 
 • ARTICLE 2: Prevalence of MAX mutations in PCC/PGL patients. 
The discovery of a new susceptibility gene should be followed by the screening of a large series of 
patients in order to elucidate the relative importance of alterations in the gene for the disease. Thus, we 
combined data from 1,694 unrelated PCC/PGL patients testing negative for mutations in the known 
susceptibility genes, which were recruited by 17 participating centers from six different countries. An 
additional series of 245 tumors were also collected140. A germline pathogenic mutation in MAX was found 
in 1.12% of the index cases included in this analysis. Thus, the contribution of MAX mutations to this 
disease iss similar to the reported for TMEM12798, and higher than the most recently identified 
susceptibility genes, FH and MDH282(in press). As a result of this study, the spectrum of patients carrying 
MAX mutations was extended to cases suffering from extra-adrenal tumors (i.e. thoraco-abdominal 
PGLs). In addition, we established that somatic mutations in MAX play a role in the sporadic presentation 
of the disease. For a long time, somatic driver mutations have been considered rare in PCC/PGL for a long 
time. However, several recent studies have positioned these mutations as important genetic events in the 
development of the disease53,63,67,96,97,106,197. The presence of MAX somatic mutations in 1.65% of tumors 
further highlights the importance of somatic driver events in the sporadic development of the disease. 
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Regarding the phenotypic characteristics of MAX mutation carriers, the presence of bilateral 
disease (in the case of PCC) in 21% of patients was consistent with the high percentage of bilateral PCCs 
observed in patients carrying mutations in other cluster 2 genes such as RET or TMEM12745,46,98,198, while 
the mean age of onset (34 years) was slightly lower than that observed in carriers of mutations in these 
other genes. It is noteworthy that in all MAX mutation carriers developing extra-adrenal tumors, their 
PGL was diagnosed following the previous development of PCC. None of the patients diagnosed only with 
PGL carried a MAX mutation. Among the patients included in this second study, only two developed 
metastasis, suggesting that, unlike what typically occurs in SDHB-mutated mutated tumors46, MAX-
mutated tumors do not have a high risk of malignancy. More than 65% of patients with MAX mutations 
had no family history of the disease, and the finding of three additional cases in which the transmission of 
the disease was paternal provided further evidence of a parent of origin inheritance. This preferential 
paternal mode of transmission may provoke generation skipping within pedigrees, with important 
consequences for genetic counseling. Further, it makes even more difficult the task of establishing the 
pathogenicity of MAX VUS because of the challenges of studying the segregation of variants with disease. 
It should be noted that, though the overall prevalence of MAX mutations in the entire series slightly 
exceed 1%, this increased to 12% in patients with isolated tumors, and to 66% in cases with bilateral PCC, 
when we considered only cases with PCC and family history. 
The biochemical characteristics of MAX-mutated tumors were intermediate, between the 
predominantly epinephrine secretion of NF1 and RET tumors and the norepinephrine secretion of VHL or 
SDHB/D tumors199. Consistent with this intermediate phenotype was the observed moderate expression 
in the tumors of PNMT, the enzyme responsible for converting norepinephrine to epinephrine. Similarly, 
urinary measures of normetanephrine compared to metanephrine confirmed significant but limited 
capacity of MAX tumors to produce epinephrine.  
The majority of the mutations found in this series were located in the conserved exons 3 and 4 of 
MAX, giving rise to truncated proteins. Further, the observed LOH affecting the remaining wild-type allele 
of MAX was corroborated by the absence of the protein according to immunohistochemistry. 
Interestingly, the c.97C>T variant, which affects a crucial residue within the MAX protein involved in the 
DNA binding, was found in unrelated patients from 5 countries (Italy, Spain, United States, France, and 
The Netherlands), suggesting that it represents the first hotspot mutation affecting MAX. This was further 
supported by the finding of a somatic c.97C>T change in a sporadic PCC112.  Overall, these findings suggest 
that two phenotypic characteristics may be used to guide the genetic testing of the patients towards 
MAX: 1) lack of nuclear immunohistochemistry staining for MAX (something useful only for variants which 
Discussion 
154 
 
produce the truncation of the protein); 2) intermediate biochemical phenotype (also detectable in 
fractioned catecholamines tested in blood or urine). 
To summarize, this second study elucidated the importance of MAX mutations in PCC/PGL 
susceptibility, pointing to the need for the inclusion of this gene in the genetic work-up of affected 
patients, particularly those with PCC (bilateral or multifocal), and/or with family history. In addition, the 
presence of several (n=8) VUS affecting MAX made fundamental the development of functional models to 
guide the prediction of the pathogenicity of this type of variants. 
 
• ARTICLE 3: Functional and in silico assessment of MAX variants of unknown significance. 
While truncating mutations in tumor suppressor genes are usually considered deleterious, to 
establish the pathogenicity of a new missense variant requires further analysis (e.g. identifying a second 
hit such as LOH of the wild-type allele). In silico algorithms are widely used to predict the biological 
consequences of VUS; however, in the absence of other clinical evidence (for example, additional 
affected family members carrying the variant) they are insufficient to conclude whether a variant is 
deleterious or not. In addition, the prediction given by different algorithms are frequently contradictory, 
making the in silico establishment of pathogenicity a very complex task. Therefore, in order to improve 
the genetic counseling and clinical follow-up of carriers it is necessary to develop functional systems to 
clarify the role that a given VUS may have in tumor development. Half of all MAX variants identified in 
patients with PCC to date have been missense changes. In these patients, the frequent absence of family 
history, probably due to the observed paternal mode of inheritance49,140, further complicated the 
assessment of the pathogenicity of the corresponding VUS very complicated. Thus, in order to determine 
the role of individual MAX missense variants in the disease, we developed a reliable PC12-based assay 
that, combined with the prediction of the effect of each alteration at the molecular level, the consensus 
prediction of five different in silico algorithms and relevant clinical patient information, enabled us to 
establish the pathogenicity of all except one of the variants considered. 
The affected residues (with three exceptions not observed in the crystallized protein) were 
modeled in the protein structure of MAX. The nine analyzable variants were classified into three groups 
depending on the function predicted to be affected:  
- Variants affecting residues implicated in the interaction with DNA: Three variants altered the 
DNA binding properties by losing a residue (arginine) commonly found in protein-DNA interactions. Only 
the p.D14N variant maintained MAX’s ability to interact with DNA, consistent with the functional assay, 
which indicated that this variant was not producing any alteration. 
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- Variants causing a change affecting the dimerization region of the protein: These variants 
strongly affected the MAX homodimer and therefore the assembly of monomers. The lack of MAX 
homodimers may make accessible for the transcription machinery the promoter regions of certain genes 
that are normally repressed by MAX, thus facilitating their expression. 
- Variants causing a change of the wild type amino acid to a destabilizing proline: Proline is a 
residue that alters the helical structure and may lead to an alteration in the hetero- or homo-dimerization 
capacity of the mutated protein. 
Overall, eight of the nine substitutions considered were predicted to cause an alteration in the 
properties of the protein, a result that is entirely consistent with those from the proposed PC12-based 
functional assay. 
Classification of the variants according to different combinations of five independent algorithms 
differed from the result of functional assay for at least two variants (range: 2-5). The prediction improved 
when we used the agreement of at least three of the algorithms. The reliability of this latter consensus 
prediction was confirmed by the results obtained assessing the only four MAX polymorphic missense 
variants described in control population databases (ESP data server: http://evs.gs.washington.edu/EVS/). 
This result is consistent with others from the literature that recommend the combination of different 
algorithms, rather than just one, to better inform the classification of VUS variants157,158. 
As mentioned previously, MAX plays a key role in cell homeostasis, heterodimerizing with MYC to 
initiate the expression of hundreds of genes100. However, the recent discovery of MAX’s involvement in 
PCC/PGL development, behaving as a classical tumor suppressor gene, suggests that its role in the axis 
most likely relates to repress the oncogenic activities of MYC, at least in this tissue. The results obtained 
from our functional assay, which showed high concordance with the results obtained from the proposed 
consensus in silico prediction, further supports this idea. Co-introduction of MYC reporter plasmid 
containing four E-box sites, together with a plasmid containing wild type MAX, decreased the luciferase 
activity of transfected cells compared to PC12 wild-type, suggesting a regulatory role of the MAX protein. 
Moreover, MAX mutant proteins less extensively repress MYC activity, thereby increasing luciferase 
activity. Of note the only variant unclassified by the prediction tools was pathogenic according to our 
functional assay (p.M65V). The result of the functional assay for this variant was further supported by the 
presence of other change affecting the same amino acid in prostate cancer (COSMIC database: 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/). Interestingly, the unique mutation 
predicted by MutPred to provoke a “gain of disorder” within the protein (p=0.0051) was the variant 
presenting the greatest difference in the luciferase activity, compared to wild type. 
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The eight individuals carrying MAX variants identified as deleterious by our functional assay and 
by the consensus prediction presented with clinical characteristics of heritability (for example 
multiplicity/bilaterality or segregation of the variant with the disease). In contrast, the three patients 
carrying a MAX VUS with no apparent effect on MYC regulation presented with isolated tumors and no 
other clinical features of heritability. Inconsistent results were obtained for the p.V9L variant, classified as 
pathogenic by the functional assay but non-pathogenic by the consensus in silico prediction. The patient 
harboring this VUS presented with multiple tumors, which suggests pathogenicity. However, the 
substitution has been observed in 4 of 31,760 unaffected individuals (EXAC server: 
http://exac.broadinstitute.org) and showed no LOH in the available tumor. Although the patient did not 
present mutations in other susceptibility genes, the inconsistent data available do not allow us to reach a 
conclusion regarding the pathogenicity of this variant. 
To summarize, in this study we demonstrated how the correct use of clinical information, 
together with a reliable functional assay and a compendium of computational methods, may inform the 
clinical management of patients carrying VUS.  
 
• ARTICLE 4: Contributing to the knowledge of EPAS1 mutations in PCC. 
 
A rare clinical feature, in association with a given pathological condition, can be used to select a 
homogenous set of patients as candidates to identify causal germline alterations in the same gene. In 
addition, over the past few years WES has become an efficient means of searching for new molecular 
defects causing rare diseases transmitted through a recessive or de novo inheritance mode200-203. Thus, 
the presence of idiopathic polycythemia (a rare condition) and multiple PCCs/PGLs in three patients from 
our series without family history of the disease (consistent with a de novo or recessive mode of 
inheritance) led us to conduct a second WES project based on the analysis of blood samples obtained 
from three trios: affected individuals and each of their biological parents. During the analysis of our WES 
data, a manuscript was published describing EPAS1 somatic post-zygotic mutations in two patients with 
the same candidate clinical features63. Somatic post-zygotic variations can occur during mitotic cell 
division following fertilization and zygote formation, giving rise to individuals that are mosaic: with 
genetically different populations of somatic cells, only a subset of them harboring the mutation204. 
Somatic post-zygotic models have been described to provoke miscarriage, birth defects, developmental 
delay and cancer205-209.  When we analyzed the tumors from our three index cases for the presence of 
alterations in EPAS1, we found mutations affecting either the Proline 531 or the residues located close to 
this primary hydroxylation site of the protein in all of them. Even though the sampling we carried out for 
WES was appropriate, we wrongly assumed a germline inheritance model would explain the absence of 
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family history of the disease. This experience highlights the importance of taking more unlikely genetic 
models into account in order to cover all contingencies. 
Subsequent analysis of a series of frozen PCCs/PGLs uncovered EPAS1 mutations in one patient 
with multiple tumors but no polycythemia, and in three additional cases presenting with single adrenal 
tumors. This latter finding revealed for the first time that EPAS1 is involved in the sporadic presentation 
of the disease. Excluding the three index patients who were initially selected for WES, we observed that 
EPAS1 mutations accounted for 10% of the frozen tumors analyzed. These results suggested that 
mutations in EPAS1 are very frequent in PCC/PGL development, placing EPAS1 in the group of genes, 
besides NF1, VHL and RET15, more frequently involved in the sporadic presentation of the disease. 
As mentioned previously, under hypoxic conditions the HIF family of transcription factors (HIF-1α, 
EPAS1 and HIF-3α) are stabilized leading to the transcription of genes related to the hypoxia response and 
resulting in the initiation of processes such as angiogenesis, glycolysis, apoptosis, proliferation, and cell 
growth210,211. Mutations in EPAS1 also stabilize the protein by abrogating its hydroxylation and 
subsequent proteosomal degradation 63. Though all reported EPAS1 mutations, either found in patients 
with familial erythrocytosis or in patients with multiple PCC/PGL and polycythemia, affect residues 
located in the proximities of the primary hydroxylation site (proline 531), we found for the first time 
mutations directly affecting the proline residue67. Moreover, with the except of a mutation affecting the 
Aspartic acid 539212, all alterations associated with the development of PCC/PGL were different compared 
to those found in patients with congenital polycythemia67. The absence of PCCs and PGLs in the reported 
cases of familial erythrocytosis carrying EPAS1 germline mutations suggests that, as occurs with 
mutations in the VHL gene, different mutations in EPAS1 predispose to different diseases. Nevertheless, 
we cannot rule out that additional genetic factors could modulate the clinical phenotype of EPAS1 
mutation carriers. On the other hand, the absence of polycythemia in a patient with multiple PGLs from 
our series carrying a mutation previously found in a patient presenting with polycythemia and PGLs63, 
points to the moment during embryogenesis at which the mutation occurs as a crucial factor in the 
clinical phenotype.  
It has been well established that the immunohistochemistry of SDHB can guide the genetic 
screening for mutations in the PCC/PGL susceptibility genes. Thus, negative staining for SDHB, partly due 
to the frequent losses of the chromosome 1q, is a good indicator for mutations in the SDH genes 173. 
Something similar occurs with NF1-mutated tumors which usually harbor concomitant chromosome 17 
losses. The finding in our series of EPAS-mutated tumors of exclusive gain of chromosome 2p, affecting 
either the mutated or the wild-type allele, could also guide the genetic testing for this gene, avoiding 
unnecessary expense. While unexpected, it has previously been shown that the gain of an extra copy of 
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an oncogene may cause alterations in cell growth. Thus, it has been demonstrated that RET-mutated 
PCCs can present with either somatic duplication of the mutated allele or loss of the wild type RET 
allele.213. The somatic gain of an extra copy of an EPAS1-mutated allele may lead to an increase in the 
amount of stabilized protein, and the gain of an extra copy of the wild-type allele can also activate the 
hypoxic response driven by EPAS1. Finally, the observation of tumors without mutations in EPAS1 
presenting a specific gain of chromosome 2p suggests that this event could be an important factor in the 
development of the disease. 
The transcriptional profile of EPAS1-mutated tumors did not fit with the typical pseudo-hypoxic 
profile of tumors harboring VHL or SDH gene mutations. In fact, hierarchical clustering of EPAS1-mutated 
tumors and a large series of PCCs/PGLs did not group them within the expected transcriptional Cluster 1 
(data not shown). Only two genes, PCSK6 and GNA14, involved in the hypoxic response, were up-
regulated in EPAS1-mutated tumors. These genes may also play an important role in the development of 
normal hematopoietic cells 214 and in susceptibility to carcinogenesis, tumor progression 215, apoptosis 216 
and tumor malignancy 217. 
To summarize, in this second WES project we learned about the risks of applying preconceived 
inheritance models to the pipeline of a given next generation sequencing experimental design. In 
addition, we have demonstrated that EPAS1 mutations are also involved in sporadic presentation of the 
disease, and found that specific copy number alteration affecting EPAS1 can be used to guide the genetic 
screening of patients with PCC/PGL for mutations in the known susceptibility genes. 
 
• ARTICLE 5: Discovery of MDH2 germline mutations in patients with PCC.  
 
Tumor multiplicity is a relatively common condition in patients affected with PCC/PGL and 
carrying a germline mutation in one of the major susceptibility genes (for example, in an SDH gene; see 
Table 1). This phenotypic feature represents one of the most clear clinical signs of disease heritability, and 
is a major indicator for genetic screening to identify a germline alteration. Of note, tumor multiplicity is 
sometimes controversial since is difficult to distinguish between the presence of multiple primary tumors 
in different locations and the local dissemination of an isolated mass. In a third WES project we selected 
for sequencing tumor DNA (and germline DNA when possible) from three unrelated patients affected 
with more than three primary PCC/PGLs but no mutations in any of the known susceptibility genes. 
Preliminary analysis of WES data looking for a common gene mutated in all patients yielded no positive 
results. Thus, we focused our attention on the analysis of each sample independently, and we present in 
this thesis the results obtained from the analysis of one of the three sequenced patients. For this 
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particular case, a patient diagnosed with five tumors and bone metastasis, WES was applied to tumor 
DNA only because we did not have sufficient germline DNA. 
First, a very stringent filtering pipeline was applied in order to obtain a reduced list of candidate 
variants. In addition to standard filtering steps, we ruled out variants with low or moderate impact (i.e. 
missense or silent variants, respectively), and used PROVEAN software 
(http://provean.jcvi.org/index.php), manual curating and additional internal exomes as final steps in the 
filtering process. After all filtering steps, we identified sixteen high-impact candidate variants (i.e. 
nonsense or frameshift changes): five single nucleotide substitutions and eleven small insertions and 
deletions. We selected for further analysis a variant (c.429+1G>T) affecting a donor splice site in MDH2. 
based on the relevant function of this gene in the Krebs cycle, a well-known PCC-related pathway. 
Disruption of the Krebs cycle is a hallmark of cancer, but this is especially relevant in the case of 
hereditary PCC/PGL, in which germline mutations affecting the SDH genes are well-known genetic drivers 
of tumor development69-72 73. Moreover, mutations in the FH gene have been recently described to be 
involved in PCC/PGL predisposition50,82, and at least one PGL has been found to carry a somatic IDH1 
mutation116. 
First, we confirmed by Sanger sequencing the presence of the variant both in the sequenced 
tumor and in peripheral blood lymphocytes from the patient. The c.429+1G>T variant affected a 
canonical donor splice site in the exon 4 of MDH2, and we demonstrated that it caused a deleterious 
effect, leading to both an altered transcript that incorporated 20 additional amino-acids into the exon 
and a premature stop codon. Moreover, the LOH of the wild type allele observed in two of the tumors of 
the patient, the absence of MDH2 protein and enzymatic activity in all available tumors, and the 
segregation of the variant with the disease in at least one relative, led us to propose MDH2 as a classical 
tumor suppressor gene. In addition, only one truncating mutation in MDH2 is recorded in COSMIC. The 
mutation was found in a neuroblastoma, a highly metastatic tumor of the sympathetic nervous system 
that is genetically related to PCC172 and that also originates primarily in the adrenal gland. 
The study of DNA methylation-associated profiles has led to the identification of characteristic 
epigenetic subtypes in several cancers80,218. Thus, a CIMP profile has been described for colorectal 
cancers219, and more recently for gliomas80, this latter associated with gain-of-function mutations in the 
IDH1 and IDH2 genes. In 2013, Letouze et al. described a well-defined CIMP for PCCs and PGLs harboring 
mutations in genes involved in the Krebs cycle (i.e. FH and SDH genes)50. To support the implication of the 
MDH2 gene in tumor development, we performed hierarchical cluster analysis of a MDH2-mutated tumor 
and a large series of PCCs/PGLs, using data from a subset of genes reported as hypermethylated and 
downregulated in CIMP-associated PCC/PGL50. The transcriptional profiling revealed that the MDH2-
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mutated tumor clustered together with PCCs/PGLs carrying mutations in the SDH genes, which also 
suggested a CIMP profile for this tumor. In addition, three apparently sporadic cases (testing negative for 
mutations in MDH2 and all other PCC/PGL susceptibility genes) were grouped in this cluster, suggesting 
that they may harbor a still unknown mutation in a Krebs cycle-related gene. 5-hmC and H3K27me3 
immunostaining was consistent with the suggested CIMP profile of all available MDH2-mutated tumors 
from the patient, as occurred with FH- and SDH-mutated PCCs/PGLs50. Amongst the genes found 
hypermethylated and downregulated in CIMP-tumors, RBP1 was especially interesting, since its silencing 
seems to be exclusive for gliomas carrying mutations in the IDH1 and 2 genes163. Our data also confirmed 
this association for PCCs/PGLs with a CIMP profile, and pyrosequencing analysis revealed that the low 
RBP1 expression levels observed in MDH2-mutated tumors was actually due to CpG island methylation. 
The abrogation of a given enzymatic activity usually provokes the accumulation of its substrates, 
leading to the absence of the reaction product. In PCC/PGL, the accumulation of substrates is a major 
feature of tumors affected by mutations in the genes encoding Krebs cycle enzymes. Thus, the 
accumulation of succinate and fumarate in tumors harboring mutations in FH and the SDH genes, 
respectively, leads to the inhibition of DNA and histone demethylases, in vitro and in vivo, producing the 
mentioned CIMP profile50,79 (Figure 4). A similar effect was observed in Fh1-deficient mouse cells167. 
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Figure 4. Representation of the oncogenic effect of the accumulation of Krebs cycle intermediates, 2-HG, 
succinate and fumarate, due to mutations in IDH1/2, SDH and FH, respectively. 
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The physiological consequences of disruption of the MDH2 enzyme in mammals have not been 
described. However, a Drosophila pupae-based model revealed the accumulation of late-stage Krebs 
cycle intermediates, such as malate, succinate, and fumarate, after MDH2 abrogation166. We 
demonstrated in this study that stable abrogation of MDH2 activity in HeLa cells leads to the expected 
accumulation of krebs cycle intermediates fumarate and malate, a condition reverted by transient 
introduction of wild-type MDH2. Although we did not observed the expected accumulation of malate in 
MDH2-mutated tumors, the high fumarate:succinate ratio observed in the MDH2-mutated tumors 
suggested an excess of fumarate, and pointed to this metabolite as the cause of the CIMP-like profile 
observed. Neither MDH1 activity nor the expression of other malate-related enzymes, such as the malic 
enzymes in frozen MDH2-mutated tumors, explained the absence of malate accumulation in the tumors. 
While we cannot rule out that malic enzyme-dependent conversion of malate to pyruvate and NADPH are 
responsible for the absence of malate accumulation in MDH2-mutated tumors, the mechanism behind 
this controversial result remains unknown.   
The detection of two additional mutation carriers within the patient’s pedigree, allowed us to 
confirm the deleterious effect of the heterozygous splicing MDH2 mutation in established lymphoblastoid 
cell lines. Moreover, subsequent clinical testing detected high levels of normetanephrine for one of the 
mutation carriers, confirming the presence of the disease in this relative and the segregation of the 
mutation with the disease in the pedigree. The norepinephrine secretion profile observed for the two 
MDH2 mutation carriers matched that described for PCC/PGL patients carrying Krebs cycle mutations. 
Moreover, the incomplete penetrance found for the MDH2 mutation (i.e. one of the two mutation 
carriers did not show evidence of disease) also agreed with that observed for SDHB, SDHA, SDHC and FH 
mutations15,46,82,170. No other MDH2 mutation carriers were detected amongst a selected series (n=29) of 
patients with clinical features of a hereditary disease. The susceptibility genes most recently described, 
TMEM12798, MAX140 or FH82, each explain 1 to 2% of cases. Moreover, a previous screening for FH 
mutations in 239 Spanish PCC/PGL patients did not revealed any mutation carrier. Therefore, it seems 
that finding additional MDH2-mutated patients amongst patients in order to establish the prevalence of 
alterations in this gene, and the associated clinical presentation of the disease will require the screening 
of a larger series of patients. 
In summary, as a result of this study we propose MDH2 as a new PCC/PGL tumor suppressor 
susceptibility gene, once again suggesting a link between Krebs cycle disruption and PCC/PGL 
development. Moreover, our data suggest a possible involvement of other still unknown Krebs cycle-
related genes in PCC/PGL cases without known genetic predisposition and showing a CIMP-like profile. 
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• General discussion of WES applications to the discovery of cancer predisposition genes.  
 
Over the last decade, research into Mendelian disorders has been eclipsed by efforts to dissect 
the genetic bases of complex traits using GWAS. In addition, the success of investigations focused on 
deciphering the molecular basis of monogenic disorders has shrunk substantially, probably because of the 
lack of newer and more powerful methods. Previously, linkage studies had been demonstrated to be the 
most useful tool in the discovery of new genes playing a role in Mendelian disorders. However the 
absence of highly informative families, a common scenario in PCC/PGL pedigrees and the major limitation 
of this approach, has slowed the number of findings during recent years. In the case of PCC/PGL, the 
genetic and phenotypic heterogeneity of the disease makes the identification of a causal gene even more 
difficult. Nowadays, high-throughput techniques, especially WES, have emerged as a panacea and the 
most cost-effective method to discover new candidate genes and causal variants. Early studies have 
shown the effectiveness of applying WES to unrelated patients who share phenotypic similarities131,134,135. 
Collectively, these studies have demonstrated the advantages of WES over the linkage study design in 
situations where only a small number of unrelated samples, or sporadic cases, are available. In the case of 
genetically heterogeneous diseases, such as PCC/PGL, stratifying the patients by focusing on a specific 
molecular feature or any singular phenotype can help in the selection of informative individuals for WES.  
In this thesis we have developed three projects applying WES to a very low number of unrelated 
individuals, all of them selected because they presented phenotypic characteristics suggesting a 
hereditary genetic condition. That selection, based on similarities in the transcriptional profile of tumors 
or on clinical features of heritability, allowed us to identify two new PCC/PGL susceptibility genes: MAX, 
the first cancer susceptibility gene discovered by WES 49, and MDH2, another gene encoding a Krebs cycle 
enzyme (in press). In addition, the EPAS1 WES project exemplifies that, while the sampling process is 
crucial, the inheritance model included in the pipeline may be no less important. In conclusion, in this 
thesis we have demonstrated the success of using WES to identify new susceptibility PCC/PGL genes 
when an adequate and rational selection of cases and pipeline is applied. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 CONCLUSIONES/CONCLUSIONS 
 
  
  
 
  
 Conclusiones/conclusions 
 
 165 
 
CONCLUSIONES 
 
1- La secuenciación masiva del exoma constituye una técnica eficaz para el descubrimiento de 
nuevos genes de susceptibilidad implicados en el desarrollo de enfermedades que siguen un 
modelo de herencia mendeliano, como es el caso de los PCCs/PGLs. La técnica debe apoyarse en 
una adecuada selección de los candidatos, así como en el correcto filtrado de las variantes 
detectadas con el fin de obtener unos resultados óptimos. Es fundamental tener en cuenta todos 
los modelos de herencia posibles durante el diseño del proyecto. 
 
2- Las mutaciones germinales en el gen MAX confieren susceptibilidad hereditaria a desarrollar 
PCC/PGL. MAX, se comporta como un gen supresor tumoral clásico; se produce LOH del alelo 
silvestre en los tumores de los pacientes portadores de mutación (debida frecuentemente a una 
disomía uniparental paterna) y ausencia de proteína MAX funcional. 
 
3- La prevalencia de las mutaciones patogénicas en el gen MAX en pacientes con la enfermedad, 
tanto con PCC como en menor medida con PGL, es de un 1,12% y la implicación del gen en la 
enfermedad esporádica explica hasta un 1,65% de los casos. Sin embargo, esta proporción 
aumenta hasta un 66% en pacientes sin mutaciones en otros genes y con PCC bilateral o 
multifocal y antecedentes familiares de la enfermedad. 
 
4- Un modelo funcional desarrollado en células PC12, permite establecer de manera robusta el 
potencial patogénico de la mayor parte de las VUS encontradas en el gen MAX en pacientes con 
PCC/PGL. Los resultados funcionales, que guardaban una gran concordancia con los obtenidos a 
partir del consenso de varias predicciones in silico y venían refrendados por la información clínica 
disponible de los pacientes, son por tanto de clara aplicación en el consejo genético que se ofrece 
a estas familias. 
   
5- Las mutaciones en el gen EPAS1 se pueden producir tanto durante el desarrollo embrionario, 
dando lugar a casos con PCC/PGL múltiple y policitemia, como somáticamente en formas 
esporádicas de la enfermedad. La ganancia específica del cromosoma 2p constituye un rasgo 
diferencial de los tumores con mutación en EPAS1 y puede utilizarse como marcador para la 
búsqueda de alteraciones en este gen. 
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6- El gen MDH2 es un gen supresor tumoral asociado al desarrollo de PCCs/PGLs hereditarios, lo cual 
supone un nuevo ejemplo de cómo defectos en el ciclo de Krebs tienen un efecto oncogénico. La 
ausencia de MDH2 en los tumores, está asociada con un fenotipo hipermetilador similar al 
descrito en PCCs con mutaciones en los genes SDH o en FH, causado posiblemente por la 
acumulación de intermediarios del ciclo de Krebs. La penetrancia incompleta de la mutación 
encontrada, así como la ausencia de más casos con alteraciones en MDH2, sugieren la necesidad 
de reclutar un gran número de pacientes para determinar la relevancia del gen en la enfermedad.  
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CONCLUSIONS 
 
1- Whole exome sequencing constitutes an efficient technique to discover susceptibility genes 
involved in the development of Mendelian hereditary diseases, such as PCCs/PGLs. This technique 
should be complemented by appropriate filtering of the detected variants and selection of 
candidates, in order to obtain optimal results. It is crucial to take into consideration in the design 
of the project all possible inheritance models.  
2- Germline mutations in the MAX gene confer hereditary susceptibility to develop PCC/PGL. MAX 
behaves as a classical tumor suppressor gene. Absence of the functional protein and LOH of the 
wild type allele is observed in the tumors of these patients, the latter frequently due to 
uniparental disomy.  
3- The estimated prevalence of pathogenic MAX mutations in patients is 1.12%, presenting more 
often in PCC than PGL. On the other hand, mutations in the gene explain an estimated 1.65% of 
sporadic cases. This percentage is 66% in patients negative for mutation in other PCC 
susceptibility gene, with bilateral or multifocal PCC and a family history of the disease. 
4- By means of a functional model developed from PC12 cells, the pathogenic potential of the 
majority of the VUS found in the MAX gene in patients presenting PCC/PGL was established. 
Results from functional assays are concordant with those obtained from the consensus of several 
in silico prediction algorithms and are supported by the clinical information from the patients. 
This model has a clear application in the genetic counseling offered to these patients.  
5- Mutations in the gene EPAS1 can appear during embryonic development, giving rise either to 
cases presenting multiple tumors and polycythemia or to sporadic presentation of the disease. 
The specific gain of the chromosome 2p constitutes a differential feature of tumors harboring 
EPAS1 mutations and can be used as a marker for directed genetic screening.  
6- The MDH2 gene is a tumor suppressor gene associated to the development of hereditary 
PCC/PGL and constitutes a novel example of the oncogenic properties of Krebs cycle inactivation. 
The absence of MDH2 in tumors is associated with a hypermethylator phenotype, similar to the 
previously described in PCCs harboring mutations in FH or the SDH genes, probably caused by the 
accumulation of Krebs cycle metabolites. The incomplete penetrance of the mutation, as well as 
the absence of more cases carrying alterations in the gene, highlight the need to recruit larger 
series of patients in order to determine the relevance of MDH2 to the development of disease. 
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1. Pharmacogenomics J. 2014 Nov 4. 
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population 
classifies CYP3A4 as a polymorphic enzyme. 
Apellániz-Ruiz M, Inglada-Pérez L, Naranjo ME, Sánchez L, Mancikova V, Currás-Freixes M, de Cubas AA, 
Comino-Méndez I, Triki S, Rebai A, Rasool M, Moya G, Grazina M, Opocher G, Cascón A, Taboada-Echalar 
P, Ingelman-Sundberg M, Carracedo A, Robledo M, Llerena A, Rodríguez-Antona C. 
 
Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have been 
reported as rare events, and the first demonstration of a CYP3A4 protein lacking functional activity is 
caused by CYP3A4*20 allele. Here we characterized the world distribution and origin of CYP3A4*20 
mutation. CYP3A4*20 was determined in more than 4000 individuals representing different populations, 
and haplotype analysis was performed using CYP3A polymorphisms and microsatellite markers. 
CYP3A4*20 allele was present in 1.2% of the Spanish population (up to 3.8% in specific regions), and all 
CYP3A4*20 carriers had a common haplotype. This is compatible with a Spanish founder effect and 
classifies CYP3A4 as a polymorphic enzyme. This constitutes the first description of a CYP3A4 loss-of-
function variant with high frequency in a population. CYP3A4*20 results together with the key role of 
CYP3A4 in drug metabolism support screening for rare CYP3A4 functional alleles among subjects with 
adverse drug events in certain populations. 
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2. Genes Chromosomes Cancer. 2011 Nov;50(11):922-9. 
VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid 
carcinoma. 
Mancikova V, Inglada-Pérez L, Curras-Freixes M, de Cubas AA, Gómez Á, Letón R, Kersten I, Leandro-
García LJ, Comino-Méndez I, Apellaniz-Ruiz M, Sánchez L, Cascón A, Sastre-Marcos J, García JF, Rodríguez-
Antona C, Robledo M. 
 
BACKGROUND: 
Tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical results in medullary thyroid carcinoma 
(MTC) patients. However, the considerable variability in patient response to treatment with TKIs remains 
largely unexplained. There is evidence that it could be due, at least in part, to alterations in genes 
associated with the disease via their effect on the expression of TKI targets. The objective of this study 
was to evaluate the influence of RAS mutations on the expression levels in MTC tumors of eight key TKI 
target proteins. 
METHODS: 
We assessed by immunohistochemistry the expression of EGFR, KIT, MET, PDGFRB, VEGF, VEGFR1, 
VEGFR2, and VEGFR3 in a series of 84 primary MTC tumors that had previously been molecularly 
characterized, including 14 RAS-positive, 18 RET(M918T)-positive, and 24 RET(C634)-positive tumors, as 
well as 15 wild-type tumors with no mutations in the RET or RAS genes. 
RESULTS: 
In contrast to RET-positive tumors, RAS-positive tumors expressed neither PDGFRB nor MET (p=0.0060 
and 0.047, respectively). Similarly, fewer RAS-positive than RET-related tumors expressed VEGFR3 
(p=0.00062). Finally, wild-type tumors expressed VEGF more often than both RAS- and RET-positive 
tumors (p=0.0082 and 0.011, respectively). 
CONCLUSIONS: 
This is the first study identifying that the expression of TKI targets differs according to the presence of 
RAS mutations in MTC. This information could potentially be used to select the most beneficial TKI 
treatment for these patients.  
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3. Endocr Relat Cancer. 2013 Jul 12;20(4):611-9. 
Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma. 
Rodríguez-Antona C, Muñoz-Repeto I, Inglada-Pérez L, de Cubas AA, Mancikova V, Cañamero M, 
Maliszewska A, Gómez A, Letón R, Leandro-García LJ, Comino-Méndez I, Sanchez L, Alvarez-Escolá C, Aller 
J, Cascón A, Robledo M. 
 
The therapeutic options for patients with metastatic medullary thyroid carcinoma (MTC) have recently 
increased due to the development of tyrosine kinase inhibitors (TKIs), some of which have achieved 
remarkable clinical responses in MTC patients. However, the molecular basis for the large variability in TKI 
responses is unknown. In this exploratory study, we investigated the expression of eight key TKI target 
proteins (EGFR, KIT, MET, PDGFRB, VEGF (VEGFA), VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)) by 
immunohistochemistry in 103 molecularly characterized MTC samples and identified the associated 
clinical and molecular features. A number of MTC samples exhibited a high expression of VEGFR2 and 
VEGFR3, which were overexpressed in 57 and 43% of the MTC samples respectively. VEGFR1, PDGFRB, 
VEGF, KIT, and MET were present in 34-20% of the cases, while EGFR was highly expressed in only 10% of 
the MTC samples. Some proteins exhibited large differences in expression between sporadic and familial 
cases, suggesting that different RET mutations may be associated with the immunohistochemical profiles. 
MTC samples with the C634 RET mutation exhibited a higher expression of VEGFR3 and KIT than the 
M918T RET-mutated and non-mutated RET tumor samples (P=0.005 and P=0.007 respectively) and a 
lower expression of VEGFR1 (P=0.04). Non-mutated RET MTC cases exhibited a lower expression of 
PDGFRB (P=0.04). Overall, this is the first study, to our knowledge, to show that multiple TKI targets are 
highly expressed in a subset of MTCs, suggesting that molecular stratification of patients may have the 
potential to improve TKI therapies for MTC. 
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4. Endocr Relat Cancer. 2013 Jun 24;20(4):477-93. 
Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma 
identifies genotype-specific markers and potentially regulated pathways. 
de Cubas AA, Leandro-García LJ, Schiavi F, Mancikova V, Comino-Méndez I, Inglada-Pérez L, Perez-
Martinez M, Ibarz N, Ximénez-Embún P, López-Jiménez E, Maliszewska A, Letón R, Gómez Graña A, Bernal 
C, Alvarez-Escolá C, Rodríguez-Antona C, Opocher G, Muñoz J, Megias D, Cascón A, Robledo M. 
 
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine neoplasias of neural 
crest origin that can be part of several inherited syndromes. Although their mRNA profiles are known to 
depend on genetic background, a number of questions related to tumor biology and clinical behavior 
remain unanswered. As microRNAs (miRNAs) are key players in the modulation of gene expression, their 
comprehensive analysis could resolve some of these issues. Through characterization of miRNA profiles in 
69 frozen tumors with germline mutations in the genes SDHD, SDHB, VHL, RET, NF1, TMEM127, and MAX, 
we identified miRNA signatures specific to, as well as common among, the genetic groups of PCCs/PGLs. 
miRNA expression profiles were validated in an independent series of 30 composed of VHL-, SDHB-, 
SDHD-, and RET-related formalin-fixed paraffin-embedded PCC/PGL samples using quantitative real-time 
PCR. Upregulation of miR-210 in VHL- and SDHB-related PCCs/PGLs was verified, while miR-137 and miR-
382 were confirmed as generally upregulated in PCCs/PGLs (except in MAX-related tumors). Also, we 
confirmed overexpression of miR-133b as VHL-specific miRNAs, miR-488 and miR-885-5p as RET-specific 
miRNAs, and miR-183 and miR-96 as SDHB-specific miRNAs. To determine the potential roles miRNAs play 
in PCC/PGL pathogenesis, we performed bioinformatic integration and pathway analysis using matched 
mRNA profiling data that indicated a common enrichment of pathways associated with neuronal and 
neuroendocrine-like differentiation. We demonstrated that miR-183 and/or miR-96 impede NGF-induced 
differentiation in PC12 cells. Finally, global proteomic analysis in SDHB and MAX tumors allowed us to 
determine that miRNA regulation occurs primarily through mRNA degradation in PCCs/PGLs, which 
partially confirmed our miRNA-mRNA integration results. 
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5. Endocr Relat Cancer. 2013 May 30;20(3):L1-6. 
Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. 
Cascón A, Inglada-Pérez L, Comino-Méndez I, de Cubas AA, Letón R, Mora J, Marazuela M, Galofré JC, 
Quesada-Charneco M, Robledo M. 
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6. Cancer Res. 2012 Sep 15;72(18):4744-52. 
Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. 
Leandro-García LJ, Leskelä S, Inglada-Pérez L, Landa I, de Cubas AA, Maliszewska A, Comino-Méndez I, 
Letón R, Gómez-Graña Á, Torres R, Ramírez JC, Álvarez S, Rivera J, Martínez C, Lozano ML, Cascón A, 
Robledo M, Rodríguez-Antona C. 
 
Cellular microtubules composed of α-β-tubulin heterodimers that are essential for cell shape, division, 
and intracellular transport are valid targets for anticancer therapy. However, not all the conserved but 
differentially expressed members of the β-tubulin gene superfamily have been investigated for their role 
in these settings. In this study, we examined roles for the hematologic isoform β-tubulin VI and functional 
genetic variants in the gene. β-tubulin VI was highly expressed in blood cells with a substantial 
interindividual variability (seven-fold variation in mRNA). We characterized DNA missense variations 
leading to Q43P, T274M, and R307H, and a rare nonsense variant, Y55X. Because variations in the 
hematologic target of microtubule-binding drugs might alter their myelosuppressive action, we tested 
their effect in cell lines stably expressing the different β-tubulin VI full-length variants, finding that the 
T274M change significantly decreased sensitivity to paclitaxel-induced tubulin polymerization. 
Furthermore, patients treated with paclitaxel and carrying β-tubulin VI T274M exhibited a significantly 
lower thrombocytopenia than wild-type homozygous patients (P = 0.031). Together, our findings define 
β-tubulin VI as a hematologic isotype with significant genetic variation in humans that may affect the 
myelosuppresive action of microtubule-binding drugs. A polymorphism found in a tubulin isoform 
expressed only in hemapoietic cells may contribute to the patient variation in myelosuppression that 
occurs after treatment with microtubule-binding drugs. 
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7. Clin Cancer Res. 2012 Aug 15;18(16):4441-8. 
Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. 
Leandro-García LJ, Leskelä S, Jara C, Gréen H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-Perez L, 
Maliszewska A, de Cubas AA, Comino-Méndez I, Mancikova V, Cascón A, Robledo M, Rodríguez-Antona C. 
 
PURPOSE: 
Peripheral neuropathy is the dose-limiting toxicity of paclitaxel, a chemotherapeutic drug widely used to 
treat several solid tumors such as breast, lung, and ovary. The cytotoxic effect of paclitaxel is mediated 
through β-tubulin binding in the cellular microtubules. In this study, we investigated the association 
between paclitaxel neurotoxicity risk and regulatory genetic variants in β-tubulin genes. 
EXPERIMENTAL DESIGN: 
We measured variation in gene expression of three β-tubulin isotypes (I, IVb, and IIa) in lymphocytes from 
100 healthy volunteers, sequenced the promoter region to identify polymorphisms putatively influencing 
gene expression and assessed the transcription rate of the identified variants using luciferase assays. To 
determine whether the identified regulatory polymorphisms were associated with paclitaxel 
neurotoxicity, we genotyped them in 214 patients treated with paclitaxel. In addition, paclitaxel-induced 
cytotoxicity in lymphoblastoid cell lines was compared with β-tubulin expression as measured by 
Affymetrix exon array. 
RESULTS: 
We found a 63-fold variation in β-tubulin IIa gene (TUBB2A) mRNA content and three polymorphisms 
located at -101, -112, and -157 in TUBB2A promoter correlated with increased mRNA levels. The -101 and 
-112 variants, in total linkage disequilibrium, conferred TUBB2A increased transcription rate. 
Furthermore, these variants protected from paclitaxel-induced peripheral neuropathy [HR, 0.62; 95% 
confidence interval (CI), 0.42-0.93; P = 0.021, multivariable analysis]. In addition, an inverse correlation 
between TUBB2A and paclitaxel-induced apoptosis (P = 0.001) in lymphoblastoid cell lines further 
supported that higher TUBB2A gene expression conferred lower paclitaxel sensitivity. 
CONCLUSIONS: 
This is the first study showing that paclitaxel neuropathy risk is influenced by polymorphisms regulating 
the expression of a β-tubulin gene. 
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8. Genes Chromosomes Cancer. 2011 Nov;50(11):922-9. 
Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family. 
Cascón A, Huarte-Mendicoa CV, Javier Leandro-García L, Letón R, Suela J, Santana A, Costa MB, Comino-
Méndez I, Landa I, Sánchez L, Rodríguez-Antona C, Cigudosa JC, Robledo M. 
 
Hereditary primary hyperparathyroidism (HPT) may develop as a solitary endocrinopathy (FIHP) or as part 
of multiple endocrine neoplasia Type 1, multiple endocrine neoplasia Type 2A, or hereditary HPT-jaw 
tumor syndrome. Inactivating germline mutations of the tumor suppressor gene CDC73 account for 14 
and 50% of all FIHP and HPT-JT patients, respectively, and have also been found in almost 20% of 
apparently sporadic parathyroid carcinoma patients. Although more than 60 independent germline 
mutations have been described, to date no rearrangement affecting the CDC73 locus has been identified. 
By means of multiplex-PCR we found a large germline deletion affecting the whole gene in a two-
generation HPT-JT family. Subsequently array-CGH and specific PCR analysis determined that the 
mutation spanned ∼ 547 kb, and included four additional genes: TROVE2, GLRX2, B3GALT2, and UCHL5. 
Although no clear mutation-specific phenotype was found associated to the presence of the mutation, 
further studies are needed to assess whether the loss of the neighboring genes could modify the 
phenotype of carriers. There was complete absence of nuclear staining in the two HPT-JT-related tumors 
available. The finding of the first rearrangement affecting the CDC73 gene warrants screening for this 
tumor suppressor gene inactivation mechanism not only in high-risk CDC73 point mutation-negative HPT-
JT families, but also in FIHP patients. 
 
 
 
 
 
